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Introduction: Drugs intended to treat incidental medical conditions could moderate host-
tumour interaction and therefore melanoma survival.  
Method: Drug exposure data were collected from the 2184 newly diagnosed melanoma 
patients in the Leeds Melanoma Cohort (recruited 2000-2012) and their primary care 
physicians. An ever-never analysis and drug usage at diagnosis of melanoma (including 
12 months prior) were chosen as the most applicable analysis methods (overall and sex 
stratified). The effects of exposure to different classes of drugs on MSS and overall 
survival (OS) were then assessed using Cox Proportional Hazards models whilst 
adjusting for confounding variables including diabetes and BMI, firstly in unadjusted 
models followed by adjustment for known predictors of MSS in a multivariate model.  
Results: For most drugs there were no statistically significant effects on MSS. The drugs 
that I ultimately chose to look at in detail were aspirin, simvastatin and metformin. 
Whilst adjusting for age and Breslow thickness, women who had ever taken aspirin were 
significantly less likely to die from their melanoma compared with those who never used 
the drug at any point in their lifetime with hazard ratios (HR) for MSS of 0.51 (95% CI: 
0.30-0.87, P= 0.014) compared to men with an HR (MSS) 0.99 (95% CI: 0.71-1.37, P= 
0.948). 
With both ever/never use of simvastatin and at diagnosis (including 12 months prior) 
analysis, when adjusting for age and Breslow thickness, men had a significantly reduced 
risk of death from melanoma with HRs of 0.54 (95% CI: 0.37-0.79, P=0.002) and 0.57 
(95% CI: 0.38-0.85, P=0.006) respectively when compared to females who had HRs of 
1.22 (95% CI: 0.82-1.83, P=0.327) and 1.21 (95% CI: 0.79-1.86, P = 0.379). 
Metformin usage was negatively associated with MSS in individuals with primaries on 
the trunk, which was used here as a surrogate marker for BRAF mutated tumours with 
an HR of 3.87 (95% CI 1.29-11.57, P= 0.02) for chest primaries. 
Conclusion: The associations seen in my thesis require further validation in larger 
international data sets as well as examination of biological models to assess if these 
represent real effects or whether confounding factors are responsible for these changes. 
I would propose that future studies looking at factors influencing melanoma survival 
should consider stratifying their findings by sex. 
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1.1 Introduction to the thesis 
In this thesis, I examine the association of incidental drug exposures associated with 
metabolic syndrome (as represented by body mass index (BMI) and diabetic status) on 
melanoma survival, in the Leeds Melanoma Cohort (LMC) of cutaneous melanoma (CM) 
patients. Incidental drugs in this context refer to any drugs the patients may have been 
exposed to during a specified period to treat any other conditions other than the 
melanoma itself, which may include the metabolic syndrome. The metabolic syndrome 
refers to a state characterised by the development of multiple cardiovascular risk factors 
including insulin resistance, obesity, dysplipidaemia and hypertension and associated 
with low-grade inflammation [1]. Although melanomas may arise in the eye or from 
mucosal surfaces, this thesis is concerned only with the most common type of 
melanoma, which arises in the skin. 
This work was prompted by – firstly, the work reported in studies of other cancers, which 
suggested that use of commonly used drugs such as aspirin [2], statins [3] or metformin 
[4] may change cancer risk. Secondly, by laboratory data, which suggested biological 
mechanisms to support the hypothesis that drugs might modify the likelihood of 
surviving, e.g. metformin in BRAF mutated melanoma [5]. Thirdly, by the observation 
that although the American Joint Committee of Cancer (AJCC) predicts survival 
reasonably well, there is still a significant degree of variance which remains unexplained 
(30 to 40%). My hypothesis is that lifestyle or exposure to drugs e.g. metformin may 
moderate host/tumour interaction and therefore survival contributing to the unexplained 
variance, as also postulated by Chen and Mellman [6]. 
Studies designed to understand the effects of concurrent drug exposure should take 
account of the following complexities. Most drugs are more frequently used in older 
individuals with concurrent diseases associated with systemic inflammation and 
increased age is associated with poorer cancer survival. That reduced survival might 
have been reported as a result of confusion of between cancer and non-cancer related 
death, reduced access to health care in the infirm, reduced tolerance of effective drugs 
or biological effects of the systemic inflammation associated with the co-morbidities. 
These drugs may also be biologically related themselves to risk, via their mechanism of 
action [7] either by reducing the mediators of systemic inflammation or as a result of as 
yet unrecognised effects.  
2 
1.2 Thesis Layout 
The layout of my thesis is as follows: 
In chapter 1, I have presented the background to the topic and arrived at the aims of the 
study.  
In chapter 2, I have presented the materials and methods used in the study. 
In chapter 3, I have described the Leeds Melanoma Cohort data (which was the study 
data set used in this thesis) and explored potential candidate drugs and arrived at my 
three chosen drugs.  
In chapter 4, I have examined the association of aspirin exposure with melanoma survival 
including undertaking a literature review, reported materials and methods specific to 
aspirin, and presented my results with respect to aspirin and concluded with a discussion 
of my findings. 
In chapter 5, I have examined the association of statin exposure with melanoma survival 
including undertaking a literature review, reported materials and methods specific to 
statins, and presented my results with respect to statins and concluded with a discussion 
of my findings. 
In chapter 6, I have examined the association of metformin exposure with melanoma 
survival including undertaking a literature review, reported materials and methods 
specific to metformin, and presented my results with respect to metformin and concluded 
with a discussion of my findings. 
In chapter 7, I have presented a general discussion of my thesis as well as reviewed the 
relevant literature in light of my findings, discussed the limitations of my approach and 
finally drawn conclusions and suggestions for future work based on my results. 
 
1.3 What is Melanoma 
Melanoma is a skin cancer that is derived from pigment cells or melanocytes. 
Melanocytes are found in the basal layer of the epidermis and are responsible for 
generating melanin, which is the pigment responsible for a “suntan” and offers protection 
for the skin against the harmful effects of ultraviolet radiation exposure.  
3 
1.4 Types of Melanoma 
Four main clinicopathological subtypes of melanoma are recognised clinically and 
histologically: superficial spreading melanoma (SSMM); nodular melanoma (NMM); 
lentigo maligna melanoma (LMM), and acral lentiginous melanoma (ALMM) [8-11]. 
There are also several uncommon variants that constitute less than 5% of the cases, for 
example desmoplastic, spitzoid, and naevoid melanoma. The term melanoma in situ 
(MMIS) is used when melanoma cells are confined to the epidermis with no invasion into 
the dermis. Criteria for the histological diagnosis of melanoma are architectural and 
cytological [12]. 
1.4.1 Superficial spreading melanoma (SSMM) 
This is the most frequently observed type of melanoma in white skinned peoples and 
accounts for 70% of cases seen within this group of people. It most commonly occurs at 
sites of intermittent, intense sun exposure (on the trunk in men, and on the legs and back 
in women) and is the most frequent type in individuals aged 30-50 years [13]. It can 
appear de novo or be associated with a naevus and slowly progresses to a plaque, often 
comprising multiple colours and pale areas of regression. The concept of radial growth 
phase was first introduced by Clark to describe a protracted phase of growth in which 
proliferation occurs first in the most superficial part of the skin (epidermis) [14]. SSMM 
has a radial growth phase (RGP), during which the lesion is predominantly in the 
epidermis but steadily increasing in diameter, followed by a vertical growth phase (VGP) 
in which the lesion extends downwards into the dermis and exhibits increased metastatic 
potential [14]. These melanomas are often found to have somatic mutations in the BRAF 
gene (most commonly V600E) [15]. It is hypothesised that these tumours result from 
sunburn associated sun bathing and occur on skin sites usually only exposed during 
recreational activities such as the back in men [13]. The term “in situ” may be used to 
describe this phase and whilst in situ lesions are typical of SSMM, they are also seen in 
LMMM and ALMM as will be discussed below. In situ disease progresses slowly, possibly 
taking many years to develop before genetic changes in the malignant cells occur which 
enable the malignant cells to invade and metastasise. During this period of relative 
quiescence these cells it might be argued, might be subject to host influences, which 
might promote tumour evolution or suppress it. My hypothesis is, therefore, that drug 
exposure in the period up to and including the period of diagnosis may modify stage at 
presentation. 
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1.4.2 Nodular melanoma (NMM) 
It accounts for nearly 5% of all melanomas in pale skinned peoples. Such tumours 
usually appear as exophytic (protruding from the skin surface), brown-black and 
frequently eroded or ulcerated tumours, occurring most commonly on the legs and trunk 
of older men (greater than 60 years old) [16]. Since they have a predominantly VGP, 
devoid of RGP, NMM has a tendency toward greater depth of invasion and is associated 
with a worse prognosis than the other common subtypes [13]. There can also be the 
presence of an NRAS mutation, which has also been associated with a tendency to 
metastasis [17]. 
1.4.3 Lentigo maligna melanoma (LMM) 
This accounts for 4-15% of melanomas in the UK. It is typically located on chronically 
sun-damaged skin (such as the head, neck, or arms) of pale-skinned older individuals 
[13]. Its benign precursor lesion (a form of in situ melanoma), lentigo maligna, is a tan 
macule that grows slowly in a radial fashion and may eventually display a palpable 
component of VGP clinically signalling progression to LMM [18]. Histologically, it is 
characterized by a lentiginous component [19]. There is proliferation of atypical 
melanocytes at the dermo-epidermal junction and features of chronic sun exposure 
(solar elastosis) [13]. In time these lesions may progress to a nodular invasive phase 
(LMM). 
1.4.4 Acral lentiginous melanoma (ALMM) 
ALMM occurs on the palms, soles, or beneath or around the nail plate (subungual 
variant) accounting for 2-8% of cases in pale-skinned persons. It accounts for 29-72% 
of melanoma in dark-skinned individuals, such as African-American, Asian, and Hispanic 
[20]. The incidence of this melanoma type is approximately similar in all ethnicities and 
there is no evidence that this form of melanoma is aetiologically related to skin colour or 
sun exposure [21]. 
 
1.5 Metastatic behaviour of Melanoma 
Although a relatively uncommon form of cancer, melanoma is the primary cause of death 
due to skin cancer, and it has continued to increase in incidence. If the diagnosis is made 
at an early stage, a surgical excision is usually enough to cure > 90% of cases.  
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Although metastatic melanoma survival is changing rapidly with the advent of adjuvant 
and palliative immunotherapy, historically patients with metastasis                                                        
(stage III and IV) survive for < 1 year, with a median survival of around 6-8 months. The 
1-year survival rate was 45%, and for ≥ 5 years, the survival rate was < 10% [22]. While, 
a minority of newly diagnosed melanoma patients (4%), have distant metastasis at the 
time of diagnosis, the majority of the patients who are diagnosed at initial stage ultimately 
progress to metastatic disease as a result of disease advancement [23]. It is reported 
that approximately 33% of all melanoma patients will have recurrence of the disease 
[24].  
In general, stage III metastatic melanoma patients (nodal metastases) have earlier 
recurrences than patients with negative lymph nodes. Additionally, age of the patient at 
the time of diagnosis also affects the timing of distant metastases i.e., patients aged > 
50 years relapse earlier compared to younger patients [25]. 
Melanoma can metastasize to any tissue or organ, involving some of the sites seldom 
observed with various solid tumours [26]. However, there are sites, which are more likely 
to act as sanctuary for primary distant metastases. The most frequently observed primary 
sites of distant metastases include the skin, subcutaneous tissue, and lymph nodes, 
which are reported in 42 to 59% of melanoma patients. However, the primary sites of 
relapse seen in around 25% of all metastatic melanoma cases remains visceral organs 
and the most frequently involved sites of visceral metastases, in the decreasing order, 
are the lungs (18–36%), liver (14–20%), brain (12–20%), and bones (11–17%) [22]. 
Among the independent predictors of survival in patients with metastatic disease, the 
site of distant metastasis is an important predictor [26, 27]. It was reported that the 
patients with visceral metastasis have poor survival rates than the patients with loco-
regional, distant nodal, and soft tissue metastasis [27, 28]. Moreover, it was reported that 
patients with lung as the only site of visceral metastasis had a superior 1-year survival 
than the patients with metastasis to other visceral organs. Median survival observed in 
patients with metastatic melanoma was 12 months and 7 months in those with 
metastasis to lungs and visceral organs other than the lung, respectively. Moreover, the 
median survival was 18 months in patients with metastasis to non-visceral sites (i.e., 
skin, subcutaneous tissue, and distant lymph nodes) [27, 29]. 
Another independent predictor of survival in patients with metastatic disease is the 
number of metastatic sites [30]. Patients with one distant metastatic site have a 
significantly improved outcome compared with those with two or more distant sites [27]. 
A study reported the 1-year survival rate of 36%, 13%, and < 1% in patients with one, 
two, and three or more metastatic sites, respectively [30]. Another study reported the 
median survival in patients with one and more than one metastases as 23 months and 8 
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months, respectively [31]. Additionally, the stage of melanoma prior to distant metastasis 
also acts as an important prognostic factor. In cases where patients progressed directly 
from stage I or II, a disease-free interval of ≥ 34 months was associated with prolonged 
survival, while in the case of patients with stage III melanoma, a disease-free interval of 
≥ 18 months was shown to be associated with prolonged survival [32]. These differences 
according to number of metastatic sites or different sites are likely to reflect biological 
differences between tumours. Later progression does however imply that tumour cells 
may sit within niches in the body for some time after removal of the primary during which 
period they may be subject to changes in the host tumour environment. 
For the purpose of this thesis it could be argued that the chances of a recurrence 
following the initial melanoma may be subject to host influences, including exposure to 
drugs or the presence of co-morbidities, which may promote tumour evolution or 
suppress it. For a majority of patients, prior to distant metastases, the time it takes for a 
recurrence or metastasis to occur appears to be inversely related to the stage of the 
tumour at presentation. In patients with thicker tumours, there is a higher risk of 
recurrence during the first year following the treatment and this decreases gradually with 
time. Following the initial diagnosis of the primary tumour, around 55 to 79% and 65 to 
85% of the recurrences become evident in 2 and 3 years, respectively. Moreover, 
patients with ulcerated tumours have significantly shorter disease-free period [24, 26] 
and a previous study conducted by our group using the data in this cohort, has shown 
that ulceration (a validated prognostic factor in the AJCC criteria) may be a marker of 
inflammation that is in turn linked to other mediators of inflammation including smoking 
status and potentially the effects of drugs such as aspirin and the metabolic syndrome 
and vitamin D [33]. 
 
1.6 Epidemiology 
1.6.1 Incidence and Future Trends 
Melanoma is responsible for the majority of deaths due to skin cancer worldwide and 
0.7% cancer-related deaths [34]. The global incidence of cancer has increased and so 
has the number of melanoma cases [20]. Melanoma was a relatively rare form of cancer, 
but in the last 5 decades its incidence has increased at a much faster pace compared to 
almost any other cancer in many countries in which the dominant skin colour is white. Its 
annual incidence has increased as rapidly as 4-6% in many pale-skinned populations 
that predominantly inhabit regions such as Northern Europe, North America, New 
Zealand, and Australia [34, 35]. In contrast, incidence rates are 10 to 20-fold lower in 
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non-white populations such as Hispanics, African Americans, American Indians, and 
Asians living in the US [36, 37]. Moreover, among the 195 countries studied, age-specific 
melanoma incidence rates and mortality rates are highest in New Zealand, Australia, 
Norway, Sweden, and the Netherlands [35].  
It has been projected that based on the trends in melanoma incidence in the period from 
1975-2004, incidence rates in many age groups will continue to increase until 2040 
(Figure 1.1). Furthermore it has been projected that the incidence rates in people aged 
60-79 years is likely to increase by a further third from current levels with the largest 
projected increase likely to be in people aged over 80 years [35, 38]. Although incidence 
rates do rise steadily with age, there is still a substantial number of cases affecting young 
adults with almost one third of all cases occurring in people aged less than 50 years, 
conferring a high burden of disease in terms of years lost and years living with a cancer 
diagnosis. However, despite the increase in the incidence of melanoma, mortality has 
been reported to have leveled off since the 1990s. This has been attributed to new 
measures for successful early detection of the condition [39]. Following the global trend, 
the incidence of melanoma has increased across Europe. Within Europe (2016), the UK 
has the 7th largest incidence rate of skin cancer, estimated at 19 per 100,000 people, 
compared to an average of 13 per 100,000 people [40]. In the UK, the incidence of skin 
cancer has increased by 45% in the last decade. Moreover, this rise in incidence has 
especially affected men, who have seen a 56% increase [41]. It is again worth 
considering whether this significant difference in risk between genders could be 
influenced by host factors and is something I will explore further in this thesis. In general, 
the number of localized thin melanomas is also increasing in white populations and 
especially, among younger women [42]. Recent epidemiological studies suggest that 
melanoma in situ, which is increasing by 9.5% annually, is responsible for a 
disproportionately higher percentage of the overall melanoma increase. But the total 





Figure 1.1: Projected incidence of melanoma of skin (on the basis of regions, both 
the genders and all age groups) per 100 000  
Data source: GLOBOCAN 2018 [44]. Generated using an on-line tool at 
http://gco.iarc.fr/ 
1.6.2 Epidemiological data relating to melanoma aetiology 
The marked difference in melanoma incidence in populations with pale skin compared 
with those with darker skin led to the hypothesis that sun exposure was an aetiological 
factor. The strongest behavioural risk factor for melanoma is sun bathing but reported 
sunburn overall irrespective of behaviours is the most robust non-phenotypic risk factor 
[45]. These observations further substantiated evidence that intense sun exposure 
causes melanoma.  
Although partly attributable to increased surveillance and early detection, a proportion of 
the current trend of increased melanoma incidence is almost certainly due to lifestyle 
factors in terms of excessive recreational exposure to high-intensity sunlight and 
sunburns [45, 46]. Cheap flights from high-latitude countries in Europe to sunny holiday 
resorts are available all year round and it has been postulated that some of the increase 
in incidence noted could be explained by greater opportunities for burning of fair, non-
acclimatised white skin [47]. 
1.6.3 Risk Factors 
Melanoma is well described as being a malignancy that is complex and heterogeneous 
in nature [48]. The majority of risk factors are non-modifiable including pale skin that 
















melanocytic naevi (moles), prior melanoma, and family history of melanoma. However, 
sunburn is one of the few modifiable risk factors for melanoma prevention. As a result, 
prevention of melanoma is primarily focused on sun protection measures and secondary 
prevention addressed to early detection of melanoma [10, 13, 47-49].  
1.6.3.1 Race 
As described above, people with type I and II skin have an increased risk of developing 
melanoma compared to people with darker skin colour (i.e., Africans, East Asians, and 
Hispanics). There are a number of pigmentation related risk factors, each of which is 
associated with an approximate doubling of risk, including pale skin, blue or green eyes, 
freckles, blonde or red hair, and sun sensitivity or inability to tan [46]. Inherited variants 
of the melanocortin-1 receptor (MC1R) gene are associated with the combination of red 
hair, freckling, and sun sensitivity. These are very common in populations living at high 
latitude, who are vulnerable to sunburn and therefore melanoma with access to sunny 
holidays. 
1.6.3.2 Excessive exposure to sun 
Excessive sun exposure is a major environmental factor for melanoma development. 
The sun is the principal source of ultraviolet (UV) radiation. Studies have shown that the 
risk of developing melanoma is most strongly linked to intermittent exposure to high-
intensity sunlight, often resulting in sunburn, such as on holidays, rather than to the 
chronic exposure seen in occupations such as farming [45, 46]. Migration studies 
suggest that severe episodic sunburn in early life correlates most strongly with 
melanoma risk [50]. UV radiation can be sub-divided into 3 different types based on the 
respective wavelengths. These are UVA with the longest wavelength (315 to 400 nm), 
UVB (280 to 315 nm), and UVC (100 to 280nm). UVA and UVB are the main causes of 
the destruction of the skin’s structure and the induction of melanocyte DNA damage, 
which leads to uncontrolled cell growth, as little UVC reaches the earth’s surface. UVA 
exposure leads to the production of reactive oxygen species (ROS) that can cause DNA 
damage, including DNA breaks and oxidative modifications of nucleic acid bases. UVB 
radiation is genotoxic to DNA by photoproduct production. Failure to repair this DNA 
damage leads to DNA mutations in epidermis [51]. Although the major UV radiation 
source is the sun, other sources are tanning beds and UV lamps. Because of the modern 
aesthetic views, the general population considers “having a tan” as healthy and beautiful; 
therefore, many people expose themselves to excessive UV radiation exposure from the 
sun or from tanning beds. The data suggest that use of sunbeds, a source of artificial 
UVR, increases the risk of melanoma especially when used before the age of 35 
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although this was not shown to be the case in our Leeds melanoma cohort [52]. Changes 
in legislation that came into effect in 2010, banned the use of sunbeds in under-18s in 
England and Wales. 
1.6.3.2.1 The evolution of SSMM from naevi 
The development of melanoma from naevi is best understood as a multistep process 
with clinical and histological characteristics [53]. SSMM development may result from 
naevoid proliferations and this can be histologically divided into five stages, but some 
SSMM are thought to begin as in situ lesions. In the first stage of development from 
naevi, acquired naevi form due to an increase in melanocyte proliferation in response to 
UV radiation. Naevi are benign skin lesions, however, they can evolve into malignant 
melanomas [54]. Normally, proliferation of naevoid melanocytes ceases with time and 
the naevus involutes, but continued proliferation may result in a clinical entity called the 
dysplastic naevus, which has some potential to evolve into a melanoma if proliferation 
continues. In this third stage, dysplastic naevi continue to grow into the radial growth 
phase (RGP) primary melanoma. RGP melanomas, by definition, develop within the 
epidermis itself and do not possess the ability to invade through the basal membrane 
into the dermis. In the fourth stage, RGP melanomas go on to acquire invasive potential 
by virtue of genetic alterations and begin to invade through the basal membrane into the 
dermis. This is known as the vertical growth phase (VGP). At this point, a melanoma 
possesses the potential of self-sufficient growth and this signals its ability to invade, thus, 
making a curative excision at this point much less likely. In the fifth and final stage of 
melanoma development, the metastatic lesion itself is formed. In this stage, VGP 
melanomas possess the ability to grow larger and to invade surrounding tissues. The 
VGP melanoma becomes a metastatic melanoma once it invades into lymphatics and 
blood vessels and has the potential to colonize distant organs.  
1.6.3.3 Dysplastic nevi 
A naevus or a mole is a benign pigmented skin lesion. However, having many unusual 
types of moles, known as dysplastic or clinically atypical naevi, is associated with an 
increased risk of melanoma. These unusual types of moles can be identified by the 
ABCDE criteria: Asymmetric shape, Border irregularity, Colour mixture, Diameter size, 
and Evolution. The strongest phenotypic risk factor for melanoma is the presence of 
increased numbers of melanocytic naevi [45, 46]. There is a substantially increased risk 
(approximately seven-fold) associated with the presence of 101-120 naevi compared 
with less than 15. Some individuals are said to have the atypical mole syndrome (AMS), 
which has been defined as the presence of at least three of the following clinical features: 
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(a) 100 or more common naevi >2 mm in diameter; (b) two or more atypical naevi; (c) 
one or more naevi on the buttock and/or two or more naevi on the dorsum of the feet; (d) 
one or more naevi on the anterior scalp; (e) one or more pigmented lesion of the iris [55]. 
The AMS phenotype is a potent risk factor for melanoma. Twin studies have 
demonstrated that the number of naevi is predominantly genetically determined, with a 
smaller effect of sun exposure [56]. Genome-wide association studies have identified 
several loci associated with naevus number [57, 58]. 
1.6.3.4 Family history of melanoma 
The risk of melanoma is greater if a person’s parents or siblings have had melanoma. 
Individuals with a family history of melanoma have approximately double the risk of 
developing the disease [46]. This may be because families share similar genetic 
backgrounds or lifestyle (i.e., excessive sun exposure). Approximately 10% of cutaneous 
melanomas can be associated with a familial setting [59]. Rare families exist in which 
large numbers of melanoma cases arise and these families are more likely to have 
inherited highly penetrant melanoma susceptibility genes. Most of these families have 
hereditary mutations in the CDKN2A (cyclin dependent kinase inhibitor 2A) gene and 
some very rare families have mutations in the CDK4 (cyclin dependent kinase 4) gene 
[60-62]. Mutations of CDKN2A and CDK4 result in cell cycle dysregulation and promote 
melanoma development [63]. In the majority of CDKN2A mutation-positive families in the 
UK and Australia, family members have an increased risk of melanoma alone but in 
mutation-positive families in North America and some parts of Europe, there is also an 
increased risk of pancreatic cancer [64]. Hereditary mutations are responsible for a very 
small proportion of melanoma. The frequency of CDKN2A mutations is 20-40% in 
families where there are three or more affected first-degree relatives, and less than 5% 
if there are only two [65]. There are very rare additional inherited mutations behaving as 
high penetrance melanoma susceptibility genes in the POT1 gene, other genes in the 
shelterin complex and one in the TERT gene. 
1.6.3.5 Impaired immune system 
People who have an impaired immune system have a higher risk of getting melanoma. 
This includes people carrying HIV or people taking immune suppressant drugs for organ 
transplantation or autoimmune disorders, again arguing for the possibility of incidental 
drugs and other host factors influencing risk of melanoma and progression of that cancer 
[66-68]. 
The effects of immune suppression were particularly highlighted by MacKie et al. who 
reported the development of fatal melanoma in two patients who had undergone kidney 
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transplantation [69]. This occurred 16 years following surgery for primary melanoma in 
the donor. However, primary melanoma was not identified in both the patients and 
secondary melanoma was diagnosed acquired from the kidney donor [69]. There are 
various cases melanoma reported in the literature that have been transferred through 
donor organs and this also illustrates that melanoma cells may survive in tissues for 
many years before proliferation and metastasis. The organs were transplanted six 
months to sixteen years after the donors had undergone melanoma surgery [69-72]. This 
represents variable time interval between melanoma surgery and organ donation 
resulting in fatal melanoma in the organ recipients, but notably is consistent with the view 
that melanoma cells may remain in the host symbiotically for many years. Thus, the usual 
advice is that patients with invasive melanoma should never donate an organ.  
 
1.7 Determinant of survival outcome in Melanoma 
1.7.1 AJCC staging system 
In terms of prognosis or outcome for melanoma patients, the strongest prognostic factors 
are histological characteristics of the primary melanoma and the sentinel node status. 
The sentinel node is the hypothetical first lymph node or group of nodes draining a cancer 
and a biopsy from these can help with staging. These factors have been identified in 
large cohorts of patients and have been integrated to form a staging guideline, which 
provides general prognostic estimates in the form of the validated and internationally 
standardised American Joint Committee on Cancer (AJCC) guidelines. This staging is 
based on the TNM criteria; that is thickness of the tumour (T), extent to which it has 
spread to lymph nodes (N) and extent to which it has metastasised to other parts of the 
body. The staging system is continuously adjusted based upon ever maturing data sets. 
The latest version was recently published (8th Edition) and I have summarised the system 
in Table 1.1 - Table 1.5 below. 
The most important prognostic factors in the AJCC staging system are tumour (Breslow) 
thickness (mm) and ulceration (microscopic ulceration reported according to strict criteria 
by the reporting histopathologist) and which will be used in this thesis for the purposes 
of staging. Depth of tumour invasion (Breslow thickness) has been shown to be the factor 
that best single correlates with prognosis for primary disease [73]. It is measured 
vertically in millimetres from the top of the granular cell layer of the epidermis to the 
deepest point of tumour. Increased tumour thickness confers a higher metastatic 
potential and a poorer prognosis. Approximate five year survival rates are: 95-100% for 
tumours <1 mm thick; 80-96% for tumours 1-2 mm thick; 60-75% for tumours 2.1-4 mm 
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thick; and 50% for tumours >4 mm thick [74]. Presence and number of mitoses present 
within a stage I/II tumour strongly also correlates with prognosis [75] but are not part of 
the current AJCC staging system. It is likely that these histological factors are strongly 
associated with outcome because they correlate with the genetic landscape of the 
tumour and therefore its biological behaviour.  
Despite taking into account the above factors there still exists some variance in outcome 
that remains unexplained. Currently, we are unable to explain why two patients exhibiting 
the same degree of invasion in their primary lesion as recorded by the Breslow thickness, 
the most powerful prognostic predictor of subsequent metastasis, can demonstrate such 
biological variability. One may be cured via a simple excisional surgery and yet another 
may present with, or go on to develop, widespread metastases [75]. 
Table 1.1: Definition of Primary Tumour (T) 
Adapted from Eighth Edition of the American Joint Committee on Cancer (AJCC) 
Melanoma Staging System, Chicago, Illinois.] [76] 
T Category Thickness Ulceration Status 
TX: Primary tumour 
thickness cannot be 
assessed (e.g., diagnosis 
by curettage) 
Not applicable Not applicable 
T0: No evidence of primary 
tumour (e.g., unknown 
primary or completely 
regressed melanoma) 
Not applicable Not applicable 
Tis (melanoma in situ) Not applicable Not applicable 
T1 ≤1.0 mm Unknown or unspecified 






With or without ulceration 
T2 >1.0–2.0 mm Unknown or unspecified 
T2a >1.0–2.0 mm Without ulceration 
T2b >1.0–2.0 mm With ulceration 
T3 >2.0–4.0 mm Unknown or unspecified 
T3a >2.0–4.0 mm Without ulceration 
T3b >2.0–4.0 mm With ulceration 
T4 >4.0 mm Unknown or unspecified 
T4a >4.0 mm Without ulceration 
T4b >4.0 mm With ulceration 
14 
Table 1.2: Definition of Regional Lymph Node (N) 
Adapted from Eighth Edition of the American Joint Committee on Cancer (AJCC) 
Melanoma Staging System, Chicago, Illinois [76]. 
 Extent of regional lymph node and/or lymphatic metastasis 
N category No. of tumour-involved regional lymph nodes 






Regional nodes not assessed (e.g., sentinel 
lymph node [SLN] biopsy not performed, regional 
nodes previously removed for another reason); 
Exception: pathological N category is not required 
for T1 melanomas, use clinical N information 
No 
N0 No regional metastases detected No 
N1 
One tumour-involved node or any number of in-
transit, satellite, and/or microsatellite metastases 
with no tumour-involved nodes 
 
N1a 
One clinically occult (i.e., detected by SLN 
biopsy) 
No 
N1b One clinically detected No 
N1c No regional lymph node disease Yes 
N2 
Two or 3 tumour-involved nodes or any number of 
in-transit, satellite, and/or micro satellite 
metastases with one tumour-involved node 
 
N2a 




Two or 3, at least one of which was clinically 
detected 
No 
N2c One clinically occult or clinically detected Yes 
N3 
Four or more tumour-involved nodes or any 
number of in-transit, satellite, and/or microsatellite 
metastases with 2 or more tumour-involved 
nodes, or any number of matted nodes without or 








Four or more, at least one of which was clinically 




Two or more clinically occult or clinically detected 




Table 1.3: Definition of Distant Metastasis (M) 
Adapted from Eighth Edition of the American Joint Committee on Cancer (AJCC) 
Melanoma Staging System, Chicago, Illinois.] [76]. CNS indicates central nervous 
system; LDH, lactate dehydrogenase. *Suffixes for M category: (0) LDH not 
elevated, (1) LDH elevated. No suffix is used if LDH is not recorded or is 
unspecified. 
 M Criteria 
M category* Anatomic Site LDH Levels 
M0 No evidence of distant metastasis Not applicable 
M1 Evidence of distant metastasis  
M1a Distant metastasis to skin, soft tissue including 
muscle, and/or nonregional lymph node 
Not recorded or 
unspecified 
M1a(0) Not elevated 
M1a(1) Elevated 
M1b Distant metastasis to lung with or without M1a 
sites of disease 
Not recorded or 
unspecified 
M1b(0) Not elevated 
M1b(1) Elevated 
M1c Distant metastasis to non-CNS visceral sites with 
or without M1a or M1b sites of disease 
Not recorded or 
unspecified 
M1c(0) Not elevated 
M1c(1) Elevated 
M1d Distant metastasis to CNS with or without M1a, 
M1b, or M1c sites of disease 
Not recorded or 
unspecified 





Table 1.4: AJCC Clinical Prognostic Stage Groups (cTNM) 
Adapted from Eighth Edition of the American Joint Committee on Cancer (AJCC) 
Melanoma Staging System, Chicago, Illinois [76]. 
When T is… And N is… And M is… Then The Clinical Stage Group is… 
Tis N0 M0 0 
T1a N0 M0 IA 
T1b N0 M0 IB 
T2a N0 M0 IB 
T2b N0 M0 IIA 
T3a N0 M0 IIA 
T3b N0 M0 IIB 
T4a N0 M0 IIB 
T4b N0 M0 IIC 
Any T, Tis ≥N1 M0 III 




Table 1.5: AJCC Pathological (pTNM) Prognostic Stage Groups 
Adapted from Eighth Edition of the American Joint Committee on Cancer (AJCC) 
Melanoma Staging System, Chicago, Illinois [76]. *Pathological stage 0 (melanoma 
in situ) and T1 do not require pathological evaluation of lymph nodes to complete 
pathological staging; use clinical N information to assign their pathological stage. 
When T is… And N is… And M is… 
Then The Clinical Stage Group 
is… 
Tis N0* M0 0 
T1a N0 M0 IA 
T1b N0 M0 IA 
T2a N0 M0 IB 
T2b N0 M0 IIA 
T3a N0 M0 IIA 
T3b N0 M0 IIB 
T4a N0 M0 IIB 
T4b N0 M0 IIC 
T0 N1b, N1c M0 IIIB 
T0 
N2b, N2c, N3b or 
N3c 
M0 IIIC 
T1a/b–T2a N1a or N2a M0 IIIA 
T1a/b–T2a N1b/c or N2b M0 IIIB 
T2b/T3a N1a–N2b M0 IIIB 
T1a–T3a N2c or N3a/b/c M0 IIIC 
T1a–T3a Any N ≥N1 M0 IIIC 
T4b N1a–N2c M0 IIIC 
T4b N3a/b/c M0 IIID 
Any T, Tis Any N M1 IV 
 
1.8 Factors other than those captured in AJCC staging which 
predict outcome 
In addition to the characteristics of the primary tumour and the draining nodes, host 
factors have been identified which are associated with outcome. These include 
increasing age [25], male sex [77], and tumour site (truncal or head/neck tumours) which 
all confer a poorer prognosis. However, these factors are currently not integrated into 
the AJCC staging. Furthermore, as has already been alluded to and which will also be 
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discussed in the ensuing sections, new immunotherapies now represent a fantastic 
development in positive treatment outcomes. 
Prognosis worsens with increasing patient age at the time of diagnosis, in part because 
other factors known to worsen prognosis are more frequent in the melanomas seen in 
older patients.  One study found that as age increased, so did the tumour thickness, 
presence of ulceration, presence of regression and proportion of men [78]. Age is 
however a predictor of poorer outcome independent of stage [79]. Both the evidence of 
thicker tumours in older people and increased death rates in older people independent 
of stage may be manifestations of  an age-related decline in functioning of the immune 
system. These age effects are reported to affect the cellular, humoural, and innate 
immunity [80] but there may also be differences related to aging stroma [81]. T-cell 
mediated adaptive immunity is vital for the response of the host to cells undergoing 
malignant changes. However, available evidence suggests that reductions in cellular 
immunity results in ineffective immune responses against tumour cells in older age. For 
example, old mice have been reported to have an intrinsic age-related defect in naive T-
cell responsiveness which is associated with cytokine secretion and gene expression 
profiles [82]. Memory CD8+ T-cells in humans have also been shown to undergo age-
related changes [83]. Increasing evidence also suggests that the capacity of DCs to 
capture and process antigen is compromised with old age [84].  
Female sex confers a better prognosis than male sex. Some of this protective effect is 
because women tend to tend to present with thinner tumours compared with men. This 
has been attributed to behavioural differences in that men are said to be less likely to 
visit a doctor and get suspicious-looking skin lesions examined [79, 85]. However, there 
may be biological differences between the sexes. It has been suggested that the 
prognosis is better because women present with melanoma at a younger age than men 
and tend to have more limb lesions than trunk lesions compared with men [79, 85, 86]. 
This may be due to the fact that truncal melanomas have been shown to spread more 
frequently to distant sites in comparison to lower extremity lesions, whilst melanomas on 
the lower extremities tend to metastasise more frequently to adjoining regions in 
comparison with the upper extremity lesions [85]. However, sex differences in tumour 
site have not been explained although it’s thought to be behavioural in terms of sun 
exposure practices.  The role of female sex hormone (oestrogen) and protective effect 
of pregnancy on melanoma survival has been explored but is not established [87]. 
Female sex is also an independent predictor of better outcome even in stage IV disease 
prior at least to the advent of immunotherapies [77] and this very interesting observation 
is not yet understood. 
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1.9 The immune system and tumorigenesis 
 It was initially postulated that the immune system has a protective role in the 
development of tumour but it has subsequently become more clear that the relationship 
between immune cells and tumour cells is a lot more complex: experimental studies have 
demonstrated that immune system itself can promote tumour development and 
progression, and functions to promote or select tumour variants with decreased 
immunogenicity [88].  
1.9.1 “Good and Bad” Inflammation 
The term “T cell inflammation” is used by Tom Gajewski to describe the sort of 
inflammation which can kill cancer cells [89].  I will refer to this in this thesis as “good 
inflammation”. “Chronic inflammation” however is also thought to drive some cancers 
e.g. squamous cell carcinoma of the skin in epidermolysis bullosa and is being explored 
as a factor in melanoma as in other cancers such as lung cancer [90]. These 
observations point to a delicate balance between “good” immune responses which kill 
cancer cells and “bad” ones which drive cancers, and the hypothesis of the Leeds group 
is that environmental exposures can affect this balance, more recently summarised by 
Chen and Mellman [6]. 
1.9.2 The immune system and melanoma  
Immune function in relation to melanoma have long been described both for 
pathogenesis and moderating progression. A possible role of sun induced 
immunosuppression in the aetiology of melanoma for example was mooted long ago in 
murine studies of melanoma pathogenesis [91].  
Analysis of > 500 primary melanoma patients with > 7 years of follow-up demonstrated 
that patients with brisk tumour infiltrating lymphocytes (TILs) live two times longer than 
patients without TILs in their tumours. Following this, similar prognostic correlation has 
been demonstrated for the presence of TILs in melanomas that had spread to lymph 
nodes [92]. A retrospective analysis of data, over a period of 30 years, from the 
Transplant Tumour Registry revealed that patients with organ transplantation had twice 
the risk of developing melanoma over the general population [70] and this provides some 
evidence for a causal effect of immunosuppression. The development of vitiligo (auto-
immune damage to normal melanocytes) was recognised as a marker of better 
responses of melanoma patients to chemotherapy and this observation is taken to reflect 
the development of immune responses to antigens shared by normal melanocytes and 
melanoma cells after tumour cell damage during chemotherapy. That the vitiligo was a 
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marker of better responses suggested that immune responses to melanoma were 
important even in terms of responses to chemotherapy. Uncommon dramatic therapeutic 
responses to interferon therapy and IL2 were reported, and now melanoma is in relative 
terms a good responder to immunotherapy. Taken together these observations strongly 
suggest a crucial role for immune responses to melanoma in survival and treatment 
responses. The complexity however of what is required for immune responses to kill 
melanoma was described by Chen and Mellman [6]. They postulated that hereditary 
differences in immune competence, environmental factors (including diet and the 
microbiome), tumour mutation rates, loss of key biological pathways mediating immune 
competence in the tumour all contribute. Although much is now understood of the 
interactions between immune cells and melanoma cells, much remains to be discovered 
and the rate of evolution of this knowledge is unexpectedly fast.   
1.9.3 Immune mechanisms in melanoma development 
Here I give a brief overview of what my reading of the literature reveals of what is known 
about the complexities of immune/cancer cell interaction in melanoma. 
A number of components of the innate and adaptive immune system contribute to and 
defend against melanoma development (Figure 1.2). When tissue homeostasis is 
broken, components of the innate immune system including neutrophils, macrophages 
and mast cells release cytokines, chemokines, matrix remodelling proteases (MMP) and 
reactive oxygen species (ROS), which induce migration and infiltration of more 
leukocytes into damaged tissue, in a process known as inflammation. This response in 
the context of a tumour microenvironment such as melanoma can enhance its 
development [93].  
In addition, local inflammation results in activation of adaptive anti-tumour immune 
responses. Antigen-presenting cells such as dendritic cells present tumour-associated 
antigens on major histocompatibility complex I molecules on their cell surface, resulting 
in the differentiation and expansion of tumour-specific cytotoxic CD8+ T cells. 
Interestingly, melanoma cells have been observed to down-regulate the MHC class I 
expression, thus preventing T cell activation and tumour elimination [94]. Melanoma 
similarly interrupts T cell co-stimulation and activation through modification of 
costimulatory molecule expression on the surface of melanoma cells including 
programmed death ligand 1 [95]. 
Other mechanism of immune evasion which melanoma employs include promoting up-
regulation of immunosuppressive cytokines such as IL-6, IL-10, TNFα, TGFβ and VEGF 
which result in the inward migration of immunosuppressive cells such as myeloid-derived 
suppressive cells, tumour associated macrophages, or tolerogenic dendritic cells [88].  
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Figure 1.2: Graphic depiction of pro- and anti-tumour effects of the immune 
system in cancer and melanoma development. 
Adapted from De Visser et al (2003) [96] and illustration created using 
www.biorender.com.  
 
1.9.4 Evidence that pro-tumourigenic inflammation may play a role 
melanoma progression 
As described above in Section 1.9, cytotoxic CD8+ T cell responses to melanoma play 
an important role in anti-melanoma responses. Infiltration of tumours with immune cells 
is however not held to be beneficial in all tumours, and the work of Lisa Coussens [97] 
and others support the view that some tumours are driven by pro-tumourigenic 
inflammation. The Coussens lab postulated that polarized M2 macrophages, resultant 
increased levels of proinflammatory cytokines, e.g. IL6 and IL8 in some tumours increase 
tumour growth and angiogenesis.  
That chronic inflammation might drive cancer initiation is not a new concept. Chronic 
inflammation has been shown to be an aetiological factor in the onset of several cancers, 
particularly in those of an epithelial origin, and therefore may serve as a potential link 
between obesity and cancer. In the middle of the 19th century, Virchow first addressed 
the contribution of immune cells to tumourigenesis [98]. His conclusions were based on 
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the fact that tumours developed in the setting of chronic inflammation and that 
inflammatory cells were present in tumour biopsy specimens [99]. 
The Leeds Melanoma Group have reported evidence that microscopic ulceration (a 
biomarker of a poor outcome) has clinicopathological and transcriptomic features of a 
pro-tumourigenic inflammatory process. The clinicopathological features included 
increased vascularity and more macrophages [100] and transcriptomic features. 
Changes associated with ulceration were increased expression of pro-inflammatory 
cytokines IL6 and IL8 [101]. The cytokine IL6 is elevated in patients with systemic 
inflammation related to smoking, hypertension, obesity and the metabolic syndrome, 
which are risk factors of cardiovascular disease. The Leeds group therefore asked if 
there might be evidence that low-grade systemic inflammation which might be 
associated with ulceration of primary melanoma as a marker of a pro-tumourigenic 
environment as described below. 
 
1.10 Can systemic low-grade inflammation also drive melanoma 
progression? 
There has been increasing reported evidence for other cancers that host factors such as 
obesity may drive cancer incidence and progression.  The Leeds group looked at data 
from the Leeds Melanoma Cohort and asked if factors related to low grade systemic 
inflammation (obesity, smoking, vitamin D deficiency and diabetes) might be associated 
with ulceration of primary melanomas [33]. It was shown that ulceration was associated 
with all of these factors in a univariate analysis lending support to the view that systemic 
inflammation may play a role in modulating host tumour interaction in melanoma and 
therefore survival. Below I report evidence from other cancers that obesity, and its 
associated systemic inflammation may be important in general and melanoma-specific 
cancer progression. 
 
1.11 Obesity and cancer incidence 
Obesity is a medical state defined usually as having a body mass index (BMI) > 30 kg/m2. 
It is argued by many that the biological impact of “obesity” is related more to central 
(visceral) fat deposits than BMI, and therefore that waist/hip ratio may be more 
meaningful than BMI alone [102]. Indeed studies now increasingly use imaging to 
estimate visceral fat deposits in viscera hypothesised to better predict biological impact 
[103]. In the Leeds Melanoma Cohort reported height and weight were used to compute 
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BMI. Obesity is reported to be the sixth most important risk factor contributing to the 
overall global burden of disease [104]. As per the estimates of the CDC/National Centre 
for Health Statistics, around 70% of the adult population in the US are either overweight 
or obese and this has reached the level of an epidemic [105].  Similarly, in England, a 
third of people over the age of 35 are now deemed to be obese [106]. 
A review of the epidemiological data indicates that over 25% of all cancers are related 
to chronic inflammation and it is also estimated that 15% of cancer deaths are associated 
with inflammation [107, 108]. Acute inflammation is a physiological and vital healing 
process, which is generated by the body in response to either an injury, an infection, or 
some sort of irritation. However, the problem arises when this process begins to become 
chronic, and it may then contribute to a variety of diseases, including cancer. 
1.11.1 Obesity and melanoma 
A number of studies have shown a link between malignant melanoma and the presence 
of excess adiposity [109-111]. Despite this potential link, another large study 
demonstrated no such association [112, 113]. Furthermore some studies are suggestive 
of obesity being associated with an increased risk of malignant melanoma in males, but 
not in females [114-116]. One theory to explain this is that women who are obese may 
be less likely to expose their bodies to the sun as compared to obese men. Moreover, a 
number of studies have assessed the effect of various so called anthropometric 
characteristics such as height, weight, body mass index (BMI) and body surface area 
(BSA), on the risk of developing CM with conflicting results.  
Studies that have demonstrated significant associations between some of these 
anthropometric characteristics and the risk of CM have included at least four different 
prospective studies as well as six separate case-control studies. One such prospective 
study conducted in Norway demonstrated a significantly higher risk of CM for the highest 
versus the lowest quintile of both height and body surface area (BSA) in both sexes. The 
effect of BMI on CM risk was positively associated in males and inversely in females 
[117]. A further cohort study conducted in Norway and which included 118 cases of CM, 
found a significant relative risk for greater height and BSA, but not for BMI [114]. Yet 
another cohort study looking at 187 women from Norway and Sweden with CM, 
demonstrated a direct association with BSA [118]. Another cohort study of more than 
4000 male US veterans with CM,showed an excess risk for obese versus non-obese 
veterans in the case of both white and black men [111]. 
In terms of case–control studies, an Australian study demonstrated a borderline 
significant trend to increased risk of CM with increasing levels of BMI [119]. Similarly a 
US case-control study, demonstrated a two-fold excess risk of CM in subjects with high 
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BMI [120]. In contrast, a study of Canadian women with CM and with matched controls, 
showed significantly greater height, but not weight and BMI [121]. A further study carried 
it out in both Australia and Scotland, demonstrated  a significantly higher risk of 
melanoma of the soles and palms in overweight and obese subjects (BMI >25 kg/m2) in 
Scotland, but not in Australia [122]. Yet another US case–control study demonstrated a 
significant excess risk in men, but not in women, for both height, weight, as well as BSA 
[123]. Furthermore a case–control study from Italy reported that BSA, and weight, but 
mostly BMI were found to be directly associated with the risk of CM but with a particularly 
stronger association between BMI and CM in postmenopausal compared to 
premenopausal women [109]. This result would suggest that potentially differing levels 
of oestrogen may be playing an underlying role in mediating this difference. 
In terms of meta-analysis, one study examining these cohort studies, demonstrated an 
elevated risk of CM with increasing BMI just among men [115]. Similarly, yet another 
meta-analysis reported an increased risk of melanoma among men with increasing BMI 
and BSA, but again this association was not evident in women. As discussed earlier, its 
possible the varying sunlight exposure in obese females may be a confounding variable 
in these studies [116]. The authors have suggested two possible mechanisms, which 
may explain this positive association between obesity and CM risk. Firstly, obesity is 
known to produce chronic insulin resistance, hyperinsulinemia, as well as 
downregulation of insulin-like growth factor (IGF) binding proteins 1 and 2 and an 
increase in activity of IGF-I. Studies have in fact shown that insulin is an independent 
risk factor for melanoma [124]. A further interesting observation is that the total circulating 
levels of IGF-I are higher in men compared to women [115] which may potentially explain 
the observations seen above in men. Secondly, a large body surface may simply be 
representing a larger area at risk for sunlight exposure, not to mention the larger number 
of exposed cells that would be at risk, thereby providing a more direct link to the 
incidence of melanoma [109]. It is also possible that obesity may moderate behaviours 
in the sun although it seems unlikely that obesity would increase sunbathing. It is also 
possible that controls may be less likely to participate in case-control studies if obese 
(bias of participation). 
In contract to the studies presented above, there are also prospective and case control 
studies that have reported no associations between obesity and the risk of CM. Two 
such prospective Scandinavian studies including a a Danish record-linkage study [125] 
and a Swedish study [126] found no increase in risk when compared to the general 
population of the respective countries. A further US study demonstrated no increased 
mortality even for higher categories of BMI in males or females [127]. Similarly in the US 
Radiologic Technologists Study, there was no association found between CM risk and 
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the higher quartiles of height, weight as well as with BMI in both women or men in the 
study [128]. A further two case–control studies looking at women from Canada and 
Western Australia showed no association between the level of obesity or BMI and the 
risk of CM [129, 130]. Another study looking at just women where eight separate case 
control studies were pooled together again showed no association between BMI or body 
surface area (BSA) and CM risk [131]. 
In summary, although there appears to be some evidence for a relationship between 
obesity and melanoma risk judging from the studies there are still many conflicting results 
and this relationship remains unclear. 
1.11.2 Obesity-related inflammation 
As already alluded to, obesity, which is defined as an abnormal or excessive fat 
accumulation in adipose tissues, is considered to be associated with a chronic 
inflammatory disease state [132] and is also characterized by the presence of increased 
circulating fatty acids, and chemo-attraction of immune cells that play a role in the 
development of this inflammatory state[133]. Although the features of chronic 
inflammation seen in obese adipose tissue appear to be fairly clearly defined, the actual 
signals and mechanisms that eventually end up triggering chronic inflammation are not 
fully understood. 
Obesity has also been shown to increase the risk for several chronic diseases including 
type 2 diabetes, cardiovascular disease, as well as fatty liver disease. Although it is 
variously defined, there is an international consensus that chronic systemic inflammation 
associated with obesity and/or insulin resistance is a recognised risk factor for cancer 
and for death from cancer, as well as for cardiovascular disease [134, 135]. By systemic, 
the Leeds Melanoma Group mean that as a result of this inflammation there are 
associated changes evident throughout the body: including in the blood, adipose tissue 
as well as the organs themselves. As already discussed there exists a strong relationship 
between metabolism and immunity and it has been postulated that this could potentially 
become harmful under conditions of metabolic stress.  
The metabolic syndrome is associated with obesity and is defined by a combination of 
cardiovascular risk factors that include increased body mass index (or waist 
circumference), high blood pressure, hyperglycaemia, and raised serum triglycerides, as 
well as a decrease in high-density lipoprotein cholesterol (although definitions do vary 
between studies). Some require an additional measure of obesity (e.g., hip to waist 
measurement ratio and additional markers), while others (e.g., the WHO definition) 
require the presence of insulin resistance [136]. The metabolic syndrome has metabolic 
implications but is also a chronic inflammatory syndrome characterised by elevated 
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circulating inflammatory proteins e.g. TNF- and IL-6, a consequent state of low grade 
inflammation and macrophage infiltration into adipose tissue [137]. 
The changes which are identified in response to obesity (e.g., which drive cardiovascular 
disease and cancer) are extremely complex, but my interpretation of the literature is that 
many changes described are associated with each other. The so-called metabolic 
inflammatory state is said to be orchestrated by metabolic cells in response to excess 
nutrients and energy [138]. The fat cells generate inflammatory responses (increased 
TNF-α, and many inflammatory cytokines such as IL-6), which sustain low-grade chronic 
inflammation in affected patients. Figure 1.3 below, illustrates a version of the hypothesis 
surrounding obesity related systemic inflammation. The recently published data by 
Ridker et al. [139] from the CANTOS trial suggest that the IL1 pathway is crucial in 
mediating cardiovascular disease, with evidence that it mediates cancer risk too. In this 
trial, more than 10,000 patients agreed to be randomised to placebo, 50, 150, and 300 
mg 3 monthly of canakinumab, which blocks IL1 signalling, after a myocardial infarction. 
Eligibility required elevation of high sensitivity C reactive protein levels. The trial reports 
describe a dramatic reduction in serious cardiovascular events in the active treatment 
arms and notably, a reduction in death from lung cancer [139]. 
 
Figure 1.3: Diagram illustrating a version of the hypothesis surrounding obesity 
related systemic inflammation 
Adapted from De Luca d'Alessandro et al. [136] 
 
Interestingly, various components of the metabolic syndrome have been linked in some 
way to the development of cancer. Studies have demonstrated a direct association 
between diabetes and pancreatic and liver cancers which is thought to be due to an 
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excess of insulin which in turn promotes the development of cancer cells in the liver and 
pancreas [140]. Obesity is reported to be a major risk factor for cancer; prospective 
studies indicate that being overweight and obese are responsible for 14% of all cancer 
deaths in men and 20% in women. Obesity has been implicated in both the aetiology as 
well as the progression of cancer at various cancer sites by virtue of a variety of signalling 
pathways that regulate key functions, including proliferation, apoptosis, metastasis, and 
angiogenesis of cancer cells [141].  
1.11.3 Markers of Inflammation 
C reactive protein (CRP) or CRP as it is more commonly referred to, is an acute-phase 
protein released by the liver and is a non-specific marker for inflammation, infection, and 
tissue injury. In clinical practice it is often used to screen for evidence of infection or 
inflammation as part of a blood panel. However, given that as already established, 
adipose tissue secretes pro-inflammatory mediators, it comes as no surprise that CRP 
levels have been shown to correlate with the amount of adipose tissue. Elevated levels 
of CRP have been noted in 35% of obese men and 60% of obese women but also in 
animal models, showing a twofold increase in obese animals, compared to lean controls 
women [142] [143]. Interestingly CRP levels have also been used to predict onset of 
diabetes in both obese men and women [144]. CRP has also been reported to be 
associated with an increase in the risk of developing a number of cancers including 
colorectal, cervical, and ovarian cancer [145], which interestingly are also cancers that 
have been associated with obesity again suggesting a link between the two. 
Furthermore, a study examining the effect of obesity on survival after colon cancer found 
that high levels of CRP correlated with a higher likelihood of death from colon cancer. 
Furthermore, levels of CRP have been found to be inversely associated with survival in 
American Joint Committee on Cancer stage II patients, raising the possibility that CRP 
could eventually be used to help make treatment decisions in this subgroup of patients. 
The authors concluded that it is actually the obesity-related inflammation, rather than the 
obesity itself, that is, linked with poorer outcomes in colon cancer [146]. In summary, 
these data do however add more evidence for a link between obesity, inflammation and 
cancer, which warrants more investigation.  
1.11.4 Obesity-related inflammation and cancer  
In 2013, Maria E Ramos-Nino presented a study examining the links between obesity 
and inflammation, as well as between chronic inflammation and cancer [135]. The study 
suggested that as suspected, inflammation may be important in the obesity-cancer link. 
The changes that occur in the adipose tissue during the process of going from lean to 
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obese were described, including modulation of adipokine levels, hypoxia, increased 
reactive oxygen species (ROS), etc. which were postulated to lead to a chronic state of 
inflammation in the obese individual. It was postulated by the authors that this increased 
risk of obesity-related cancers could be mediated in part by these changes in the adipose 
tissue. A few of the key elements of this association are, amongst others, insulin 
resistance; overexpression of leptin, inflammatory cytokines, sex hormones, 
transcription factors like NF-κB, AP-1, STAT3, and oxidative stress; and down-regulation 
of the expression of anti-inflammatory factors like adiponectin and PPARγ, which disrupt 
the balance between cell proliferation and apoptosis [135].  
Some authors such as Johanna Joyce have attempted to summarise some of the many 




Figure 1.4: Interaction between obesity and cancer development 
Adapted from Joyce et al. [147]  
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1.11.5 Mechanism of association 
1.11.5.1 Increased leptin 
Leptin causes activation of the leptin receptor long isoform (LEPRb) situated in the 
hypothalamus, which in turn acts on both POMC neurons and agouti related protein 
(AgRP) neurons [148]. This subsequently results in increased activation of melanocortin 
3 (MC3R) and MC4R which leads to suppression of appetite [149] and in turn inhibits 
feeding behaviours [148, 150]. Leptin has a number of roles including causing inhibition 
of insulin secretion as well as lipogenesis [151], stimulating lipolysis and fatty acid 
oxidation, suppression of appetite, and promoting energy expenditure, ultimately 
resulting in a reduction in body weight [148]. However leptin resistance can develop 
which can result from defects with leptin transport, impaired LEPRb signalling, neuronal 
energy imbalance, or endoplasmic reticulum (ER) stress [148, 152, 153]. Leptin 
deficiency and leptin resistance are both known risk factors for obesity [148, 154] and 
can be associated with insulin resistance [155] as well as hypogonadism [154, 156]. 
Leptin resistance can promote ER stress and chronic inflammation that can then 
contribute to insulin resistance [157]. Interestingly, ER stress itself inhibits leptin 
signalling [158]. 
An increase in the circulating levels of leptin results in metabolic disturbances that are 
further compounded by inflammation [155]. Leptin has also been found to be structurally 
similar to pro-inflammatory cytokines and in this respect may also modulate CRP [159]. 
It is therefore plausible that the positive associations found between serum leptin levels 
and skin cancer may be due to inflammation secondary to leptin resistance and obesity. 
A further mechanism by which Leptin may result in growth of a melanoma is via 
increased nitric oxide (NO) production and increased levels of circulating endothelial 
progenitor cells (EPCs), which can ultimately promote angiogenesis and vasculogenesis 
also mediated by VEGF and endogenous fibroblast growth factor 2 (FGF-2) [160-162]. 
Leptin therefore behaves as a pro-inflammatory adipokine that in turn influences cytokine 
production, cellular immunity, and ultimately inflammation [163]. Furthermore it has been 
shown that leptin results in the decreased expression of the tumour suppressor p53 in 
order to promote cell cycle progression [164]. As melanoma cells, but not melanocytes, 
express the leptin protein, this results in the creation of a positive autocrine feedback 
loop that then stimulates uncontrolled proliferation of melanoma tumour cells [165]. 
1.11.5.2 Decreased adiponectin 
Adiponectin has been found to exert anti-tumour effects by its ability to inhibit cell 
proliferation [166]. Interestingly, Adiponectin levels have been found to be  approximately 
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50% lower in obese individuals compared to non-obese individuals [166]; resulting in 
increased cell proliferation and therefore potentially playing a role in carcinogenesis.  
However a study examining the relationship between serum Adiponectin levels and 
melanoma incidence showed no significant association between the two.  [167]. 
1.11.5.3 Insulin resistance and insulin-like growth factor (IGF) 
There is evidence to show that an increase in levels of insulin, IGF-1, and IGF-2 can 
induce tumourigenesis by virtue of its effects on the insulin receptor [168]. There is also 
evidence to show that inflammatory kinases can inhibit both insulin action as well as 
glucose uptake in obese individuals [169]. Therefore, it would seem that both 
hyperinsulinemia as well as increased levels of IGF-1 may be contributing to an 
increased cancer risk as well as cancer progression. It has similarly also been shown 
that undertaking calorie restriction, intentional weight loss measures, and treatment of 
diabetes can actually result in a reduction of the risk and rate of progression of skin 
cancer [170].  
A further pathway that has been identified that induces insulin resistance is the 
phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway whereby a PI3K 
inhibitor and an MTOR inhibitor have been shown to induce proliferation and prolonged 
survival of melanoma cells. Activation of this pathway is also thought to mediate 
melanoma cell resistance to chemotherapeutic drugs [171]. 
Abnormal levels of insulin and IGF are have been shown to be associated with 
inflammation, decreased physical activity, and impairment of the immune system. The 
evidence suggests that IGF-1, in particular, is associated with VEGF resulting in 
neovascularization and metastases. In addition, IGF-2 is also thought to play a role in 
tumorigenesis via both insulin and IGF receptors [172]. 
Studies have demonstrated that serum levels of IGF-1 can be significantly higher in 
patients with melanoma together with lower levels of insulin-like factor-binding-proteins 
3 and 5 (IGFBP-3 and IGFBP-5) potentially resulting in melanoma cell proliferation, 
metastases, and reduced survival rates [173, 174]. 
 
1.12  The obesity paradox 
Despite the reported relationship between obesity, inflammation and the risk of several 
cancers, perplexingly, recent studies have reported that obesity is associated with 
improved survival in cancers [175, 176] such as colorectal cancer [177], non-small cell 
lung cancer [178], and renal cell carcinoma [179]. Based on these findings, the term 
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“obesity paradox” has been introduced which suggests improved survival outcomes 
among overweight/obese patients relative to normal weight patients [180]. In a meta-
analysis looking at the effects of increased BMI in patients with a number of different 
malignancies, excluding melanoma, who had received treatment with either cytotoxic 
chemotherapy or targeted therapy, results demonstrated variable benefit ranging from 
beneficial to adverse across tumour types, but interestingly were almost universally 
found to be beneficial in male patients [175]. A pooled meta-analysis, in patients with 
metastatic melanoma being treated with immune checkpoint inhibition as monotherapy 
(PD-1/PD-L1 or CTLA-4) and targeted therapy showed similar results [181]. The 
mechanism by which this phenomenon develops is unclear. Some concerns have been 
raised regarding bias in the epidemiological analyses, and this is an important area for 
future research [180]. 
 
1.13 Incidental drugs and effects on the skin 
Cancer patients are often prescribed drugs intended to treat incidental medical 
conditions, which potentially could have effects on host-tumour interaction and therefore 
survival. These interactions are likely to be very complex and the effects might be 
positive or negative. Some of these effects may be directly attributed to the skin. 
For instance, a potential association with the skin in seen in the effects of certain 
medications that can potentially contribute to both obesity as well as photosensitization. 
Obesity can result in a reduction in the rate of metabolism of a photosensitive drug, which 
in turn increases the intensity and duration of photosensitization [182], which 
theoretically could contribute toward the development of melanoma.  
Diuretics or “water tablets” as they are often referred to are commonly used in the 
treatment of hypertension in elderly patients [183]. As discussed previously obesity and 
an increase in leptin levels can promote hypertension. Studies have demonstrated that 
people who are overweight and obese who are also on diuretics have an increased risk 
of a different type of skin cancer, called a basal cell carcinoma (BCC) [184, 185] and this 
is again thought to be as a result of diuretics increasing the risk of phototoxicity and 
photocarcinogenesis [186].  
Patients who are obese are also likely to be treated with medications such as non-
steroidal anti-inflammatory drugs (NSAIDs) either for cardiovascular benefit or potentially 
for analgesic benefit for joint pain and such like. These NSAIDs have also been shown 
to be associated with heightened photosensitivity [187, 188]. These cutaneous reactions 
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could be in addition to the drug’s potential effects on inflammation and the immune 
system which will be discussed in more detail in the ensuing chapters. 
 
1.14 Oncogenic Pathways involved in the development of 
Melanoma 
Melanomas utilise a number of signalling pathways to regulate their activities, including 
proliferation, migration, differentiation, and apoptosis. De-regulated signalling pathways 
often lead to melanoma progression. Broadly speaking, these signalling pathways fall 
into two categories depending on how signalling pathways are activated. Signal 
pathways can be activated as a result of external stimuli which can result in a signalling 
cascade from the cell surface right down to the intracellular downstream effectors. 
Alternatively, signal pathways can also be activated as a result of constitutively activated 
internal oncogenes in the absence of external stimuli. The oncogenic signalling pathways 
at least in part promote carcinogenesis as a result of deregulated cell proliferation and 
effects on apoptosis. 
The variation in outcome even within patients whose tumours have evidence of activation 
of these oncogenic signalling pathways may result from host/tumour interactions, genetic 
factors and environmental factors. We hypothesise that one such environmental factor 
may be incidental drug exposures that these patients are exposed to during this period.  
As already alluded to, most patients over their lifetime are exposed to several different 
drugs, some of which may have incidental beneficial effects on disease states other than 
that for which they were originally prescribed. For instance, the cancer-preventative 
properties of NSAIDs are accepted in patients with colorectal cancer taking COX-2 
inhibitors or aspirin and so far at least four studies have reported a similar effect in 
prevention of melanoma [189, 190]. Beta-blockers are another group of drugs that have 
also been shown to have a potential effect on melanoma incidence [191, 192]. Analysing 
such interactions could pave the way for the identification of drugs that could potentially 
be used for chemoprevention. 
 
1.15 Vitamin D 
Vitamin D is a fat-soluble steroid hormone, which is thought to exert its genetic effects 
through binding to the vitamin D receptor (VDR). Vitamin D exerts its effects via and 
although long known to be crucial to bone health, it has now been recognized to have 
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pleiotropic effects, and is postulated to play a role in cancer, cardiovascular disease, 
autoimmune diseases, as well as to susceptibility to infections and even in physiological 
ageing in animal models [193]. Vitamin D levels have also been reported to be lower in 
the elderly and in the obese and in the next section I will summarise what is known of 
the role of vitamin D and melanoma. 
1.15.1 Vitamin D and melanoma 
The published data on the association between vitamin D levels and melanoma risk are 
controversial. A few studies have prospectively measured serum vitamin D levels prior 
to the development of melanoma, whereas most investigations have looked at serum 
vitamin D levels close to the time of diagnosis, leading to concerns that low levels of 
vitamin D in people who later die of melanoma might reflect bias associated with poorer 
health. In further studies, as discussed below, vitamin D status at the time of diagnosis 
has been examined and patients were followed up looking at effects on survival. These 
studies appear to suggest that correlations between serum vitamin D levels and 
melanoma risk or serum vitamin D levels and survival from melanoma need to be 
accounted for whenever examining incidence and survival from melanoma [194]. 
There has been an increasing focus recently on understanding this link between vitamin 
D status and melanoma as well as with other cancers and chronic diseases. Despite this 
the relationship between serum levels of vitamin D and the genetic factors which govern 
melanoma risk and melanoma mortality remains unclear. There are however a number 
of fairly robust epidemiological studies which appear to confirm the hypothesis that 
higher vitamin D levels might protect from melanoma, with a number of cohort studies 
having addressed a potential protective effect of vitamin D [194]. The results of some 
studies do not indicate a statistically significant association between serum 25-(OH)D 
levels and melanoma [195]. In addition, others have stated that there remains insufficient 
evidence to be able to recommend vitamin D supplementation to decrease melanoma 
risk [194]).  
In terms of laboratory studies however, there is clear evidence that vitamin D has anti-
proliferative activity on melanoma cell lines in vitro. There is also evidence of a  reduction 
in expression of the vitamin D receptor with progression from a naevus through to a 
primary and eventually a metastatic melanoma. These observations would suggest that 
if vitamin D shows anti-proliferative effects on melanoma cells in vivo, then those cells 
may be less likely to respond to the anti-proliferative effects of vitamin D as progression 
is happening [194]. Further studies indicate that high levels of vitamin D may correlate 
with the development of less aggressive tumours and reduced progression, with some 
studies suggesting that simply normal levels of vitamin D3 at the time of diagnosis are 
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associated with a better prognosis and yet other studies showing that patients with low 
Vitamin D levels tend to have thicker tumours. In addition to this reduced vitamin D levels 
have also been reported in patients with stage IV melanoma compared with those with 
stage I [196, 197]. 
 
1.16 Chemoprevention  
Cancer prevention strategies can be broadly divided into three primary types [198, 199]: 
• Primary prevention of cancer.  
• Secondary prevention of invasive cancer in patients with premalignant 
conditions, or prevention of recurrence in which case the treatment is known as 
adjuvant therapy. 
• Tertiary prevention of second and subsequent primary cancers. 
In the case of melanoma, most primary prevention strategies have targeted sun 
protection, but with variable results. Chemoprevention has, therefore, been proposed as 
an alternative measure for the prevention of cutaneous melanoma. SSMs are relatively 
slow to progress, making this common type of melanoma ideally suited to 
chemopreventive interventions, by attempting to target the processes and molecular 
pathways that have been described to be involved in the progression of melanoma [199]. 
The term "chemoprevention" refers to efforts to prevent, delay or suppress the process 
of carcinogenesis with the help of dietary means, natural agents, synthetic agents, 
vitamins, etc. [199]. Furthermore chemoprevention can also refer to the use of the same 
types of agents to reduce the risk of reoccurrence of cancer in patients who have 
undergone successful primary cancer treatment and are in remission [199], which is the 
focus of this thesis. An ideal agent should have major additional health benefits, few 
adverse effects and be inexpensive. In has been postulated that in the ideal world, 
agents that are selected for the purpose of development as a chemopreventative should 
have evidence of potential activity based on data from a number of sources including 
experimental (mechanistic, in vitro, animal), epidemiologic (case-control, cohort, 
ecologic, secondary analyses), and clinical (phase I, IIA, IIB) trials [200].  
Chemoprevention in cancer has become of interest following the success of drugs such 
as tamoxifen for breast cancer and celecoxib for familial adenomatous polyposis [201]. 
However, some potential candidate drugs such as rofecoxib have adverse thrombotic 
and cardiovascular safety profiles making them unsuitable as chemo-preventative 
agents [202], which is an important consideration when trying to identify potentially 
beneficial drugs. Similarly, some drugs may also produce unintended harm, and it’s 
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equally important to recognise this and consider stopping such drugs in potentially 
susceptible patients, if it is possible to do so.  
Based on the above, we postulate that the effects of the drugs on the carcinogenic 
process may also be of relevance in preventing secondary relapse of cancer. Therefore 
commonly prescribed drugs might have an effect on survival and if so, there may be a 
complex relationship between the medical conditions for which such drugs are 
prescribed, incidental drugs, and survival from melanoma that requires careful 
investigation. 
 
1.17 Management of Melanoma  
Early detection of melanoma is vital, since the five-year survival rate of a patient without 
metastatic disease is 98%. Furthermore, patients with metastatic tumours until recently, 
have had a poor prognosis and have a five-year survival rate of around 23% and a limited 
overall median survival of 6 to 9 months [203]. However, early melanoma detection is 
hindered by late presentation (probably related to a lack of public education), the 
difficulties of educating the elderly in whom new benign skin lesions are common and 
the absence of clinically significant symptoms until the disease has reached an advanced 
stage [204]. The histopathological diagnosis of melanocytic lesions is also difficult. 
Patients who have had one melanoma have been shown to be at higher risk of 
developing a further melanoma with this risk being elevated for up to 20 years and is 
found to be10 times greater than the risk of a first melanoma in the general population. 
In populations with genetic mutations, 12.7% developed a second primary melanoma 
within 2 years of the initial diagnosis and 19.1% by 5 years after diagnosis [202]. 
Currently, there are five types of standard treatment for melanoma patients including 
surgery, chemotherapy, radiation therapy, biologic (immuno-) therapy, and targeted 
therapy as summarised in the Table 1.6 below [205]. A detailed discussion of treatments 
for melanoma is beyond the scope of this thesis although some of the treatment options 
listed serve to highlight the immunogenic nature of melanoma and potential 




Table 1.6: Summary of management of melanoma 
Adapted from Domingues et al [205]  
Treatment Type Details 
Surgery First line treatment for all stage melanomas. Often (in advanced melanoma) combined with chemotherapy, radiation therapy, 
biologic therapy, and targeted therapy. 
Chemotherapy One of the earliest treatment options for advanced melanoma. 
Dacarbazine - the standard chemotherapy medication for metastatic melanoma. 
Temozolomide (TMZ) - an oral prodrug of the active metabolite of dacarbazine, used in advanced melanoma. Shown reduced 
improvement in median progression free survival when compared to dacarbazine. 
Electrochemotherapy (ECT) - a technique combining cytotoxic drugs, bleomycin and cisplatin, with high-intensity electric 
pulses, facilitating drug delivery into cells. 
Effective for the treatment of cutaneous and subcutaneous nodules of melanoma. 
Radiation therapy High-energy radiation (external and internal) to induce melanoma cell death. 
Biological 
(immuno-therapy) 
Interferon (IFN) α-2b - Used as adjuvant therapy for the resected stage IIB/III melanoma. Demonstrates an immunomodulatory 
antitumour effect with a dose-dependent pro-apoptotic effect. 
Pegylated interferon (IFN) α-2b - Used as adjuvant therapy for stage III melanomas. Combination of IFN α-2b with the 
molecule polyethylene glycol (Peg)- improves the therapeutic effect by facilitating the compound to stay in the blood for longer. 
Interleukin -2 - Used as a treatment for metastatic melanomas. 
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade - Ipilimumab (an anti-CTLA-4 antibody) used in the 
treatment of advanced melanomas. 
Programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade - Used in the treatment of metastatic melanoma. 





Treatment Type Details 
• Pembrolizumab, an anti-PD-1 antibody, used in the treatment of advanced melanomas (treatment of ipilimumab refractory 
melanomas). 
Oncolytic virus therapy - The first oncolytic virus for the treatment of melanomas and leads to tumour cell lysis and the release 
of tumour-specific antigens in melanoma cells. 
• Coxsackievirus (CVA21) or CAVATAK is an oncolytic virus in late-stage clinical development where lytic activity against 
melanomas has been seen in vitro cultures and in vivo. 
gp100 Peptide vaccine - Limited clinical benefit as monotherapy can be used as adjuvant therapy 
Toll-like receptor (TLR) agonists - A potent adjuvant for vaccines and can activate the immune system 
Adoptive T-cell therapy - Infusion with melanoma specific T-cells. Involves inducing the formation of memory T-cells which 
can improve anti-tumoral functions.  
Targeted Therapy BRAF inhibitors - Vemurafenib, a selective oral BRAF-mutant inhibitor used for the treatment of unresectable or metastatic 
melanomas harboring activating BRAFV600E mutations. 
MEK inhibitors - Trametinib, a pharmacological MEK1/2 inhibitor with antitumoural activity, used for the treatment of 
unresectable or metastatic malignant melanomas with BRAF mutations. Decreases tumour cell proliferation. 
CKIT inhibitors - Imatinib is an oral c-KIT used in patients with metastatic melanoma harbouring c-KIT aberrations. 
VEGF inhibitors  - Bevacizumab, an anti-VEGF monoclonal antibody, able to target and neutralise VEGF inhibiting tumour 
growth. 
PI3K-AKT-mTOR pathway inhibitors - Combination of PI-103, a PI3K inhibitor, with the mTOR inhibitor rapamycin may 
effectively block the growth of melanoma cells inducing autophagy. 
Cyclin-dependent kinase (CDK) inhibitors - Selective CDK4/6 inhibitors, including ribociclib, abemaciclib, and palbociclib. 
Abemaciclib may induce growth regression in vemurafenib-resistant melanoma models. 






1.18 Summary and aims 
This introduction has explored the clinical presentation, epidemiology and known 
determinants of melanoma survival. I have outlined the complex role of the immune 
system in the promotion and prevention of cancer, in addition to specific mechanisms by 
which the immune system interacts with melanoma. I have described obesity as a 
physical characteristic which is independently associated with the development of 
multiple types of cancer and which is associated with a state of low-grade systemic 
inflammation.  On the basis of these findings, I have hypothesized that drugs incidentally 
used to treat obesity and conditions related to metabolic syndrome may affect survival 
outcomes in melanoma.  
The specific aims of my project are therefore as follows: 
(i) To test the hypothesis that BMI and Diabetes, as components of the 
inflammation/metabolic syndrome may independently be associated with 
melanoma survival outcomes in the Leeds Melanoma Cohort (LMC). 
(ii) To test the hypothesis that there are incidental drugs that the LMC may have 
been exposed to, having examined the literature, that is associated with 
survival outcomes independent of the effects on the inflammation/metabolic 
syndrome.  
(iii) To test the hypothesis that my selected drugs, namely aspirin, statins and 
metformin are associated with survival outcomes in the LMC independent of 
the underlying medical problem for which these drugs have been prescribed 
or as moderators of the inflammation/metabolic syndrome which may also 




Materials and Methods 
2.1 Aims  
The aims of this chapter are:  
• To describe the studies from which patient samples and clinical data have been 
derived for work presented in this thesis.  
• To describe the sources and types of data collected including the process and 
strategies for ensuring the quality of the collected data and subsequent analysis 
• To describe the methodology used throughout the thesis and describe methods 
considered and justify the chosen methods and outline any limitations   
 
2.2 The Leeds Melanoma Cohort  
The Leeds Melanoma Cohort is the largest cohort in the world of primary melanoma 
patients consisting of 2184 melanoma patients recruited in the period between 2001 and 
2012 and who have consented to the use of their medical records and tissue samples 
(MREC 01/3/057). Participants also gave consent to allow researchers to access their 
medical records and flag them with the Office for National Statistics (ONS) to enable 
ascertainment of the date and cause of their death should they die. Patients were 
recruited with the help of specific pathology and clinical registers within a geographically 
defined area of the Northern part of the UK, as shown in Figure 2.1, with further 
recruitment from 32 other clinical centres that also undertake sentinel node biopsy (total 
342 recruits) and of rare subtypes with melanomas arising in sun-protected sites (total 
76 recruits). Patients were subsequently invited to participate at 3 months after diagnosis 
with the intention of interviewing and sampling them within a defined period of between 
3 to 6 months after diagnosis. There was some variability in how quickly patients 
responded and the median time to interview was found to be 5.2 months. Each patient 
completed a series of detailed questionnaires, which included questions about their drug 
usage history, concurrent illnesses and smoking status at recruitment [33].  
Cohort members were then followed up both directly (by annual re-contact of the majority 
of the participants) as well as passively by regular review of national registers and their 
medical records.  For each patient responding to an annual follow up review, information 
regarding drugs and co-morbidities was supplemented: 1647 of the 2184 agreed to at 
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least one annual review. In cases were patients died, the death certificate (or cause of 
death data taken from the death certificate obtained from the office of national statistics 
(ONS)) and medical records were obtained.  Melanoma specific survival (MSS) data was 
generated by research nurses and Professor Newton-Bishop who reviewed the evidence 
relating to cause of death from these sources and determined whether the cause of death 
for each case was melanoma related or non-melanoma related.  Thus a cancer registry 
reported cause of death was assessed and compared with medical records (primary, 
secondary and tertiary care) and patient reports of disease progression to derive the best 
possible measure of melanoma specific death [33]. 
 
Figure 2.1: Leeds Melanoma Cohort and location of Leeds on a map of  the UK 
 
2.3 Data collected from cohort 
At the point of recruitment into the cohort patients were asked to complete a 
questionnaire that included information regarding weight and height (from which BMI was 
calculated); usage of drugs and over the counter medication as discussed in detail below, 
diabetes at diagnosis; and smoking history. Variables for each of these measures were 
created from the Cohort questionnaire data. Seasonally adjusted serum vitamin D levels 
were generated by fitting levels in a linear model with test batch and season of blood 
draw (Jan‐Mar, Apr‐Jun, Jul‐Sep, Oct‐Dec) using Apr‐Jun as the baseline. Vitamin D 
levels were classified as either deficient (less than 20 nmol/L), suboptimal (20–59.9 
nmol/L) and three further levels of sufficient vitamin d levels – (60-84.9nmol/L), (85-
99.9nmol/L), and (>100nmol/L). The 20–59.9 nmol/L category was used as the baseline 
Leeds 
41 
as this was the largest group. BMI (kg/m2) was classified using the standard classification 
system defined by the World Health Organization of underweight (<18.5), normal (18.5–
25), overweight (25–30) and obese (30+) [33]. 
In addition to this, cases were also interviewed about whether they had diabetes and 
also with regards to their smoking habits. Four smoking‐related variables were generated 
from these data: patient ever regularly smoked (yes/no); patient current smoker (yes/no); 
duration for which patient smoked (in 5 year units); and an estimate of the quantity the 
patient smoked in pack years based upon self-reported consumption of commercial 
cigarettes, hand rolls, small cigars, large cigars and/or pipe tobacco (in units of 10 pack‐
years). Breslow thickness and ulceration status were derived from histopathology 
reports; in instances where no explicit mention of ulceration was made it was assumed 
that the primary had not been ulcerated. Survival time was defined as the period between 
the date of surgical excision of the primary and date of melanoma-specific death or last 
date of follow‐up (at which point records were censored). Cases with multiple primaries 
and/or who had responded to the request to participate later and were therefore recruited 
more than 2 years after diagnosis, were excluded from survival analysis [33]. 
 
2.4 Drug Data Collection  
Drug data provided by the patient at the time of recruitment in the form of completed 
questionnaires were further supplemented with data from annual follow up data collection 
in patients who participated in these. Further data was then obtained from GP records in 
cases where the GP did return data.  
Once received, the GP records were firstly anonymised and then the data linked to the 
cohort via study numbers and then I scrutinised drug exposure data individually for each 
patient in the cohort. I then combined these data with the drug information from the initial 
questionnaire as well as the annual questionnaires for the patients participating in annual 
follow up (See Appendix A) which was a significant undertaking given the large numbers, 
accounting for much of the time on the project and this triangulation process helped to 
ensure optimal quality of data given the three sources as shown in the Figure 2.2 below. 
All patients provided drug data on recruitment into the cohort and 1647 of these agreed 
to at least one annual follow up. There were 1152 patients for whom we received GP 
returns and out of these 901 patients also had at least one annual follow up returned. 
251 patients had GP returns only with no annual follow-up data at all, leaving 286 patients 
with just the data provided at the time of recruitment into the study as shown in Figure 
2.2.  
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Figure 2.2: Sources of data including overlap between GP return data and annual 
follow up data 
 
As seen in Table 2.1 and Table 2.2 there were 1647 patients who had at least one annual 
follow, 1140 with at least two and 249 patients who had 5 years of annual follow up. 
 
Table 2.1: Breakdown of follow-up return data based on minimum number of 
returns per patient 














only - 286 
Total GP returns = 1152 
(251+ 901) 
At least one annual 
follow up = 1647 
 (901 +746) 
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Table 2.2: Number of patients followed up per year 







Information regarding the name of the drug, the British National Formulary (BNF) code, 
dosage, frequency and start date/end date or last known date of being on the drug were 
also recorded.  Only medications prescribed for more than a month were recorded as 
anything less than this was felt to be unlikely to result in a biological effect. Duration of 
drug usage was measured as the time between reported starting taking of the drug and 
stopping or until date of interview; cases for which no start date could be attributed were 
treated as missing data. Only drugs given systemically were included on the basis that it 
was postulated that their effects would be more consistent and measurable and therefore 
topical treatments, inhalers, and supplements were also excluded, which as will be 
discussed may be a limitation of the study. On occasions where no clear start/end date 
were available, the first known point at which a drug was started or the last available 
known point at which they were on a drug were recorded.  
In most of the literature, researchers have classified duration of use of drugs in terms of 
short-term use versus long term use, but these studies have been concerned with 
investigating the effects of drugs on new cancer incidence whilst in our study we looked 
at relapse. As a result the time scales used in our study were considerably shorter and 
grouping of duration of drugs for the point of analysis had to take this into consideration. 
Furthermore, we considered comparing exposures at different dosages as suggested in 
the literature (low dose aspirin vs high dose aspirin for example) but given the short time 
scales as above, this led to further loss of power as well as further difficulties when trying 
to work out when dose changes occurred in the same patient and on discussion with the 
in-house statisticians I decided not to examine dosages in my analysis. Furthermore, as 
will be discussed in the results chapters, in most cases, patients were actually found to 
be on a standard dose of the drugs in question making it less likely that we would have 
missed a dose related effect. 
Decisions about data analysis based upon biochemical groupings, functional analyses, 
and management of treatment over different time periods were made by: 
• Examining the data and determining the distribution of exposures 
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• Consultation with Dr Barry Strickland-Hodge (Retired Senior Pharmacy Lecturer, 
University of Leeds)  
 
2.5 Drug Grouping and Classification 
All drugs recorded for the study were labelled with their designated British National 
Formulary (BNF) Code and this was considered to be the main reference for classifying 
and potentially grouping drugs with similar biochemical profiles and actions, with the 
intention of potentially increasing our statistical power for some of the rarer drugs. 
Common drugs were initially sub-classified as shown in Appendix B with the help of 
Senior Pharmacy Lecturer (Dr Strickland-Hodge). However, grouping of drugs with 
different BNF codes but presumed similar actions (Immunosuppressants for example) is 
fraught with high potential for error as the mechanism of action for the individual drugs 
is so varied. Furthermore, as can be seen from my literature analysis as well as the 
reviews specific to the individual drugs, the effects of drugs on melanoma and other 
cancers seem to be very specific to individual drugs within the same class of drugs, e.g. 
some effects are only seen with aspirin and simvastatin but not with the other cox 
inhibitors or other statins for instance. Additionally, many patients are switched between 
different drugs in the same class at different time periods, including being switched back 
to a previously taken drug. For instance, some patients would start out on simvastatin to 
control their hypercholesterolemia but then be switched to atorvastatin if they had for 
instance a stroke or a heart attack. A proportion of these, were subsequently found to 
have been switched back to simvastatin either as a result of side effects with atorvastatin, 
or due to cost saving measures. Having discussed this issue with our statisticians this 
was felt to be too complex for our proposed analysis methods as well as the fact that 
analysis of individual drugs would be a much cleaner approach in terms of looking for 
effects and any proposed underlying biological pathways.  
 
2.6 BMI and Diabetes data as part of the Metabolic Syndrome 
The data with regards to BMI and diabetes were readily available for the cohort and were 
used in analysing melanoma survival outcomes and together with the incidental drug 
exposures were the main focus of my thesis as my title suggests. However, ideally, I 
would have liked to investigate all the parameters of the metabolic syndrome including 
lipid profile and blood pressure. Unfortunately this was found to be inconsistently 
recorded in our cohort and although I looked at capturing this data by recording the use 
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of an anti-hypertensive as a marker that a patient has a diagnosis of hypertension, this 
was flawed by the fact that certain drugs like diltiazem or bisoprolol can be used both as 
an anti-hypertensive but also to treat arrhythmia and this approach was abandoned.  
Also as previously mentioned the approach is complicated as both the drugs mentioned 
and the disease states for which they are prescribed could can have an effect on 
melanoma outcome. 
 
2.7 Study Design 
To achieve the aims of my thesis, several research designs could have been be 
considered. These include prospective cohort study, retrospective cohort study or a case 
control study potentially using telephone surveys or pharmacy databases. However, 
given access to this large cohort dataset as well as considering my aims and the agnostic 
approach adopted, a study design that allows one to consider multiple possible factors 
in the form of an observational longitudinal cohort study was felt to be an ideal starting 
point.  
For the majority of the candidate drugs such as aspirin and statins, it is reasonable to 
assume that exposure allocation is unrelated to the outcome of interest, melanoma. 
Considering the fact that at the time of prescribing a drug, both the doctor and the patient 
are completely unaware of any potential effects on melanoma, the prescriber is 
effectively blind for the potential effect being investigated. It has been postulated that in 
such scenarios observational research may be as credible as randomised controlled 
trials [206]. 
 
2.8 Analysis of data 
An issue considered in the early phases of the work described, was that many individuals 
in the study reported the use of multiple drugs and therefore I had to consider means of 
dealing with concurrent exposures in this observational study. Ideally then I would have 
considered exposure to combinations of therapies as well as individual exposures. 
However in discussion with my supervisors and the section statistical group, it was 
concluded that the study size was insufficient to allow this comparison and therefore that 
in this initial analysis, I would consider exposures to single drugs with an agnostic 
approach, accepting that this is a weakness of this approach. 
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Selection of an appropriate analysis method for investigating the effects of drugs on 
melanoma survival was one of the most challenging aspects of our study. We considered 
the following analysis methods and their limitations 
2.8.2 Ever-never analysis 
This is the simplest and most frequently used analysis method in the literature and 
divides the cohort into patients that have been exposed to the drug at some point (we 
only included patients into this group if we had evidence that they had been on the drug 
for at least 30 days) and those that had never been exposed to the drug in question. 
Although this type of analysis works well in studies looking at the effects on incidence of 
cancer, in studies like ours looking at survival, it does however introduce a potential bias 
referred to as the guarantee-time bias. This refers to the bias introduced by comparing 
survival across groups, which are defined by an event, which can occur at any time 
during the follow-up period. Patients experiencing the event may do so at any time during 
the study, with the likelihood being higher if the patient survives. 
2.8.3 Duration Analysis 
This analysis, which again is used routinely in studies looking at incidence of cancer, 
takes account of the effects of duration of usage of the drug in question. In a cohort study 
this however introduces a very obvious bias referred to as a survivorship bias whereby 
patients who have survived the longest would have in effect been on the drug for longer 
in which case it would be impossible to determine whether the drug allowed them to 
survive longer or whether they were on the drug longer because they survived longer for 
an unrelated reason. This bias, in addition to the lack of accurate drug use data over 
time in our cohort, precluded our use of this method of analysis. 
2.8.4 Drug usage up until diagnosis 
This method of analysis essentially replicates the traditional methods used in cancer 
incidence studies with no inherent bias but as the Leeds Melanoma Cohort data was not 
collected with this type of analysis in mind, we experienced problems with the poor 
quality data available before diagnosis and with some loss of power due to exclusion. 
Table 1 below demonstrates our power calculations and the likelihood of determining the 
degree of changes in hazard ratios proposed. Despite the limitations above, given the 
lack of any bias we included this type of analysis in our study. 
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2.8.5 Time-dependent or time-varying covariate analysis 
This type of analysis is particularly suited for survival analysis and aims to minimise the 
biases discussed above. It reflects the phenomenon that a covariate such as drug use 
is not necessarily constant through the whole study. For instance, a patient may have 
been on and off a drug at different time points in the study and this could then be 
introduced in the statistical model as a time-varying covariate. In survival analysis, this 
would be done by splitting each study subject into several observations, one for each 
period of drug use/non-use. This method of analysis apart from being very complicated 
was not ideally suited to our data as we had to make some assumptions regarding 
continued use of drugs due to a lack of such specific drug usage data. The results from 
this type of analysis were therefore largely unchanged for any drug in our cohort and the 
approach was abandoned (See Appendix C).  
 
2.9 Statistical Methods 
The effects of exposure to different classes of drugs on melanoma specific (MS) and 
overall survival (OS) were assessed using Cox Proportional Hazards models. Data was 
first checked to ensure that the proportional hazards assumption was met. Hazard ratios 
(HR) and 95% Confidence intervals (CI) were estimated and Kaplan-Meier curves were 
plotted. Firstly, unadjusted models were examined and then adjustment for common 
confounders were applied; firstly gender and age at diagnosis, then Breslow thickness, 
ulceration, other comorbidity measures (smoking, body mass index (BMI), and serum 
level of vitamin D adjusted for seasonal variation. Analyses was conducted both with and 
without adjustment for stage (represented by Breslow thickness and ulceration), since a 
drug may influence outcome through an effect on the growth of the tumour, which may 
be captured by stage at diagnosis. No adjustment was made in the analyses for adjuvant 
cancer therapy since no therapy has been shown to influence melanoma survival until 
very recently. All the data was analysed using STATA 12.1 software (Stata Corp., 2003).  
Multiple testing will be accounted for in these analyses by using Bonferroni correction to 
adjust the family wise error rate to 5%. The below power calculations have been run 
assuming the type I error rate is 0.1% which would be equivalent to a test at the 5% level 
adjusted using the Bonferroni correction for 50 simultaneous tests. Table 2.3 below 
shows the results of power calculations for our cohort and the resultant minimum 
detectable hazard ratios. The hypothesis-generating analysis looking for associations 
between other drugs and outcome will be conducted in a similar fashion using Cox 
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proportional hazard models. Significant findings would then need to be validated, by 
combining data from other large registries.  
 
Table 2.3: Power Calculations 
Prevalence of risk factor 
Minimum detectable hazard ratio 
80% 90% 
331 melanoma specific deaths 
0.03 2.5 2.8 
0.11 1.6 1.8 
0.15 1.5 1.6 
0.2 1.5 1.6 
0.3 1.4 1.5 
0.4 1.4 1.4 
417 deaths from any cause 
0.03 2.2 2.5 
0.11 1.6 1.7 
0.15 1.5 1.6 
0.2 1.4 1.5 
0.3 1.3 1.4 
0.4 1.3 1.4 
 
As shown in Chapter 3, based on our power calculations above, I then determined for 
which drugs in the cohort I had sufficient statistical power. I also combined this with 
evidence from the literature of previous reports of effects in cancer and melanoma (see 
extract example in Appendix C) and finally ended up examining three drugs in more 
detail, namely aspirin (Chapter 4), statins (Chapter 5) and metformin (Chapter 6) followed 
by an overall discussion (Chapter 7) where I also discuss in detail the pros and cons of 




Descriptive analysis of cohort and results 
3.1 Aims  
The aims of this chapter are:  
• To describe the characteristics of the Leeds Melanoma Cohort used in the thesis; 
• To examine the effects of BMI and diabetes as part of the metabolic syndrome in 
our cohort; 
• To summarise the literature survey approach and drug classes that have been 
reported to have effects on melanoma incidence and survival; 
• To identify potential drug exposures of interest in our cohort and demonstrate 
survival analysis results for a selection of drugs examined; 
• To describe how I arrived at the main drugs that will be covered in detail in the 
ensuing chapters of my thesis and to examine how commonly these are used 
together. 
 
3.2 Characteristics of the Leeds Melanoma Cohort 
As outlined in the last chapter, the Leeds Melanoma Cohort is the largest cohort in the 
world of primary melanoma patients consisting of 2184 melanoma patients recruited in 
the period between 2001 and 2012 from a geographically defined area of the Northern 
part of the UK, with additional recruitment from 32 other clinical centres carrying out 
sentinel node biopsy (total 342 recruits). To increase the data set of rare subtypes 
(melanomas arising in sun-protected sites) was the second reason for broadening 
recruitment to additional centres (total 76 recruits). Cases with multiple primaries and/or 
nodal primaries (patients with presenting with lymph node disease in the absence of a 
known skin primary) who had responded to the request to participate later and were 
therefore recruited more than 2 years after diagnosis, were excluded (67 patients) from 
the survival analysis as outlined in this chapter leaving 2117 patients for the purposes of 
my analysis. 
As outlined in the methods chapter, each participant completed detailed questionnaires, 
which included questions about their drug usage history, concurrent illnesses, 
information regarding weight and height (from which BMI was estimated), diabetes status 
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and smoking history. Variables for each of these measures were created from the Cohort 
questionnaire data, as outlined below, in order to examine the components of the 
metabolic syndrome (BMI and Diabetes) as per my aims.   
A variable for vitamin D levels was generated by fitting levels in a linear model with test 
batch and season of blood draw (Jan‐Mar, Apr‐Jun, Jul‐Sep, Oct‐Dec) using Apr‐Jun as 
the baseline. This was necessary to allow for seasonal variation in vitamin D level. The 
justification for seasonal adjustment was that deficiency is known to predict bone health 
and higher summer levels might obscure winter nadirs if the data were not adjusted. 
Vitamin D levels were classified as either deficient (less than 20 nmol/L), suboptimal (20–
59.9nmol/L) and three further levels of sufficient vitamin D levels – (60-84.9nmol/L), (85-
99.9nmol/L), and (>100nmol/L). I used the 20–59.9nmol/L category as the baseline as 
this was the largest group.  
Body mass index (BMI kg/m2) was classified using the standard classification system 
defined by the World Health Organization of underweight (<18.5), normal (18.5–25), 
overweight (25–30) and obese (30+). The two main smoking‐related variables used in 
my analysis below, generated from these data were: patient ever regularly smoked 
(yes/no); patient current smoker (yes/no). Breslow thickness and ulceration status were 
derived from histopathology reports; in instances where no explicit mention of ulceration 
was made it was assumed that the primary had not been ulcerated. Survival time was 
defined as the period between the date of surgical excision of the primary and date of 
death or last date of follow‐up (at which point records were censored) and I also analysed 
overall survival in addition to melanoma specific survival for each drug.  
The characteristics of the Leeds Melanoma Cohort are summarised in Table 3.1. 
Patients ranged from 17 to 90 years of age (mean age 54) as shown in the table and 
depicted in Figure 3.1. Of the 2117 patients 57% were female and 43% were male. In 
terms of risk factors for the metabolic syndrome within our cohort, 4% of patients were 
diabetic and 63% of patients were overweight or obese and with 22% being specifically 
classed as obese (Figure 3.2). In terms of smoking, 45% of patients had smoked at some 
point in their life whilst only 26% were current smokers. In terms of Breslow thickness 
the majority of patients (39%) had melanomas between 1.01-2.00mm in thickness with 
the thicker tumours (>4mm) only accounting for 11% with just 20% of tumours being 
ulcerated. In terms of Vitamin D levels, a large proportion (73%) had a less than normal 
Vitamin D (<60nmol/L). With regards to melanoma outcomes within the cohort, 427 
patients (20%) of the cohort relapsed from their melanoma whilst 343 (16%) eventually 
died from their melanoma and 86 (4%) died from causes other than melanoma as shown 
in Table 3.1 below. Figure 3.3 below shows the various body sites of the primary 
melanomas in the cohort with the back being the most common site. 
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Table 3.1: Leeds Melanoma Cohort 
For some variables, the summed total is less than the total number of patients 
because of missing values. 
Baseline Characteristics n (%) 
Total no of patients 2,117(100) 
Gender  
     Female 1208 (57) 
     Male 909 (43) 
Diabetes   
     No 1948 (96) 
     Yes 81 (4) 
Body Mass Index  
     </=24.9kg/m2 790 (38) 
     >24.9-29.9kg/m2 854 (41) 
     >29.9kg/m2 455 (22) 
Vitamin D  
     <20nmol/L 108 (6) 
     20-59.9nmol/L 1157 (67) 
     60-84.9nmol/L 391 (23) 
     85-99.9nmol/L 54 (3) 
     >100nmol/L 25 (1) 
Ever-Never Smoked   
     Ever Smoked 917 (45)    
     Never Smoked 1126 (55) 
Current Smoking Status  
     Not currently smoking 679 (74)    
     Currently smoking 239 (26) 
Breslow thickness  
     </=1mm 595 (28) 
     1.01-2mm 806 (39) 
     2.01-4mm 464 (22) 
     >4mm 228 (11) 
Ulcerated Tumour  
     Yes 429 (20) 
     No 1682 (80) 
No of patients who relapsed 427 (20) 
No of patients who died from Melanoma 343 (16) 
No of patients who died from other causes 86 (4) 
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Figure 3.1: Distribution of age at diagnosis for LMC 
  
 




Figure 3.3: Sites of primary melanomas within the LMC 
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3.3 Effect of BMI and Diabetes on melanoma survival in the 
LMC 
Before I examined the effects of incidental drug exposure, I needed to understand the 
relationship between the comorbidities being treated and melanoma survival. As per my 
aims I therefore assessed this by examining the association of BMI and Diabetes on 
melanoma survival in the LMC as outlined in the methods chapter by undertaking a Cox’s 
proportional hazards regression analysis of melanoma-specific and overall survival 
dependent on BMI and diabetes separately. I first undertook an unadjusted analysis and 
then adjusted for known co-founders using the same approach I did with the incidental 
drug exposures.  
3.3.1 BMI and melanoma survival in the LMC 
As shown in Table 3.1 above, 63% of patients were classed as overweight or obese, 
with 22% being specifically classed as obese, which is less than what would be expected 
in the population as evidence suggests that (as discussed in Chapter 1), one third of the 
UK population are reported to be obese.  
Table 3.2 below shows the results of the Cox’s proportional hazards regression analysis 
of melanoma-specific and overall survival dependent on patients’ body mass index. For 
both MSS and OS, the unadjusted model appears to show a statistically significant 
negative association with survival. However, increasing age and male sex are known 
predictors of melanoma survival but also for overall survival and when the model was 
adjusted for age at diagnosis and sex, these associations were no longer statistically 
significant and remained non-significant even in the multivariate analysis. This would 
therefore suggest that BMI in our cohort does not appear to have a directly significant 
association on survival for either MSS or OS. This could be a power effect if the risk is 
small, but the observation suggests that there was no strong association between 




Table 3.2: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival dependent on patients’ body mass index 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration. Significant p-values are in bold. 





 HR (95% CI) p-value HR (95% CI) p-value 
Unadjusted or crude 
model 
1.01 (0.99-1.04) 0.074 1.02 (1.00-1.04) 0.055 
Adjusted for age at 
diagnosis and sex 
1.01 (0.98-1.04) 0.298 1.01 (0.99-1.03) 0.320 
Adjusted for age at 
diagnosis, sex and Breslow  
1.005 (0.98-1.02) 0.625 1.01 (0.98-1.02) 0.630 
Adjusted for other risk 
factors* 
1.01 (0.99-1.04) 0.364 1.01 (0.98-1.04) 0.468 
 
3.3.2 Diabetes and melanoma survival in the LMC 
As shown in Table 3.1 above, 81 patients (4%) in the cohort were diabetic. Table 3.3 
below shows the results of the Cox’s proportional hazards regression analysis of 
melanoma-specific and overall survival dependent on diabetes. In both MSS and OS, 
the unadjusted model appears to show a statistically significant negative association with 
survival. However, as shown above and as will be shown with the same analysis for 
incidental drugs, increasing age and male sex are known predictors of melanoma 
survival and when the model is adjusted for age at diagnosis and sex, these associations 
were no longer statistically significant for MSS. Interestingly the negative association with 
overall survival remains significant despite adjusting for age and sex although the 
significance just disappears when adjusting for Breslow. The association remained 
statistically significant in the multivariable analysis suggesting that although diabetes 
does not appear to have a directly significant effect on melanoma specific survival it does 
predict overall survival. Given that a diagnosis of diabetes is associated with a greater 
mortality in the general population, the association with overall survival seen would be in 
keeping with this [207]. 
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Table 3.3: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival dependent on diabetes status 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, body mass index, vitamin D levels, ulceration. Significant p-values are in 





 HR (95% CI) p-value HR (95% CI) p-value 
Unadjusted or crude model 1.85 (1.19-2.88) 0.006 2.16 (1.47-3.18) <0.001 
Adjusted for age at 
diagnosis and sex 
1.37 (0.87-2.14) 0.164 1.52 (1.03-2.24) 0.034 
Adjusted for age at 
diagnosis, sex and Breslow 
1.24 (0.80-1.94) 0.336 1.43 (0.97-2.10) 0.073 
Adjusted for other risk 
factors* 
1.51 (0.74-3.07) 0.250 2.37 (1.31-4.30) 0.004 
 
In conclusion, from our analysis above it can be seen that in our cohort neither BMI nor 
diabetes alone appear to have a statistically significant association on melanoma specific 
survival although diabetes does appear to effect overall survival, and I cannot exclude a 
small association not detectable with confidence in this data set. This therefore would 
appear to reduce the complexity of any subsequent analysis of incidental drugs although 
I will continue to adjust for both BMI and diabetes in my drug analysis.  
As discussed in Chapter 1, diabetic men have been shown to have inferior cancer 
outcomes and some studies have also demonstrated an elevated risk of CM with 
increasing BMI just among men [115]. Given this literature evidence of differential effects 
on sex in terms of diabetes and obesity and associations with cancer I therefore also 
undertook a stratification by sex analysis as shown in Table 3.4. 
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Table 3.4: Diabetes and Obesity – stratification by sex 
* Adjusted for age at diagnosis and Breslow’s thickness. Significant p-values are in 
bold figures 








Melanoma-specific     
     Male 1.68 (1.00-2.82) 0.050 0.99 (0.96-1.03) 0.588 
     Female 0.71 (0.29-1.74) 0.449 1.02 (0.99-1.05) 0.205 
Overall survival     
     Male 1.77 (1.11-2.81) 0.016 1.01 (0.97-1.04) 0.740 
     Female 0.98 (0.48-2.00) 0.951 1.01 (0.98-1.04) 0.576 
 
The table above shows an association of men with diabetes having a significantly poorer 
overall survival with a HR (OSS) of 1.77 (95% CI 1.11-2.81, p= 0.016) whilst diabetic 
men in the cohort also appear to have a negative association with melanoma survival 
which just falls short of being statistically significant with  HR (MSS) of 1.68 (95% CI 
1.00-2.82, p= 0.050). This would be in keeping with the literature evidence of such 
associations with diabetes in men for both for overall and melanoma specific survival as 
discussed in Chapter 1 [208]. 
As shown there appears to be no association between sex and obesity on either MSS or 
OS in our cohort which is contrary to the studies that have demonstrated an elevated 
risk of CM with increasing BMI particularly among men as referenced above. It is possible 
that this could be due to the fact that as pointed out earlier, only 22% of our cohort are 
classed as obese, which is less than what would be expected in the population as 
evidence suggests that (see Chapter 1), one third of the UK population are reported to 
be obese. 
 
3.4 Summary of literature survey approach for drug selection 
In order to gain insight into the current evidence for incidental drug exposures and 
chemoprevention in melanoma and cancer incidence and survival, a comprehensive 
literature review was undertaken (Figure 3.4).  
An initial search was conducted on Pubmed using the terms melanoma and 
chemoprevention in the first instance to get an overview of the topic but then followed by 
separate searches with specific drug names and “cancer” and “melanoma” and any 
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reported effect on cancer in general and on melanoma specifically, were then recorded 
in a database along with the specific reference and article summary (see extract from 
database in Appendix C). In order to identify relevant drugs for analysis I then cross-
referenced my findings with the most common drugs used in our cohort that would give 
me the best statistical power as described in the next section. 
 
 
Figure 3.4: Search strategy to identify drugs affecting survival in melanoma 
 
Examination of the results of my literature survey revealed some recurring drug groups 
with a body of evidence of reported effects on cancer and in melanoma but in most cases 
pertaining to melanoma incidence rather than survival. The main groups that emerged 
with evidence in human studies on melanoma included NSAIDs (including selective 
cyclooxygenase-2-inhibitors and in particular aspirin), statins, fibrates, and retinoids.  
In addition to this, other drug groups like b-blockers, ace inhibitors, and calcium channel 
antagonists, which are commonly prescribed for high blood pressure, were also reported 
in the literature to have potential effects on cancers including in melanoma although there 
were also several reports showing no effect. As described in Chapter 1, melanoma is a 
very immunogenic tumour and is susceptible to the effects of immunosuppressants and 
Database: Pubmed
Terms: Melanoma AND Chemoprevention 
Terms: + Last 10 Years 
Database: Pubmed
Terms: Melanoma AND Name of drug AND
last 10 years AND cancer AND English
Articles screened on basis of title and abstract
Most studies related to incidence of Melanoma
Cross-referenced with cohort drug data
Evidence collated for each drug and then cohort 
drug data examined for usage and sufficient 
statistical power to be analysed
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I was therefore also keen to see if any of these prescribed to patients in the cohort for 
treatment of conditions other than melanoma could be moderating survival.  
Finally, metformin, a drug used in diabetes, has been previously shown in a smaller 
unpublished study looking at usage in our cohort, to have a trend towards a negative 
effect on melanoma survival. Although the literature in terms of epidemiological studies 
suggest a potentially positive association on melanoma outcome in patients some 
laboratory studies of melanoma cells with somatic BRAF mutations have shown that 
metformin has a negative effect on these cells as will be discussed in more detail in 
chapter 6. In addition, due to its potential link with chronic inflammation and the metabolic 
syndrome, metformin was therefore also of particular interest in this study.  
 
3.5 Identification of relevant drug exposures within Leeds 
Melanoma Cohort 
In order to identify relevant drug exposures, it was important to look at the prevalence of 
the relevant exposures and compare this with our power calculations and then tie it in 
with the results of the literature review above. I therefore firstly looked at the number of 
patients on medications as listed in Table 3.5 below by searching based on ever-never 
exposure and the specific BNF codes.  
As discussed in the methodology section these BNF groups contain quite a 
heterogeneous group of drugs and cannot be analysed in this manner and need to be 
broken down into individual drugs. At this point it is worth re-visiting our power 
calculations as shown in Table 3.6 below. As can be seen a prevalence of 3% (0.03) (a 
drug being used in 3% of the cohort) gives us the ability only to identify a significant 
change in hazard ratio for MSS of 2.5 or 2.8 with 80% and 90% power respectively whilst 
at a prevalence of 15-20% (0.15-0.20) our power increases substantially as highlighted 
in the table. This sort of prevalence of 15-20% of a drug in our cohort would equate to 
between 317 to 423 exposures respectively to the particular drug. Although I am still able 
to analyse drugs below this threshold, I would only be able to pick up very significant 
changes in hazard ratios in terms of the effect of the drugs on MSS. 
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Table 3.5: Drug use by British National Formulary classification 
BNF, British National Formulary 
BNF Classification No. % 
1: Gastrointestinal system 1,434 8.22 
2: Cardiovascular system 7,215 41.38 
3: Respiratory system 1079 6.19 
4: Central nervous system 2,298 13.18 
5: Infections 276 1.58 
6: Endocrine 1480 8.49 
7: Obstetric and genitourinary 717 4.11 
8: Malignant disease and immunosuppression 216 1.24 
9: Nutrition and blood 501 2.87 
10: Musculoskeletal and joint disease 1,106 6.34 
11: Eye 262 1.50 
12: Ear, nose and throat 162 0.93 
13: Skin 692 3.97 
Total 17,438 100.00 
 
Table 3.6: Power Calculations 
Prevalence of risk factor 
Minimum detectable hazard ratio 
80% 90% 
343 melanoma specific deaths 
0.03 2.5 2.8 
0.11 1.6 1.8 
0.15 1.5 1.6 
0.2 1.5 1.6 
0.3 1.4 1.5 
0.4 1.4 1.4 
429 deaths from any cause 
0.03 2.2 2.5 
0.11 1.6 1.7 
0.15 1.5 1.6 
0.2 1.4 1.5 
0.3 1.3 1.4 
0.4 1.3 1.4 
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I therefore examined this further by looking at the power for the drugs in the literature 
above as having effects on cancer. 
 
Table 3.7: Drugs from literature review 
Drugs of interest from 
literature review 
Sufficient number of individual drugs in cohort 
for meaningful analysis? 
Aspirin Yes- see analysis below 
Statins Yes- see analysis below 
Fibrates 
No- only 37 patients on bezofibrate, ezetimibe and 
fenofibrate together 
Retinoids No- only 2 patients on Acitretin noted 
B blockers Yes- see analysis below 
Ace inhibitors Yes- see analysis below 
Calcium channel 
antagonists 
Yes- see analysis below 
Immunosuppressants No- See table below for breakdown 
Metformin 
Yes- but power sufficient only to detect a significant 
change in HR - see analysis below 
 
As can be seen, unfortunately there were not enough patients on fibrates, retinoids or 
individual immunosuppressants to carry out a meaningful analysis.  
Next, I looked at individual drugs with the largest frequency of use (giving us the most 
power) together with the ones specifically reported in the literature (Table 3.8). 
Table 3.8: Frequency of regular drugs ever taken by participants 
NSAID, non-steroidal anti-inflammatory 
Drug Yes - No. (%) No  - No. (%) 
Aspirin 347 (16.39) 1,770 (83.61) 
Atorvastatin 116 (5.48) 2,001 (94.52) 
Clopidogrel 34 (1.61) 2,083 (98.39) 
Metformin 88 (4.14) 2,040 (95.86) 
NSAID 255 (12.05) 1,862 (87.95) 
Omeprazole 177 (8.31) 1,952 (91.69) 
Simvastatin 345 (16.20) 1,785 (83.80) 
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Of the drugs reported in the literature, as can be seen aspirin and statins were the most 
commonly used drugs and therefore the ones for which the study was better powered. 
As metformin has previously been shown to have a possible negative association in an 
unpublished study from our cohort this was also selected for detailed analysis despite 
the low statistical power. These three drugs (aspirin, statins, and metformin) will be 
presented separately in the ensuing chapters although I will examine how many of the 
same patients are each of these groups at the end of this chapter. 
Given the immunogenic nature of melanoma as discussed earlier, I was keen to examine 
the types of immunosuppressants our cohort had been exposed to and this is presented 
in Table 3.9 below. The 14 patients on Mycophenolate Mofetil were the largest group on 
an individual drug, which would give us insufficient power to carry out a meaningful 
analysis. Also, as can be seen, a number of these drugs were used to treat the 
melanoma itself and therefore this could not be explored further although this would be 
something that could be important to examine in any potentially larger validation cohorts 
for my study generally.  
I did however examine a number of the other drugs in our cohort based on the literature 
evidence and prevalence in our cohort but none of this showed any statistically significant 
results as summarised in Table 3.10. Since I designed my study proton pump inhibitors 
such as omeprazole have attracted much attention as modifiers of the gut microbiome  
which is now understood to be related to host immune responses to melanoma [209]. 
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Table 3.9: No. of patients receiving immunosuppressant drugs or chemotherapy 
Immunosuppressant/Chemotherapy No. % 
Azathioprine 3 0.10 
Bevacizumab 5 0.16 
Capecitabine 1 0.03 
Chlorambucil 3 0.10 
Ciclosporin 1 0.03 
Cyclophosphamide 8 0.26 
Dacarbazine  1 0.03 
Estramustine 2 0.07 
Fludarabine 2 0.07 
Fludarabine 2 0.07 
Hydroxycarbamide 3 0.10 
Imatinib 1 0.03 
Interferon alpha 1 0.03 
Melphalan 1 0.03 
Methotrexate 4 0.13 
Miscellaneous 1 0.03 
Mycophenolate mofetil 14 0.46 
Prednisolone 1 0.03 
Rituximab 3 0.10 
Sirolimus 1 0.03 
Sunitinib 2 0.07 
Tacrolimus 6 0.20 
Temozolomide 3 0.10 
Thalidomide 1 0.03 
Vemurafenib 7 0.23 
Vindesine 1 0.03 




Table 3.10: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients who received a given drug (ever-never) 
Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. 
 Hazard Ratio P-value 95% Confidence Intervals 
Melanoma-Specific Survival 
Diclofenac 1.16 0.53 (0.73, 1.82) 
Omeprazole 1.09 0.67 (0.73, 1.63) 
Atorvastatin 0.67 0.12 (0.40, 1.11) 
Overall Survival 
Diclofenac 0.97 0.91 (0.62, 1.53) 
Omeprazole 1.17 0.40 (0.81, 1.68) 
Atorvastatin 0.69  0.11 (0.44, 1.08) 
 
As shown in Table 3.10 above, there is no evidence of any significant associations with 
ever use of diclofenac, omeprazole or atorvastatin on either overall survival or melanoma 
specific survival. 
I have also shown the complete results in terms of our analysis subtypes as per our 
methodology below for a selection drugs after this for atenolol (Table 3.11 - Table 3.14), 
bisoprolol (Table 3.15 - Table 3.17) and diclofenac (Table 3.18 - Table 3.22). 
3.5.1 Atenolol 
As per Table 3.11 looking at the characteristics of patients on atenolol, the majority of 
these were women (95, 50.80%) although the difference between men and women was 
not statistically significant (p<0.070). In terms of BMI, patients on atenolol were more 
likely to be overweight or obese (p<0.001) which given that atenolol is used in patients 
with high blood pressure would be in keeping with this finding.  
Table 3.12 demonstrates how there is no association of atenolol ever use with either 
MSS or OS in both unadjusted and adjusted models in our cohort. As mentioned 
previously this has been reported in the literature to have some associations in limited 
studies but this was not the case in my analysis. 
Table 3.13 demonstrates how there is no association of atenolol use at diagnosis (or 
within 12 months) with either MSS or OS in both unadjusted and adjusted models in our 
cohort. 
65 
Table 3.14 demonstrates how there is no association of atenolol use when stratified by 
sex with either MSS or OS in both unadjusted and adjusted models in our cohort. 
 
Table 3.11: Characteristics of patients ever treated with atenolol 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05. 
Ever Treated with Atenolol? Yes - n (%) No - n (%) P-value 
Total no of patients 187 (100) 1,930 (100)  
Gender    
     Female 95 (50.80) 1,113 (57.67) 0.070 
     Male 92 (49.20) 817 (42.33)  
Diabetes     
     No 170 (92.39) 1,778 (96.37) 
0.009 
     Yes 14 (7.61) 67 (3.63) 
Body Mass Index    
     </=24.9kg/m2 29 (15.51) 761 (39.80) 
<0.001      >24.9-29.9kg/m2 92 (49.20) 762 (39.85) 
     >29.9kg/m2 66 (35.29) 389 (20.35) 
Smoking status    
     Not currently smoking 68 (87.18)    611 (72.74)        
0.005 
     Currently smoking 10 (12.82) 229 (27.26) 
Breslow thickness    
     </=1mm 49 (26.34) 546 (28.63)        
0.144 
     1.01-2mm 62 (33.33) 744 (39.01)        
     2.01-4mm 48 (25.81) 416 (21.81)          
     >4mm 27 (14.52) 201 (10.54)       
Vitamin D    
     <20nmol/L 5 (3.03) 103 (6.56)         
0.056 
     20-59.9nmol/L 124 (75.15) 1,033 (65.80) 
     60-84.9nmol/L 33 (20.00) 358 (22.80)       
     85-99.9nmol/L 1 (0.61) 53 (3.38)         
     >100nmol/L 2 (1.21) 23 (1.46)          
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Table 3.12: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients who received atenolol (ever-never) 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
Model Parameter 
Atenolol (ever-never) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 1.29 (0.94-1.77) 1.21 (0.90-1.63) 
p-value 0.113 0.207 
Age at diagnosis & 
sex-adjusted 
HR (95% CI for HR) 0.92 (0.66-1.28) 0.87 (0.64-1.18) 
p-value 0.630 0.365 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.91 (0.65-1.26) 0.85 (0.62-1.15) 
p-value 0.555 0.287 
Adjusted for other 
risk factors* 
HR (95% CI for HR) 0.86 (0.59-1.25) 0.86 (0.61-1.22) 
p-value 0.434 0.401 
 
Table 3.13: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients who received atenolol within 12 months of 
diagnosis 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
Model Parameter 
Atenolol 
(use within 12 months of diagnosis) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 1.27 (0.91-1.80) 1.22 (0.89-1.68) 
p-value 0.158 0.225 
Age at diagnosis & 
sex-adjusted 
HR (95% CI for HR) 0.91 (0.64-1.29) 0.86 (0.62-1.18) 
p-value 0.606 0.352 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.90 (0.64-1.28) 0.84 (0.61-1.17) 
p-value 0.569 0.304 
Adjusted for other 
risk factors* 
HR (95% CI for HR) 0.87 (0.59-1.29) 0.86 (0.60-1.24) 
p-value 0.483 0.434 
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Table 3.14: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival stratified by sex in patients treated with atenolol 
*Adjusted for age at diagnosis and Breslow’s thickness. Significant p-values are in 
bold figures. HR, hazard ratio; 95% CI, 95% confidence interval. 
Sex 







Melanoma-specific     
     Male 0.90 (0.58-1.39) 0.632 1.00 (0.64-1.59) 0.984 
     Female 0.94 (0.57-1.56) 0.825 0.81 (0.47-1.40) 0.452 
Overall survival     
     Male 0.81 (0.54-1.21) 0.298 0.85 (0.56-1.31) 0.468 
     Female 0.94 (0.60-1.50) 0.798 0.85 (0.52-1.39) 0.508 
 
The above tables for atenolol have demonstrated the full range of analysis that I will carry 
out as per our methodology for our chosen drugs.  
3.5.2 Bisoprolol  
As per Table 3.15 looking at the characteristics of patients on bisoprolol, the majority of 
these were men (56, 66.67%) compared to women (28, 33.33%) and this difference was 
statistically significant (p<0.001). No other significant differences between users and 
non-users are shown in the table.  
Table 3.16 demonstrates how there is no association of bisoprolol ever use with either 
MSS or OS in both unadjusted and adjusted models in our cohort. As mentioned 
previously with atenolol, these beta-blockers have been reported in the literature to have 
some associations in limited studies but this was not the case in my analysis. 
Table 3.17 demonstrates how there is no association of bisoprolol use when stratified by 





Table 3.15: Characteristics of patients ever treated with bisoprolol 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05. 
Ever Treated with Bisoprolol? Yes - n (%) No - n (%) P-value 
Total no of patients 84 (100) 2,033 (100)  
Gender    
     Female 28 (33.33) 1,180 (58.04) 
<0.001 
     Male 56 (66.67) 853 (41.96) 
Diabetes     
     No 74 (91.36) 1,874 (96.20) 
0.029 
     Yes 7 (8.64) 74 (3.80) 
Body Mass Index    
     </=24.9kg/m2 22 (26.51) 768 (38.10) 
0.089      >24.9-29.9kg/m2 38 (45.78) 816 (40.48) 
     >29.9kg/m2 23 (27.71) 432 (21.43 
Smoking status    
     Not currently smoking 38 (80.85)    641 (73.59)        
0.269 
     Currently smoking 9 (19.15) 230 (26.41) 
Breslow thickness    
     </=1mm 21 (25.30) 574 (28.56) 
0.764 
     1.01-2mm 32 (38.55) 774 (38.51) 
     2.01-4mm 22 (26.51) 442 (21.99) 
     >4mm 8 (9.64) 220 (10.95) 
Vitamin D    
     <20nmol/L 4 (5.63) 104 (6.25)         
0.610 
     20-59.9nmol/L 48 (67.61) 1,109 (66.65) 
     60-84.9nmol/L 15 (21.13) 376 (22.60)       
     85-99.9nmol/L 4 (5.63) 50 (3.00)         




Table 3.16: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients who received bisoprolol (ever-never) 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
Model Parameter 
Bisoprolol (ever-never) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 0.65 (0.36-1.25) 1.12 (0.71-1.77) 
p-value 0.210 0.633 
Age at diagnosis & 
sex-adjusted 
HR (95% CI for HR) 0.44 (0.23-0.83) 0.68 (0.43-1.09) 
p-value 0.012 0.107 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.52 (0.27-0.98) 0.79 (0.50-1.25) 
p-value 0.045 0.315 
Adjusted for other 
risk factors* 
HR (95% CI for HR) 0.49 (0.25-0.96) 0.78 (0.47-1.29) 
p-value 0.068 0.338 
 
Table 3.17: Cox’s proportional hazards regression analysis of melanoma-specific 
survival stratified by sex in patients treated with bisoprolol 
*Adjusted for age at diagnosis and Breslow’s thickness. Significant p-values are in 
bold figures. HR, hazard ratio; 95% CI, 95% confidence interval. 
Sex 
Ever-never* 
Mortality HR (95% CI) p-value 
Melanoma-specific   
     Male 0.63 (0.61-1.47) 0.376 
     Female 0.36 (0.16-0.82) 0.015 
 
3.5.3 Diclofenac 
As per Table 3.18 looking at the characteristics of patients on diclofenac, the majority of 
these were female (72, 54.55%) compared to males (60, 45.45%) although this 
difference was not statistically significant (p<0.546). No other significant differences 
between users and non-users were seen, although the association with Breslow 
thickness fell just short of being significant.  
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Table 3.18: Characteristics of patients ever treated with diclofenac 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05 
Ever Treated with Diclofenac? Yes - n (%) No - n (%) P-value 
Total no of patients 132 (100) 1,985 (100)  
Gender    
     Female 72 (54.55) 1,136 (57.23) 
0.546 
     Male 60 (45.45) 849 (42.77) 
Diabetes     
     No 125 (96.90) 1,823 (95.95) 
0.593 
     Yes 4 (3.10) 77 (4.05) 
Body Mass Index    
     </=24.9kg/m2 34 (26.15) 756 (38.40) 
0.002      >24.9-29.9kg/m2 54 (41.54) 800 (40.63) 
     >29.9kg/m2 42 (32.31) 413 (20.98) 
Smoking status    
     Not currently smoking 42 (73.68)    637 (73.98) 
0.960 
     Currently smoking 15 (26.32) 224 (26.02) 
Breslow thickness    
     </=1mm 44 (33.33) 551 (28.10) 
0.008 
     1.01-2mm 61 (46.21) 745 (37.99) 
     2.01-4mm 22 (16.67) 442 (22.54) 
     >4mm 5 (3.79) 223 (11.37) 
Vitamin D    
     <20nmol/L 4 (3.39) 104 (6.43)  
0.699 
     20-59.9nmol/L 78 (66.10) 1,079 (66.73) 
     60-84.9nmol/L 30 (25.42) 361 (22.33) 
     85-99.9nmol/L 4 (3.39) 50 (3.09) 




Given that Breslow thickness is an independent predictor of melanoma survival, I 
explored the association between diclofenac use and Breslow thickness by performing 
a univariable analysis modelling the association of diclofenac use with age at diagnosis, 
gender, diabetes status, BMI, Breslow thickness and vitamin D status (Table 3.19). From 
this, it was observed that age at diagnosis, BMI >29.9kg/m2 and Breslow thickness 
(>4mm category only) were associated with a statistically significant higher odds of 
diclofenac use. I then performed a multivariable regression analysis to explore if any of 
the association of diclofenac use with higher Breslow thickness was accounted for by 
these other associated variables (Table 3.20). Importantly, this analysis demonstrated 
that higher Breslow thickness category was not associated with a higher odds of 
diclofenac use following adjustment for age, male gender, diabetes and BMI. 
 
Table 3.19: Univariable analysis of diclofenac use (ever-never) 
Regression analyses were performed using a logistic regression approach with 
diclofenac use as a dependent variable and age, gender, diabetes status, body 
mass index, Breslow thickness, and vitamin D as independent variables in each 
univariable analysis. 
 Odds Ratio 95% Confidence Interval P-value 
Age at diagnosis 1.02 1.00-1.04 0.011 
Male gender 1.09 0.76-1.56 0.648 
Diabetes 1.26 0.54-2.96 0.591 
Body mass index    
     >24.9-29.9kg/m2 1.44 0.03-2.25  0.106 
     >29.9kg/m2 2.08 1.29-3.35 0.002 
Breslow thickness    
     1.01-2mm 0.96 0.63-1.45 0.840 
     2.01-4mm 0.67 0.40-1.13 0.132 
     >4mm 0.23 0.08-0.65 0.005 




Table 3.20: Multivariable analysis of diclofenac use (ever-never) 
Regression analyses were performed using a logistic regression approach with 
diclofenac use as a dependent variable and age, male gender, body mass index 
and Breslow thickness as independent variables. 
 Odds Ratio 95% Confidence Interval P-value 
Age at diagnosis 1.02  1.01- 1.04 0.004 
Male gender 0.93  0.64-1.36 0.700 
Body mass index     
     >24.9-29.9kg/m2 1.37    0.87-2.17 0.175 
     >29.9kg/m2 2.11    1.30-3.44 0.002 
Breslow thickness     
     1.01-2mm 0.87    0.57-1.32  0.518 
     2.01-4mm 0.56    0.33-0.96 0.034 
     >4mm 0.19    0.07-0.53 0.002 
 
Table 3.21 demonstrates how there is no association of diclofenac ever use with either 
MSS or OS in both unadjusted and adjusted models in our cohort. 
 
Table 3.21: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients who received diclofenac (ever-never) 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
Model Parameter 
Diclofenac (ever-never) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 0.90 (0.60-1.35) 0.90 (0.61-1.32) 
p-value 0.608 0.597 
Age at diagnosis & 
sex-adjusted 
HR (95% CI for HR) 0.84 (0.56-1.26) 0.82 (0.55-1.20) 
p-value 0.392 0.298 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 1.15 (0.76-1.73) 1.03 (0.70-1.52) 
p-value 0.513 0.863 
Adjusted for other 
risk factors* 
HR (95% CI for HR) 1.11 (0.70-1.75) 0.97 (0.61-1.52) 
p-value 0.657 0.883 
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Table 3.22 demonstrates how there is no association of diclofenac use when stratified 
by sex with MSS when adjusted for age at diagnosis and Breslow’s thickness.. 
Table 3.22: Cox’s proportional hazards regression analysis of melanoma-specific 
survival stratified by sex in patients treated with diclofenac 
*Adjusted for age at diagnosis and Breslow’s thickness. Significant p-values are in 
bold figures. HR, hazard ratio; 95% CI, 95% confidence interval. 
Sex 
Ever-never* 
Mortality HR (95% CI) p-value 
Melanoma-specific   
     Male 0.60 (0.32-1.13) 0.116 
     Female 1.13 (0.65-1.95) 0.672 
 
 
3.6 Drug combinations of selected drugs for analysis within 
LMC 
Of the drugs reported in the literature, as can be seen aspirin and statins were the most 
commonly used drugs and therefore the ones for which the study was best powered to 
study. As metformin has previously been shown to have a potentially negative 
association with melanoma survival in a small unpublished study in our cohort this was 
also selected for detailed analysis despite the low statistical power. These three drugs 
(aspirin, statins, and metformin) will be presented separately in detail in the ensuing 
chapters but I will present the number of patients on combinations of these drugs in Table 




Table 3.23: Patients receiving two drug combinations 
Drug 1 
Drug 2 
No - n (%) Yes - n (%) 
Aspirin Metformin 
    No 1,723 (84.84) 47 (54.65) 
    Yes 308 (15.16) 39 (45.35) 
Aspirin Simvastatin 
    No 1,589 (89.2) 181 (53.87) 
    Yes 192 (10.78) 155 (46.13) 
Aspirin Atorvastatin 
    No 1,734 (86.66) 36 (31.03) 
    Yes 267 (13.34) 80 (68.97) 
Metformin Simvastatin 
    No 1,749 (97.78) 291 (84.84) 
    Yes 36 (2.02) 52 (15.16) 
Metformin Atorvastatin 
    No 1,933 (96.60)         98 (84.84) 
    Yes 68 (3.4)          18 (15.52) 
 
Table 3.24: No. patients receiving a combination of aspirin, metformin and 
simvastatin 
 Simvastatin 
 No Yes 
Aspirin 
Metformin Metformin 
No Yes No Yes 
     No 1570 19 153 28 
     Yes 175 17 133 22 
 
As can be seen 155 patients were on both aspirin and simvastatin and 80 patients on 
both aspirin and atorvastatin. This would be in keeping with what we would expect in that 
these drugs are often prescribed together for primary and secondary prevention of 
ischaemic heart disease.  
In terms of metformin, 39 patients were on this as well aspirin and 52 patients on 
metformin as well as simvastatin, and 18 patients on metformin and atorvastatin. As 
above diabetes is a risk for cardiovascular disease and therefore patients on metformin 
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are often prescribed a statin or aspirin as well. 22 patients were on all three medications 
(aspirin, simvastatin and metformin).  
The above findings demonstrate the complexity of trying to analyse drug effects of our 
chosen three drugs, aspirin, statins and metformin and also highlights one of the 
drawbacks of our study approach, as we are only able to analyse one drug at a time as 
will be discussed in further detail in the ensuing chapters. 
Ideally a population based study using public data bases could be used to address the 
relative associations of exposure to pairs of drugs but after discussion with the team and 
in particular Professor Jenny Barrett, I accepted that the data set was sufficient only to 
look at exposures independent of each. 
 
3.7 Summary 
In this chapter I have firstly, introduced the Leeds Melanoma Cohort and described the 
characteristics of the cohort highlighting aspects pertinent to my study aims. I have 
shown how I derived the different variables known to influence melanoma survival, such 
as Vitamin D status, BMI, and smoking status for instance and how they will be analysed. 
Before examining the effects of incidental drug exposure I have then tried to accomplish 
at the outset one of my aims in terms of identifying any associations of BMI and diabetes 
as part of the metabolic syndrome in the cohort, as I needed to understand the 
relationship between the comorbidities being treated and melanoma survival. I therefore 
assessed this by examining the association of BMI and Diabetes on melanoma survival 
in the LMC as outlined in the methods chapter by undertaking a Cox’s proportional 
hazards regression analysis of melanoma-specific and overall survival dependent on 
BMI and diabetes separately. I first undertook an unadjusted analysis and then adjusted 
for known confounders and found that in our cohort neither BMI nor diabetes alone 
appear to have a statistically significant association on melanoma specific survival 
although diabetes does appear to be negatively associated with overall survival, and I 
cannot exclude a small association not detectable with confidence in this data set. This 
therefore would appear to reduce the complexity of any subsequent analysis of incidental 
drugs although I will continue to adjust for both BMI and diabetes in my drug analysis. 
Given the literature evidence of differential effects on sex in terms of diabetes and obesity 
and associations with cancer I therefore also undertook a stratification by sex analysis 
for diabetes and obesity. This showed an association of diabetic men having a 
significantly poorer overall survival with a HR (OSS) of 1.77 (95% CI 1.11-2.81, p= 0.016) 
whilst diabetic men in the cohort also appear to have a negative association with 
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melanoma survival which just falls short of being statistically significant with  HR (MSS) 
of 1.68 (95% CI 1.00-2.82, p= 0.050). This would be in keeping with the literature 
evidence of such associations with diabetes in men for both for overall and melanoma 
specific survival as discussed in Chapter 1 [208]. There was however no association 
seen between sex and obesity on either MSS or OS in our cohort which is contrary to 
the studies that have demonstrated an elevated risk of CM with increasing BMI 
particularly among men as discussed in chapter 1. It is possible that this could be due to 
the fact that only 22% of our cohort are classed as obese, which is less than what would 
be expected in the population as evidence suggests that (see chapter 1), one third of the 
UK population are reported to be obese. 
Following this I then went on to summarise the literature survey approach undertaken 
and drug classes that have been reported to have effects on melanoma incidence and 
survival. The main groups that emerged with evidence in human studies on melanoma 
included NSAIDs (including selective cyclooxygenase-2-inhibitors and in particular 
aspirin), statins, fibrates, and retinoids. In order to identify relevant drug exposures, it 
was important to look at the prevalence of the relevant exposures and compare this with 
our power calculations and then tie it in with the results of the literature review above. 
Although there were specific drug groups such as immunosuppressants which would 
have been of interest in terms of their biological effects, I had insufficient numbers of 
patients on these drugs to be able to carry out an analysis. I have also presented some 
sample analysis of other drugs that were examined in this chapter. Ultimately I chose to 
examine aspirin, statins and metformin which will be covered in detail in the ensuing 
chapters and as a preliminary check I also examined how many patients were receiving 






Aspirin and Melanoma Survival 
4.1 Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are traditionally prescribed because of 
their analgesic, antipyretic, and anti-inflammatory effects. NSAIDs inhibit the 
cyclooxygenase (COX) enzyme reversibly leading to reduced synthesis of 
prostaglandins (PGs), and thromboxanes (TXs). 
Based upon their pharmacological effects, NSAIDs can be subdivided in three groups:  
• First, traditional NSAIDs, e.g. diclofenac, naproxen, sulindac, indomethacin, and 
piroxicam, reversibly inhibit both the constitutively expressed COX-1 and the 
inducible COX-2 isoforms of the enzyme (i.e., nonselective COX-inhibitors).  
• Secondly, the selective COX-2-inhibitors, e.g. celecoxib, etoricoxib, and 
rofecoxib, in regular doses, inhibit only the COX-2 isoform.  
• Aspirin forms the third group, because it irreversibly inactivates COX-1 by 
acetylating a serine residue in its active site and, therefore, reduces thromboxane 
A2 (TXA2) in platelets. Due to the fact that platelets cannot synthesize new 
enzyme, TXA2 synthesis does not recover until new platelets arise after 7-10 
days. 
4.1.1 Biological effects of NSAIDs 
The conversion of arachidonic acid to PGs and TXs is dependent on the enzyme 
cyclooxygenase (COX). The non-selective NSAIDs, including aspirin, act by inhibiting 
the activity of COX. Their capacity to decrease the inflammation is mainly due to the 
inhibition of COX activity, thus, decreasing the formation of pro-inflammatory PGs [192].  
Two isoforms of COX are recognised i.e., COX-1 and COX-2 [210]. COX-1 is thought to 
be responsible for homeostatic or maintenance levels of PGs; although high levels are 
reported in some cancers. Whereas, COX-2, responsible for various inflammatory 
actions, is activated by a range of pro-inflammatory cytokines and growth factors in 
specific pathophysiologic conditions, and is overexpressed in many premalignant and 
malignant conditions, including Barrett’s oesophagus, oesophageal cancer, gastric 
cancer, colorectal adenomas and cancer, and a wide range of other malignant 
conditions[191, 211, 212]. 
Overexpression of COX, especially COX-2, has been demonstrated in human cancer 
cells of several tumour types. Based upon these observations, the COX-pathway was 
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identified as a possible mediator of carcinogenesis. Indeed, the ras oncogene stimulates 
and p53, a tumour suppressor, down-regulates COX-2 expression. Moreover, COX-2 
expression also seems to enhance metastatic potential of colon cancer cells and may 
be involved in resistance to chemotherapeutic drugs [213]. Thus, the primary potential 
mechanism of action of NSAIDs in cancer chemoprevention is considered to be COX 
inhibition [214]. 
Increased COX-2 expression has been noted in the majority, but not all, melanoma cell 
lines [215, 216]. Denkert et al. showed that five melanoma cell lines (A375, MeWo, SK-
Mel-13, SK-Mel-28, and IGR-37) and 26 out of 28 (93%) patient derived primary 
melanomas showed COX-2 expression, whereas benign nevi (n=4) and epithelial cells 
were negative. After introduction of a COX-2 blocking agent, NS-398, cell line growth 
and invasive potential were inhibited [215]. Similarly, in a series of 101 ex vivo melanoma 
cell cultures, 96 (95%) showed COX-2 expression. More importantly, in this study, the 
level of COX-2 expression was also negatively associated with disease-specific survival 
(p = 0.046) [216]. Increasing evidence suggests that NSAIDs inhibit tumour growth and 
invasion [215, 217, 218] and can induce apoptosis [218, 219]. Roh et al. demonstrated 
an inhibitory effect of both celecoxib and indomethacin on melanoma cell growth in a 
murine B16F10 melanoma model [220]. Also, in a study of human A-375 melanoma cells, 
incubations for 72-hour of 50 and 100 micromolar (µM)of celecoxib showed reduced 
proliferation. Additionally, in a Toxilight TU-cytotoxicity assay, 100 (µM) celecoxib was 
toxic to the cancer cells. In this experiment, indomethacin (240 and 480 µM) also 
inhibited cell proliferation, but was only slightly toxic. Neither aspirin nor piroxicam 
exhibited cytostatic or cytotoxic effects. Thus, of the tested NSAIDs (aspirin, 
indomethacin, piroxicam, and celecoxib), only celecoxib and indomethacin reduced 
proliferation. Because these NSAIDs inhibit COX-2 in these concentrations, the authors 
suggested that the growth inhibitory effect of celecoxib cannot be explained solely by its 
COX-inhibitory activity [217]. 
Additional COX-independent pathways have also been suggested in other cancer types 
[221, 222]. Numerous possible targets, such as lipoxygenase metabolism (ALOX15), the 
pro-apoptotic gene PAWR, the anti-apoptotic gene BCL2L1, activation of caspases, 
activation of p38 MAP kinase, release of mitochondrial cytochrome c, and activation of 
the ceramide pathway have been suggested to be involved [223-229]. These COX-
independent pathways, however, need further study. For example, some investigators 
have suggested that only higher aspirin doses lead to these COX-independent molecular 
mechanisms [230]. Moreover, aspirin may have additional anticancer pathways as 
compared to other NSAIDs, such as inhibition of thrombocyte-aggregation [231], NF-κB, 
DNA-repair systems, apoptosis, oxidative stress, or mitochondrial calcium uptake [221]. 
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Recently, Thyagarajan et al. [232] assessed the mechanism of action of aspirin in a 
highly aggressive melanoma and reported that aspirin acts by inhibiting the survival of 
murine melanoma cells via inducing apoptosis, suppresses the in-vivo growth of 
melanoma tumours, sry-related high-mobility box-2 (SOX2) mediates ASA-induced 
decreased growth of melanoma tumours in-vivo, PGF2α modulates SOX2 in mediating 
ASA-induced effects, SOX-2 up-regulation blocks ASA-induced effects, and SOX-2 up-
regulation blocks PGF2α mimetic-induced effects. These findings suggest that the SOX2 
signalling pathway mediates aspirin-induced decreased growth of highly aggressive 
melanoma [232]. 
4.1.2 Review of literature of associations of aspirin usage with cancer 
Various studies have highlighted that the use of NSAIDS, especially Aspirin is associated 
with the reduced incidence of cancer. Moreover, there is extensive experimental 
evidence on how platelets and the coagulation system protect tumour cells within the 
circulation from immune elimination, enable cancer cells to adhere to vascular 
endothelium and thereby, enhance the growth of the metastatic cells [233]. Therefore, a 
reduction in metastatic spread by Aspirin is a highly plausible explanation. 
Moreover, several trials have suggested protective effect of Aspirin in various cancers. 
A study by Holmes et al. demonstrated an association between use of anti-platelet drugs 
and reduced prevalence of cancer in patients with diabetes [234]. In another trial, Shebl 
et al. concluded that daily use of aspirin, but not ibuprofen, is liked with lower risk of 
prostate cancer [235]. Similarly, Soriano et al. observed that amongst majority of 
individuals without prior CVD, commencing low-dose aspirin is associated with a 
decreased incidence of CRC [190]. 
A possible role for aspirin in reducing the mortality associated with cancer has been best 
explored in colorectal cancer (CRC). Epidemiologic studies, over the last two decades, 
have reported that patients receiving non-selective NSAIDs such as Aspirin, experience 
around 40-50% decrease in mortality from colorectal cancer (CRC), than those not 
receiving Aspirin [191]. As discussed earlier, the evidence suggests, however, that there 
may be different levels of benefit in a variety of cancer types. Thus, there appears to be 
about a 25% reduction with Aspirin in the mortality of colon cancer (HR = 0.75; 95% CI 
= 0.68–0.83), about 20% reduction in breast cancer mortality (HR = 0.80; 95% CI = 0.66, 
0.97), and a probable 15% reduction in prostate cancer deaths (HR = 0.86 (95% CI = 
0.78, 0.95). There is also evidence of a substantial reduction in the incidence of 
metastatic spread of these cancers, together with a reduction in all-cause mortality 
across all the cancers [236]. However, various studies have reported conflicting results 
and are described below. 
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Aspirin and other non-aspirin NSAIDs are recognised for the prophylactic effect against 
CRC [221, 237-241]. Previously, it was thought that only high dose Aspirin exerts these 
effects, but recent findings support that prophylactic doses of Aspirin (75 mg per day) 
may be equally efficacious [242, 243]. Moreover, other findings suggest that patients 
receiving NSAIDs prior to the diagnosis have improved survival following the diagnosis 
of CRC [241, 244]. Additionally, in these studies, the greatest effects were seen in 
patients who commenced the use of Aspirin following diagnosis. Another study reported 
that CRC patients with high levels of COX-2 benefited the most from Aspirin [245]. 
Din et al. performed the first study to demonstrate a protective effect against CRC 
associated with the lowest dose of Aspirin (75 mg per day) after only 5 years use in the 
general population. Low-dose Aspirin use was associated with decreased CRC risk (p = 
0.004), evident after 1 year and increasing with duration of use (ptrend = 0.004). NA-
NSAID and any NSAID use were also inversely associated with CRC. There was no 
demonstrable effect of NSAIDS on all-cause (p = 0.22) or CRC-specific survival (p = 
0.93). Additionally, the use of NSAID prior to CRC diagnosis did not influence the survival 
[242]. In another study, Walker et al. concluded that the use of Aspirin during the first 5 
years may be beneficial in reducing the mortality in CRC patients. However, the same is 
not true for other NSAIDs, where a small rise in mortality was seen [246]. Regarding the 
survival in patients with oesophageal or gastric cancer, Spence et al. observed that use 
of low-dose Aspirin was not associated with increased survival [247]. Similarly, 
McMenamin et al. reported little evidence of a protective association between low-dose 
Aspirin use and cancer-specific mortality in a large population-based lung cancer cohort 
[248]. Another study by Verdoodt et al. concluded that low-dose Aspirin does not result 
in reduced mortality among women with ovarian cancer [249]. However, in another study, 
Flahavan et al. observed that the use of Aspirin was associated with a non-significant 
reduced risk of prostate cancer-specific mortality in men with localised prostate cancer. 
However, men receiving higher doses of Aspirin had a statistically significant reduced 
risk of prostate cancer-specific mortality [250].  
Contrary to these findings, McNeil et al. [251]reported a higher all-cause mortality 
amongst apparently healthy older adults receiving daily Aspirin than among those who 
were receiving placebo and this was attributed primarily to cancer-related death [251]. 
4.1.3 Associations in melanoma 
Healthy cohort studies are the best means of identifying the effects of concurrent drug 
use on cancer risks, however, conflicting results exist on NSAIDs in melanoma 
prevention. Initially, Harris et al. [252] reported a small case control study (110 cases, 
609 controls, all females) in which regular NSAID use showed a significantly decreased 
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relative risk (RR) of melanoma (RR = 0.45; 95% CI = 0.22-0.95). With increasing NSAID 
use, melanoma risk further decreased (p <0.05). Estimates for daily use of aspirin were 
similar (RR = 0.55) [252]. 
Subsequently, in a small retrospective cohort study ( 83 melanoma patients), users of 
NSAIDs or COX-2-inhibitors, as compared with nonusers, had a lower incidence of new 
melanoma, recurrence, and metastasis (combined end point; odds ratio (OR) = 0.08, 
95% CI = 0.01-0.77) [253]. However, it is possible that a bias referred to as the 
guarantee-time bias may have influenced these results. In explanation, NSAID exposure, 
in this study, was defined as any prescription after first diagnosis of melanoma and prior 
to development of a new melanoma, a recurrence or metastatic lesion. Consequently, 
patients with longer survival are more likely to be categorized as a NSAID user, due to 
the simple fact that their follow-up period was longer, referred to as the guaranteed-time 
bias. More complex study designs and statistical analyses are required to prevent such 
a bias as explored in our methodology chapter, although we have found that they are 
difficult to implement and interpret [254]. 
In a secondary analysis of the Women’s Health Study, Cook et al. [255] studied low-dose 
aspirin (100 mg every other day) versus placebo. Among the 39,885 women included in 
this RCT, low-dose aspirin was not associated with melanoma risk (RR = 0.97, 95% CI 
= 0.70-1.36) [255]. Similar results were obtained in a secondary analysis of the Cancer 
Prevention Study II Nutrition Cohort. Although long-term adult-strength aspirin (≥325 mg 
for ≥5 years) was associated with lower overall cancer incidence in men and a non-
statistically significant lower overall cancer incidence was observed in women, 
melanoma incidence was not reduced (current daily use, ≥5 years: RR = 1.15, 95% CI = 
0.83-1.59; <5 years: RR = 0.99, 95% CI = 0.79-1.25) [256]. 
Recently, in the Vitamins and Lifestyle (VITAL) cohort study, Asgari et al. [257] examined 
the association between NSAID use and melanoma risk. Among 63,809 men and 
women, during a 10-year follow-up period, 349 patients with incident melanomas were 
identified including 157 in situ melanomas. Use of any NSAID for at least 4 days per 
week as compared to non-use, did not seem to reduce the melanoma hazard rate (HR 
= 1.12, 95% CI = 0.84-1.48). Similar results were obtained for any NSAID excluding low-
dose aspirin (HR = 1.03, 95% CI = 0.74-1.43), for regular- or extra-strength aspirin (HR 
= 1.10, 95% CI = 0.76-1.58), and for non-aspirin NSAIDs (HR = 1.22, 95% CI = 0.75-
1.99). Additionally, NSAID use was not associated with tumour invasion (p-interaction = 
0.38), tumour thickness (p-linear trend = 0.98), or risk of metastasis (HR = 1.09, 95% CI 
= 0.32-3.62) [257]. 
In a large population-based case control study of groups including 1,318 patients with 
invasive melanoma and 6,786 controls, incident melanoma was not associated with 
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aspirin use (OR = 0.92, 95% CI = 0.76-1.12) or non-aspirin NSAID use (OR = 1.10, 95% 
CI = 0.97-1.24). However, continuous use of low-dose aspirin was associated with a 
significant reduction of melanoma risk in women (OR = 0.54, 95% CI = 0.30-0.99), but 
not in men (OR = 1.01, 95% CI = 0.69-1.47). A significant linear trend (p = 0.04) from 
non-use, non-continuous use, to continuous use was observed in women [258]. 
In summary, due to heterogeneity in study design (ascertainment and definition of 
exposure, type of NSAID, dose, duration, patterns of use, drug adherence, study 
population, etc.), conflicting results and the limited number of epidemiological studies, 
the efficacy of NSAIDs and aspirin for melanoma prevention remains unclear. The results 
of in vitro and animal studies as discussed above, however, are promising. A pivotal 
unresolved problem is the definition of the temporal and dose-response cause effect 
relationships between NSAIDs use and incident invasive melanoma. Thus, additional 
experimental and observational research is warranted, particularly on required dosages 
and duration. 
4.1.4 Safety and Compliance 
Side effects of NSAIDs are gastrointestinal (GI) such as nausea, vomiting, dyspepsia 
(10-20%), diarrhoea, duodenal or gastric ulcers (10-30%), sometimes even leading to GI 
bleedings or perforation (± 2%) [259]. In addition, skin reactions, cardiovascular (CV) 
and cerebrovascular events, and decreases in renal function also occur. Rare, but 
serious, side effects are bone marrow disturbances and hepatotoxicity. The prevalence 
of GI related side effects differs substantially between several traditional NSAIDs, being 
less pronounced for aspirin and diclofenac compared to piroxicam. 
COX-2-inhibitors have been developed to selectively inhibit COX-2 and thus, to reduce 
side effects related to COX-1-inhibition, most importantly duodenal and gastric ulcers. 
Indeed, duodenal or gastric ulcers are less prevalent (± 2%) for this class of NSAIDs 
[259]. However, thrombotic CV events observed in the APPROVe trial, a 
chemopreventive trial in which patients with a history of colorectal adenomas were 
randomized to receive rofecoxib or placebo [260], have raised safety concerns regarding 
the risk-benefit ratio of COX-2-inhibitors in cancer chemoprevention [261]. Subsequent 
epidemiological studies have suggested that these events are also associated with 
traditional NSAIDs, such as ibuprofen or diclofenac [262]. In these studies, naproxen, as 
an exception, was reported to be associated with a reduced CV event rate [262]. To 
prevent GI ulcers and bleeds, additional interventions such as Helicobacter pylori 
eradication and concomitant use of a proton pump inhibitor to the chemopreventive 
strategy could be considered, but this introduces new adverse effects and additional 
costs. Thus, in the AspECT trial, a combination of aspirin plus proton pump inhibitor was 
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studied for the chemopreventive activity on cancer among patients with Barrett’s 
oesophagus [238]. And, it was observed that high-dose (40 mg twice-daily) PPI 
(omeprazole) with aspirin significantly and safely improved outcomes in patients with 
Barrett's oesophagus [68].  
Aspirin may also cause bleeding through inhibition of thrombocyte aggregation. Due to 
this feature, however, aspirin does not cause an excess of CV events and actually has 
the advantage of protection against CV disease and apart from its use as an anti-pyretic 
and painkiller, it is used in both primary and secondary prevention of CV disease as well 
as in patients who have had coronary stents inserted. Moreover, aspirin may have 
additional chemopreventive effects as compared to other COX-inhibitors [221, 231]. 
 
4.2 Materials and Methods 
Having collected the drug data for all drugs used in our cohort, which is the largest cohort 
of melanoma patients as detailed in Chapter 2, and having identified Aspirin as drug of 
interest with sufficient power to potentially demonstrate a significant effect, various 
further drug specific considerations were considered as detailed below.  
Firstly, I had to ensure all entries for Aspirin were identified accurately by accounting for 
trade names, BNF codes, misspellings in data entry, and missing data by cross-checking 
all data sources. The most common dose for aspirin within our cohort was 75 mg with 
over 90% of patients on this, although there were some entries without a dosage 
specified. As discussed in Chapter 2, I, therefore, did not examine the effects of drug 
dosages given the standard doses used (which are generally the same in studies which 
looked at CRC and aspirin as discussed), additional complexity of the analysis as well 
as the perceived lack of a significant biological effect of dosage over duration, which was 
felt to be more significant from the review of the literature, as demonstrated above.  
I then interrogated the data further by looking at the demographics of the population 
taking Aspirin by examining the number of males and females on the drug in our cohort, 
their smoking status, their diabetic status, vitamin D levels, and the distribution based on 
Breslow thickness. As Aspirin is prescribed to the same group of patients who are likely 
to have features of the metabolic syndrome with increased BMI and Diabetes and 
ischaemic heart disease (IHD), we expected to see some common trends within our 
analysis.  
Given that men have a higher risk of these conditions, we would expect to see more men 
being prescribed Aspirin than women and we would also expect to see more smokers 
and diabetics having been prescribed Aspirin, as these are independent risk factor for 
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IHD. We would also expect this group of patients to be overweight compared to the rest 
of the cohort population (BMI > 25 Kg/m2). 
As detailed in the methodology chapter, I then undertook a survival analysis, based on 
firstly, the ever vs never approach with the accepted guarantee-time bias, first examining 
the adjusted model and then, adjusting for known confounders. 
The second approach was a survival analysis looking at the effects of aspirin up to 
diagnosis or within 12 months of diagnosis. This method of analysis, used frequently in 
cancer incidence studies has no inherent bias, but as discussed in the methodology 
section our study was not geared up for this, as we experienced problems with some 
loss of power due to exclusion as well as the issue of poorer quality data before 
diagnosis. As with the previous approach, we first examine the unadjusted model and 
then, adjusted for the known confounders. 
Finally, given the significant literature evidence of potential varying effects of drugs on 
survival based on sex, as demonstrated in our literature survey with the large Dutch 
population based study on melanoma incidence showing that continuous use of low-
dose aspirin was associated with a significant reduction of melanoma risk in women (OR 
= 0.54, 95% CI = 0.30-0.99) but not in men (OR = 1.01, 95% CI = 0.69-1.47) as described 
above. We also carried out a survival analysis, whereby, we stratified study population 
by sex to identify any sex specific trends. As with the previous approaches, I first 
examined the unadjusted model and then adjusted for known confounders including age 
and Breslow thickness. 
 
4.3 Results 
Having implemented the methodology as detailed above and in Chapter 2, the results 
indicate that 347 (16%) of the 2158 participants in the Leeds Melanoma Cohort had ever 
taken aspirin at some point.  
As per Table 4.1 below, the majority of these were men, with nearly twice as many men 
(226, 65.13%) as women (121, 34.87%) taking aspirin (p<0.001). This would be 
expected given that studies suggest that men are twice as likely as females to have IHD 
and as discussed, aspirin is often prescribed to reduce this risk.  
Similarly analysis of the cohort showed that a higher proportion of people on Aspirin were 
diabetic (37, 10.95% vs. 44, 2.6%; p<0.001) or ever smokers (186, 54.87% vs. 731, 
42.9%; p<0.001) compared to those not on Aspirin. This would be expected given that 
both diabetes and smoking are risk factors for IHD and this population is, therefore, more 
likely to be prescribed Aspirin. Interestingly people who had ever used Aspirin were more 
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likely to be current non-smokers (153, 82.26% vs. 526, 71.86%; p=0.004), and may have 
stopped smoking possibly due to cessation advice. In terms of BMI, patients on Aspirin 
were more likely to be overweight or obese (p<0.001), as this is a risk factor for IHD. As 
discussed earlier, vitamin D is one of the factors thought to influence melanoma survival 
and we, therefore, wanted to analyse our cohort to see if there was a statistical difference 
in vitamin D levels between users and non-users by defining different ranges of vitamin 
D and comparing with the base group and we observed no statistical difference as shown 
(p=0.273). 
As a result of the observed higher proportion of participants ever treated with aspirin who 
had Breslow thickness of 2.01-4mm (90, 26.24% vs. 374, 21.37%) and >4mm (48, 
13.99% vs. 180, 10.29%) in participants who had ever received aspirin compared to 
those never treated, I explored the association between aspirin use and Breslow 
thickness by performing a univariable analysis modelling the association of aspirin use 
with age at diagnosis, gender, diabetes status, BMI, Breslow thickness and vitamin D 
status (Table 4.4). From this, it was observed that age at diagnosis, male gender, 
presence of diabetes, BMI and Breslow thickness (2.01-4mm and >4mm categories only) 
were associated with a statistically significant higher odds of aspirin use. I then 
performed a multivariable regression analysis to explore if any of the association of 
aspirin use with higher Breslow thickness was accounted for by these other associated 
variables (Table 4.5). Importantly, this analysis demonstrated that higher Breslow 
thickness category was not associated with a higher odds of aspirin use following 
adjusted for age, male gender, diabetes and BMI. 
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Table 4.1: Characteristics of patients ever treated with aspirin 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05. 
Ever Treated with Aspirin? Yes No P-value 
Age at diagnosis 66 (11.5) 54 (20.1) <0.001 
Sex    
Female 121 (34.87) 1,087 (61.41) 
<0.001 
Male 226 (65.13) 683 (38.59) 
Diabetes     
No 301 (89.05) 1,647  (97.4) 
<0.001 
Yes 37 (10.95) 44 (2.6) 
Body Mass Index    
</=24.9kg/m2 89 (25.8) 701 (39.97) 
<0.001 >24.9-29.9kg/m2 163 (47.25) 691 (39.4) 
>29.9kg/m2 93 (26.96) 362 (20.64) 
Smoking status    
Never 153 (45.13) 973 (57.1) 
 <0.001 
Ever 186 (54.87) 731 (42.9) 
Smoking status    
Not currently smoking 153 (82.26) 526 (71.86) 
0.004 
Currently smoking 33 (17.74) 206 (28.14) 
Breslow thickness    
</=1mm 79 (23.03) 516 (29.49) 
0.011 
1.01-2mm 126 (36.73) 680 (38.86) 
2.01-4mm 90 (26.24) 374 (21.37) 
>4mm 48 (13.99) 180 (10.29) 
Vitamin D    
<20nmol/L 22 (7.72) 86 (5.93) 
0.273 
 20-59.9nmol/L 176 (61.75) 981 (67.66) 
 60-84.9nmol/L 70 (24.56) 321 (22.14) 
 85-99.9nmol/L 12 (4.21) 42 (2.9) 
>100nmol/L 5 (1.75) 20 (1.38) 
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Table 4.2: Univariable regression analysis of aspirin use (ever-never) 
Regression analyses were performed using a logistic regression approach with 
aspirin use as a dependent variable and age, gender, diabetes status, body mass 
index, Breslow thickness, and vitamin D as independent variables in each 
univariable analysis. 
 Odds Ratio 95% Confidence Interval P-value 
Age at diagnosis 1.10 1.08-1.11 <0.001 
Male sex 2.97 2.34-3.78 <0.001 
Diabetes 4.60 2.92-7.25 <0.001 
Body mass index    
     >24.9-29.9kg/m2 1.86 1.41-2.46  <0.001 
     >29.9kg/m2 2.02 1.47-2.78 <0.001 
Breslow thickness    
     1.01-2mm 1.21 0.89-1.64 0.218 
     2.01-4mm 1.57 1.13-2.19 0.007 
     >4mm 1.74 1.17-2.59 0.006 
Vitamin D 1.00 1.00-1.01 0.265 
 
Table 4.3: Multivariable analysis of aspirin use (ever-never) 
Regression analyses were performed using a logistic regression approach with 
aspirin use as a dependent variable and age, male gender, diabetes, body mass 
index and Breslow thickness as independent variables. 
 Odds Ratio 95% Confidence Interval P-value 
Age at diagnosis 1.10  1.08- 1.12 <0.001 
Male sex 2.27  1.74- 3.00 <0.001 
Diabetes 2.69  1.61-4.49 <0.001 
Body mass index     
     >24.9-29.9kg/m2 1.40    1.00- 1.88 0.052 
     >29.9kg/m2 1.80    1.25-2.60 0.002 
Breslow thickness     
     1.01-2mm 0.98    0.70-1.38  0.911 
     2.01-4mm 0.97    0.67-1.41 0.866 
     >4mm 0.91    0.58-1.41 0.665 
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4.3.1 Effects of aspirin use on survival outcomes 
As described in the methodology chapter, a comparison of melanoma-specific and 
overall survival distributions amongst participants who had ever used aspirin and those 
who used aspirin within 12 months of diagnosis was performed. I have discussed the 
results for aspirin ever-use and aspirin use within 12 months separately below.  
4.3.1.1 Ever-never aspirin use 
Unadjusted survival curves comparing melanoma-specific survival in participants who 
did or did ever use Aspirin is shown in Figure 4.1. This figure showed that melanoma-
specific survival was significant reduced in patients who had ever used aspirin (logrank 
test p=0.045). 
 
Figure 4.1: Kaplan-Meier survival plot comparing melanoma-specific survival in 
participants receiving aspirin (ever-never use). 
 
A similar observation was made in the unadjusted Cox regression analysis (Table 4.4) 
and there was a significant increase in the risk of death in melanoma participants who 
reported having ever taken aspirin as compared to participants who had never used 
aspirin (HR = 1.30; 95% CI = 1.01-1.68; p-value = 0.046). A similar finding was observed 
for overall survival (HR = 1.53; 95% CI = 1.22-1.93; p-value < 0.001), which was 
statistically significant. However, increasing age and the male sex are known predictors 
of melanoma and overall survival. When the model was adjusted for age at diagnosis 
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and sex, this effect disappeared for melanoma specific (HR MSS = 0.81; 95% CI = 0.61–
1.06; p-value = 0.120) and for overall survival (HR = 0.88; 95% CI = 0.69-1.12; p-value 
= 0.308) and in fact, suggested a non-significant protective effect. The same was true in 
the model adjusted for age at diagnosis, sex, and the other known confounding factors 
in a multivariable analysis as shown in the table below  with melanoma specific (HR = 
0.78; 95% CI = 0.56–1.08; p-value = 0.131) and for overall survival (HR = 0.88; 95% CI 
= 0.66-1.18; p-value = 0.398). However, as discussed in the methodology section, this 
analysis was subject to the guarantee time bias, by virtue of the fact that, the longer 
someone lives, the higher the likelihood of them becoming part of the aspirin-ever 
category. 
 
Table 4.4: Cox’s proportional hazards regression analysis on the association 
between ever having taken aspirin regularly (ever-never) with survival 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and BMI. Significant p-values are 
in bold figures 
Model Parameter 
Aspirin (ever-never) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 1.30 (1.01-1.68) 1.53 (1.22-1.93) 
p-value 0.046 < 0.001 
Age at diagnosis 
& sex-adjusted 
HR (95% CI for HR) 0.81 (0.61-1.06) 0.88 (0.69-1.12) 
p-value 0.120 0.308 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.85 (0.64-1.10) 0.93 (0.73-1.18) 




HR (95% CI for HR) 0.78 (0.56-1.08) 0.88 (0.66-1.18) 
p-value 0.131 0.398 
 
4.3.1.2 Aspirin use up to or within 12 months of diagnosis 
Similar to the findings in Figure 4.1 among participants who had ever or never used 
aspirin, Figure 4.2 suggests that participants who had used aspirin up to or within 12 
months of diagnosis of melanoma, had a significantly poorer melanoma-specific survival 
compared with those who reported no use of aspirin (logrank test p=0.008). 
90 
  
Figure 4.2: Kaplan-Meier survival plot comparing melanoma-specific survival in 
participants receiving aspirin within 12 months of diagnosis. 
 
As seen with the previous analysis, Table 4.5 shows that in the unadjusted model, there 
appeared to be an increased risk of death from melanoma or all causes with HR of 1.49 
(95% CI = 1.11-2.01, p-value = 0.009) and 1.58 (95% CI = 1.20-2.08, p-value = 0.001), 
respectively. This risk again was statistically significant, however when adjustment is 
made for age and sex, the HR was reversed, suggesting a non-significant protective 
effect with no statistically significant difference between melanoma specific survival and 
overall survival that was maintained in the multivariate analysis with HR of 0.93 (95% CI 
= 0.64-1.35, p-value = 0.706) and 0.87 (95% CI = 0.62-1.23, p-value = 0.442) 
respectively. A similar finding was found in the models adjusting for age, sex, Breslow 
thickness, and other risk factors. This analysis does not appear to have any inherent bias 
as with the previous analysis type, which is subject to the guarantee time bias. However 
the fact that the results are very similar would suggest the guarantee time bias didn't play 
such a large role in the previous analysis.  
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Table 4.5: Cox’s proportional hazards regression analysis on the effect of aspirin 
use within 12 months of diagnosis on survival 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, microscopic ulceration, and BMI. Significant 
p-values are in bold figures 
Model Parameter 
Aspirin 
(use within 12 months of diagnosis) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 1.49 (1.11-2.01) 1.58 (1.20-2.08) 
p-value 0.009 0.001 
Age at diagnosis 
& sex-adjusted 
HR (95% CI for HR) 0.91 (0.66-1.25) 0.90 (0.68-1.20) 
p-value 0.573 0.491 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.91 (0.66-1.25) 0.91 (0.68-1.21) 




HR (95% CI for HR) 0.93 (0.64-1.35) 0.87 (0.62-1.23) 
p-value 0.706 0.442 
 
4.3.1.3 Stratification by sex 
Based on literature evidence that women present with thinner melanoma and that 
women do better than men independent of thickness [86], I carried out a survival analysis 
stratified by sex. Concerning the effect of Aspirin use on survival when stratified by sex, 
the relative differences between these hazard ratios are tested as seen in Table 4.6. Sex 
did indeed confer a statistically significant influence on the risk of mortality in terms of 
both melanoma-specific and overall survival (p-value < 0.05). Female participants who 
had ever taken Aspirin appeared to be less likely to die from melanoma when compared 
with other females who never use the drug at any point in their lifetime with HR for 
melanoma specific survival of 0.51 (95% CI = 0.30-0.87, p-value = 0.014) and for overall 
survival of 0.61 (95% CI = 0.38-0.97, p-value = 0.035), suggesting that as compared to 
males, Aspirin use may have a preferentially protective effect in female participants.  
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Table 4.6: Cox’s proportional hazards regression analysis of the association 
between aspirin use on survival stratified by sex 
* Adjusted for age at diagnosis. Significant p-values are in bold figures 
Sex 







Melanoma-specific     
     Male 0.99 (0.71-1.37) 0.948 1.07 (0.74-1.55) 0.717 
     Female 0.51 (0.30-0.87) 0.014 0.60 (0.30-1.18) 0.135 
Overall survival     
     Male 0.99 (0.71-1.37) 0.948 0.99 (0.70-1.38) 0.932 
     Female 0.61 (0.38-0.97) 0.035 0.68 (0.37-1.22) 0.197 
 
4.4 Discussion 
In this section I will discuss my findings in relation to the literature and what we already 
know about potential associations of aspirin on inflammation, cancer and melanoma and 
to determine whether these associations can explain my findings. I will also discuss the 
limitations of our study approach in examining these associations. 
As already demonstrated, inflammation is driven by complex metabolic pathways, with 
arachidonic acid (AA) as one important molecule of origin in these pathways. The 
metabolism of AA is fundamental for both promotion and inhibition of inflammatory 
processes. As discussed in vitro studies demonstrate COX-2-expression in melanoma 
and suggest effects of NSAIDs on growth inhibition, invasiveness and apoptosis. COX 
independent pathways, however, may also be involved in these anti-tumour effects. 
Initial reports on aspirin and cancer described a reduction in metastatic spread and 
focused primarily on the role of platelets, consistent with a treatment, rather than a 
preventive effect. Later, evidence emerged regarding the potential effects of aspirin on 
certain biological mechanisms relevant to cancer growth and to metastatic capacity 
which justified an expectation of benefit from aspirin treatment in cancer. Some of the 
long-term follow-up studies of early vascular trials gave evidence of reductions 
attributable to aspirin in the metastatic spread of a range of cancers in subjects who had 
been free of metastases at diagnosis, again suggesting a treatment effect of aspirin. 
Furthermore, while there is usually a delay before evidence of a reduction in incidence 
of cancer becomes apparent, typically with the need for large observational studies over 
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a long period, a reduction in mortality in patients with metastases appears to be easier 
to detect, strengthening a potential treatment effect of aspirin [263].  
The role of low-dose aspirin prophylaxis however, has now become well accepted in the 
case of vascular disease and in the reduction of CRC, and probably other cancers, and 
it has even been predicted that ‘prevention of cancer could become the main justification 
for aspirin use [263].  
The results of my study demonstrate a non-significant protective effect of aspirin on both 
melanoma specific and overall survival, when adjusting for known confounders such as 
age and sex as well as in multivariate analysis accounting for multiple factors such as 
age, sex, diabetes, BMI, vitamin D, smoking status, and Breslow thickness. This was 
demonstrated by the ever-never analysis showing a HR (MSS) of 0.81 (95% CI = 0.61–
1.06, p-value = 0.120) and for overall survival a HR (OS) of 0.88 (95% CI = 0.69-1.12, p-
value = 0.308) in the multivariate model, with similar findings in the aspirin up to or within 
12 months of diagnosis analysis, with the multivariate analysis showing a HR (MSS) of 
0.93 (95% CI = 0.64-1.35, p-value = 0.706) and HR (OS) of 0.87 (95% CI = 0.62-1.23, 
p-value = 0.442) respectively. Therefore I was unable to show a significantly protective 
association with aspirin use and melanoma survival in our cohort. One limitation of our 
study, which may play a role in this result, particularly when comparing to associations 
seen with CRC as described before, is that I was unable to account for duration of aspirin 
use. Studies in CRC suggest protective effects of aspirin are seen only after 5 years with 
prophylactic doses of aspirin (75mg) [242]. Although we did not specifically look at 
dosage either, as mentioned in the results, the majority of patients in the cohort were 
prescribed this particular dose and therefore the absence of duration data appears to be 
the main limitation of our approach. Potentially stratifying patients based on duration of 
use would have helped to see if this could be playing a role in our results.  
However, my significant finding from the study relates to when the analysis was stratified 
by sex, whilst still adjusting for age and Breslow thickness. As shown, female participants 
who had ever taken aspirin were significantly less likely to die from melanoma, when 
compared with others who had never used the drug at any point in their lifetime with 
hazard ratios for melanoma specific survival of 0.51 (95% CI = 0.30-0.87, p-value = 
0.014) compared to men with an HR (MSS) 0.99 (95% CI: 0.71-1.37, P= 0.948), 
suggesting that aspirin use may have a preferentially protective effect in females.  
There are two main studies that have reported a general survival benefit in melanoma 
patients receiving aspirin.  
The first study performed by Famenini et al. was a cross-sectional retrospective study 
involving 39 patients with melanoma and aspirin use before the diagnosis of melanoma 
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and 109 patients with melanoma without prior aspirin use [264]. They reported a 
significant difference in Breslow thickness between aspirin users versus non-users (95% 
CI = 0.0297-0.8127, p-value = 0.03517). No significant difference was found in presence 
of ulceration or metastasis, Clark’s stage, or mitotic activity between the 2 groups. 
Although the study was limited by sample size and as in our study, a lack of information 
regarding duration of aspirin treatment and exposure, it was concluded that aspirin may 
be associated with reduced Breslow thickness [264]. My initial findings also suggested a 
potential association with Breslow thickness as a result of the observed higher proportion 
of participants ever treated with aspirin who had Breslow thickness of 2.01-4mm (90, 
26.24% vs. 374, 21.37%) and >4mm (48, 13.99% vs. 180, 10.29%) in participants who 
had ever received aspirin compared to those never treated. I therefore explored this 
association between aspirin use and Breslow thickness further by performing a 
univariable analysis, modelling the association of aspirin use with age at diagnosis, 
gender, diabetes status, BMI, Breslow thickness and vitamin D status (Table 5.2). From 
this, it was observed that age at diagnosis, male gender, presence of diabetes, BMI and 
Breslow thickness (2.01-4mm and >4mm categories only) were associated with a 
statistically significant higher odds of aspirin use. I then performed a multivariable 
regression analysis to explore if any of the association of aspirin use with higher Breslow 
thickness was accounted for by these other associated variables (Table 5.3). 
Significantly, this analysis demonstrated that higher Breslow thickness category was not 
associated with a higher odds of aspirin use following adjusted for age, male gender, 
diabetes and BMI. 
The second study performed by Rachidi et al. was a retrospective cohort study involving 
1,522 patients diagnosed with melanoma [265]. They reported that aspirin use was 
associated with longer overall survival in a similar univariate analysis as I performed 
above, with them adjusting for age, sex, stage, and treatment modalities (HR = 0.58, 
95% CI = 0.45-0.75). Moreover, aspirin use was not associated with survival in patients 
with in situ and stage I melanoma, but was associated with better survival in stages II 
(HR = 0.45, 95% CI = 0.24-0.82) and III (HR = 0.57, 95% CI = 0.34-0.96). No statistical 
significance was observed in stage IV patients (HR = 0.55, 95% CI = 0.27-1.13). In turn, 
patients using Aspirin before diagnosis were less likely to be diagnosed in stages III or 
IV disease. Thus, authors concluded that aspirin could provide a survival advantage in 
melanoma [265].  
However, neither of these studies reported any preferential survival advantage in female 
sex. Moreover, the only literature evidence of a potential survival advantage in women 
comes from studies looking at incidence of new melanomas and which was one of the 
reasons we considered an analysis looking at stratification by sex. A report by Gamba 
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et al. from the Women’s Health Initiative demonstrated a 20% reduction in melanoma 
incidence in women taking aspirin suggesting a potential chemopreventive benefit of 
aspirin to reduce melanoma risk which may explain our findings and hint at a possible 
biological mechanism for this effect [266]. Similarly, a study by Joosse et al. looking at 
incidence of cutaneous melanoma in a large Dutch population based study 
demonstrated continuous use of low-dose aspirin was associated with a significant 
reduction of cutaneous melanoma (CM) risk in women (adjusted OR = 0.54, 95% CI = 
0.30-0.99), but not in men (OR = 1.01, 95% CI = 0.69-1.47). A significant trend (p-value 
= 0.04) from no use, non-continuous use to continuous use was observed in women. 
Continuous use of low-dose aspirin may, therefore, be associated with a reduced 
incidence of CM in women, but not in men [258].  
My study examined the largest cohort of melanoma patients in the world and to my 
knowledge is the first study showing that aspirin use may have a potentially preferential 
protective association in females in terms of melanoma survival as opposed to 
melanoma incidence as seen in the Dutch study, described above. This may therefore 
point towards a possible common biological pathway mediating this association in both 
incidence and survival. This discrepancy between men and women could potentially be 
explained by either pharmacological or melanoma differences. One consideration 
proposed by the Dutch group is that pharmacodynamics and pharmacokinetics of Aspirin 
differ between men and women. The effect on platelets differs across sexes and it seems 
that women achieve higher concentrations with equal doses being administrated [267]. 
As Aspirin may influence oxidative stress, the sex difference in antioxidant enzymes may 
also play a role. This is explained by the fact that certain disease states are linked with 
platelet oxidative stress, and it has been demonstrated that Aspirin inhibits the 
expression of lectin-like oxidized LDL receptor 1 (LOX-1) on platelets, in part by 
favourably affecting the ROS species and NO release from the activated platelets [69]. 
Interestingly, an RCT investigating antioxidant supplementation showed an increase in 
the incidence of CM in women, but not in men [268]. Another explanation may be that 
biology of melanoma itself may not be comparable in men and women, as CM survival 
differs significantly across the sexes when adjusted for other prognostic factors [79, 269]. 
Although behavioural differences such as compliance in taking the medication, with 
women being more likely to adhere to drug usage could have played a role in our study, 
studies suggest that differences in adherence to cardiovascular drugs are unlikely to 
explain the observed sex differences [270].  
The main limitation of our approach in relation to this result is that of statistical power. 
When conducting the sex based stratification, I lose significant statistical power, as there 
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were nearly half the number of females on Aspirin when compared to males (as shown 
in Table 4.1).  
Furthermore we were unable to adjust for associations related to patients being on a 
combination of drugs, which may be associated with inflammatory pathways as will be 
discussed in subsequent chapters. This could be significant in the case of aspirin, 
because as shown in table 3.20 in Chapter 3, in terms of the 347 patients ever on aspirin 
in our cohort, nearly a half were on simvastatin 155 (44%) 80 (23%) on atorvastatin, and 
18 (5%) on metformin. Therefore it is difficult to ascertain if the associations could have 
been strengthened or weakened because of potential synergistic or opposing effects. 
The other main drawback, common to the whole thesis, is with problems of differentiating 
the effects of the co morbidities from these drugs used to treat them. 
Further limitations include the retrospective approach and quality of drug data prior to 
diagnosis and the lack of a national cancer linked pharmacy database. Our study options 
were also limited from an analysis approach as we were unable to look at dose and 
duration given the potential biases in our methodology, as we were unable to perform 
the analyses with a time-dependent approach. These biases generally would result from 
not properly classifying exposure during the follow-up period as well as the guarantee 
time bias discussed in our methods section with our ever-never analysis. Although the 
guarantee time bias should have meant that it would be very difficult to look at exposure 
to the drugs after diagnosis interestingly my results were very similar to the at diagnosis 
or within 12 months of diagnosis analysis which does not have an inherent bias, 
suggesting that the guarantee time bias may not be such an issue in my analysis.  
On the other hand, in terms of strengths of the study, we had the largest cohort of 
melanoma patients allowing us the ability to perform an epidemiological study on the 
effects of aspirin on melanoma survival given the shortage of such studies in the 
literature. I also had access to high-quality survival data given that it was a cohort study, 
which utilised multiple routes to obtaining those data. Given the significant amount of 
data collected at recruitment were also able to adjust for several known variables that 
can effect melanoma survival unlike other studies.  
The next step following this would then be to try to determine the mechanism, whereby 
Aspirin exerts these effects. As discussed, various in vitro studies have demonstrated 
COX-2-expression in melanoma and suggested effects of NSAIDs on growth inhibition, 
invasiveness, and apoptosis. COX independent pathways, however, are also involved in 
these anti-tumour effects, as discussed. These pathways should be further investigated 
in order to disentangle dose-response and duration relationships, in terms of Aspirin. 
Although as discussed promising efficacy data were shown in other cancers, NSAIDs, 
especially Aspirin have yet to demonstrate sufficiently convincing evidence for 
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efficacious melanoma chemoprevention. Convincing evidence is lacking and comparing 
the conflicting results of the limited number of published studies discussed in our 
literature review is challenging due to heterogeneity in study design and uncertainties in 
temporal and dose-response relationships. Moreover, concerns over the long-term 
safety of COX-2 inhibitors, aspirin, and other NSAIDs have tempered the enthusiasm for 
their use in chemoprevention. Therefore, if sufficient data on efficacious drug dosages 
and temporal cause effect relationships become available, formal risk-benefit analyses 
should be performed on different scenarios of chemopreventive strategies. 
A clinical trial is currently on-going to assess the impact of long term Aspirin intake on 
recurrence and survival in colorectal, gastro-esophageal, prostate, and breast cancers 
[70], and a similar trial in melanoma is warranted.  
In conclusion, although my results in terms of sex stratification are interesting, and 
backed up by other studies, looking at incidence of melanoma rather than survival within 
a cohort they do require further validation in larger international data sets as well as an 
examination of biological models to assess if these represent real associations either 
related to pharmacological or melanoma differences or whether confounding factors are 
responsible for these changes. One possibility is to look at using Public Health England 
data as this is an increasingly common approach although it will be limited in terms of 
having access to other variables known to effect melanoma survival as was available in 




Statins And Melanoma Survival 
5.1 Introduction 
Statins, or 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, are 
very frequently used group of drugs intended to reduce cholesterol levels aiming to 
prevent cardiovascular events. This drug class currently consists of atorvastatin, 
fluvastatin, lovastatin, mevastatin, simvastatin, pitavastin, pravastatin, and rosuvastatin. 
The various statins although grouped together, differ in several aspects. For instance, 
lovastatin, simvastatin, and pravastatin were originally derived from fungi, whereas 
atorvastatin and fluvastatin are synthetically derived. Additionally, some statins are 
prodrugs, e.g. simvastatin and lovastatin, and have a closed lactone ring that is 
converted by carboxyesterases to the open-ring acid form that inhibits HMG-CoA 
reductase. Atorvastatin, lovastatin, and simvastatin are lipophilic which implies they can 
cross the blood brain-barrier and cause central nervous system side effects (like 
insomnia) whereas pravastatin, rosuvastatin, and fluvastatin are more hydrophilic, which 
may also a play role in their biological effects [271]. 
Historically, an inverse association between cholesterol and the incidence of (smoking-
related) cancers has been observed [272], suggesting a link between low cholesterol 
and cancer. In addition, lovastatin and gemfibrozil (a fibrate- another lipid lowering drug) 
were shown to promote development of liver cancer in rodents [273]. However, 
subsequent research demonstrated paradoxical results suggesting decreased cancer 
incidences with use of lipid-lowering drugs. In this chapter, I will explore this further, but 
it is first worth reviewing the biological effects of statins.  
 
5.2 Biological effects of statins 
As a class, statins (HMG-CoA reductase inhibitors) cause reduction in the serum 
cholesterol levels by inhibiting HMG-CoA reductase, a rate-limiting enzyme in the 
mevalonate synthesis pathway [274]. Increased use of statins over the last 30 years has 
been reported to be associated with a decrease in cholesterol levels and cardiovascular 
mortality [275].  
The putative mechanism of action for both the cholesterol lowering and anticancer 
effects of statins is considered to be inhibition of HMG-CoA reductase, an enzyme 
upstream in the mevalonate biosynthetic pathway. Inhibition of HMG-CoA reductase 
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leads to reduced synthesis of mevalonate and its downstream products. 
Farnesylpyrophosphate (FPP), a C15-moiety, is one of these downstream products and 
is the precursor of both geranylpyrophosphate (GPP), a C20-moiety, and cholesterol. 
Thus, statins reduce cholesterol levels by reducing mevalonate levels.  
Statins, however, also reduce the levels of additional intracellular proteins, such as ras, 
rho, nuclear lamins, transducin c, rhodopsin kinase, and G proteins. Consequently, 
statins lead to pleiotropic effects [276] which is consistent with the reported reduced 
mortality in takers of statins independent of their effects on cholesterol levels. 
A number of authors have reported evidence of a relationship between the use of statin 
and the risk of cancer [61-66]. Furthermore, some experimental studies report that 
statins may have a promising function in cancer chemoprophylaxis [271, 277, 278].  
Various preclinical in vitro studies using different cell lines have demonstrated the 
propensity of statins to restrain the growth and development of tumour. Statins have pro-
apoptotic, anti-proliferative, and anti-invasive properties and this has been reported in 
different cancer cell lines and with different sensitivity. In humans, the anti-myeloma 
property of statins was first demonstrated with the simultaneous administration of 
simvastatin in patients with refractory multiple myeloma (MM), resulting in decreased 
drug resistance [67]. Atorvastatin-induced effects on tumor proliferation and HMGCR 
expression were studied in a pre-operative study involving patients with primary invasive 
breast carcinoma and it was concluded that, in breast cancer cells (in vivo), HMGCR is 
targeted by statins and statins may have an anti-proliferative effect in HMGCR-positive 
tumors [68]. Additionally, fluvastatin was evaluated in patients with invasive, high-grade, 
stage 0/1 breast cancer and it demonstrated reduced tumour proliferation and increased 
apoptotic activity [69].  
Apart from in vitro efficacy, various animal models of cancer have demonstrated in 
vivo antitumor effects of statins as an efficacious chemopreventive agents and includes 
radiation-induced mammary tumorigenesis [70], chemical-induced colon tumorigenesis 
in rodent models [71], and chemical-induced lung tumour in mice [72]. Additionally, 
statins have also been reported to decrease metastasis in mouse mammary tumour [73], 
murine colon tumour [74], and mouse melanoma [75]. Moreover, three tumour models 
have demonstrated that statins result in increased in vivo antitumor effect of doxorubicin 
and this is accompanied by attenuation of its cardiotoxicity [76]. Similarly, a murine 
tumour model has demonstrated that statins lead to an increase in antitumor effect of 
tumour necrosis factor by inhibiting the tumour-induced angiogenesis [77]. 
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5.2.2 Review of literature of associations of statin usage with cancer 
5.2.2.1 Epidemiological data on statins and in cancer other than melanoma 
The first suggestion of a possible decreased cancer incidence with statin use resulted 
from observations made in participants in randomised clinical trials of statins and 
cardiovascular disease [271]. Cancer incidence in these studies was included as a 
secondary safety outcome because of concerns that reducing cholesterol might actually 
increase cancer risk. In a meta-analysis, however, published in The Lancet, the 
Cholesterol Treatment Trialists’ (CTT) Collaborators included 14 RCTs of statins and 
found no evidence for a decreased cancer incidence (RR = 1.00, 95% CI = 0.95-1.06) 
[279].Since then, a large number of meta-analyses and observational studies 
investigating statin use and cancer incidence have been performed.  
Looking at cancer in general, two large population-based studies reported decreased 
incidences of cancer [280, 281]. While, one reported that statin use was associated with 
a 20% decrease in cancer incidence (OR = 0.80, 95% CI = 0.66-0.96) and this 
association was more pronounced with prolonged use (statin use ≥ 4 yrs, OR = 0.64, 
95% CI = 0.44-0.93) [280], other reported a significantly reduced risk of CRC (OR = 0.50, 
95% CI = 0.40-0.63) with the use of statins (≥ 5 years versus nonusers) [281]. 
Additionally, a Danish Registry based study reported that the cumulative incidence of 
death from any cause as a function of follow-up time from the date of the cancer 
diagnosis was significantly lower among statin users than among patients who had never 
used statins (p-value < 0.001). Also, absence of a dose–response relationship for statins 
and cancer-related mortality suggests that any statin dose will suffice in reducing 
mortality among patients with cancer [282]. Similarly, the PRIME study reported a 
reduced cancer mortality, although statistically non-significant, among dyslipidemic men 
using statins as compared to untreated dyslipidemic men (OR = 0.41, 95% CI = 0.19-
1.06) [283]. These findings are also supported by the observation that use of statin is 
associated with the reduced cancer-related mortality among patients with advanced 
prostate cancer and a correspondingly reduced recurrence among patients with prostate 
or breast cancer [284-287]. Additionally, various recent epidemiologic studies have 
shown reductions in mortality risk among statin users with ovarian, prostate, and renal 
cell cancers compared with non-users [288-290].  
A systematic review and meta-analysis demonstrated that statin exposure is associated 
with a 21%, 17%, and 15% reduced risk of all-cause mortality, lung cancer-specific 
mortality, and risk of recurrence, respectively [291]. Another systematic review and meta-
analysis reported that statin use is associated with reduced overall mortality and CRC-
specific mortality. Analyses stratified by statin use before and after CRC diagnosis 
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showed that post-diagnosis statin use led to a 30% reduction in CRC-specific mortality 
and a 24% reduction in overall mortality compared with non-users. However, their 
findings showed that pre-diagnosis statin use led to a 20% reduction in CRC-specific 
mortality and a 30% reduction in overall mortality compared with non-users. However, 
post-diagnosis statin use did not improve disease-free survival (DFS) and recurrence-
free survival (RFS) [292].Thus, after reviewing all the above cited studies (i.e., both 
preclinical and clinical), I can conclude that compared to statin non-users, statin users 
have significantly lower cancer specific and overall mortality.  
5.2.2.2 Laboratory data relating to statins and cancers other than 
melanoma 
Various studies have evaluated the efficacy of atorvastatin in different cancers other than 
melanoma [293][23]. An in-vitro study evaluated the effects of atorvastatin on 
proliferation of cells in ovarian cancer and observed that atorvastatin inhibited the 
proliferation of both the Hey and SKOV3 ovarian cancer cells in a dose-dependent 
manner. This activity was linked with induction of apoptosis, autophagy, cellular stress, 
and cell cycle (G1) arrest through induction of the MAPK and blocking of AKT/mTOR 
pathways. Additionally, atorvastatin resulted in decreased expression of VEGF and 
MMP9 as well as inhibition of cell adhesion and invasion. Ovarian cancer cells exposed 
to atorvastatin had down regulation of c-Myc. JQ1 mediated inhibition of c-Myc 
synergistically enhanced the sensitivity of ovarian cancer cells to atorvastatin. Thus, the 
authors concluded that atorvastatin may have a role in the treatment of ovarian cancer 
and requires further exploration in clinical trials [293]. Another study assessed the effect 
of atorvastatin (40 mg) on biomarkers of risk in breast cancer in high-risk premenopausal 
women i.e., mammographic density (MD) and insulin growth factor 1 (IGF-1) and 
reported a significant reduction in the levels of cholesterol and low-density lipoprotein 
(LDL). After taking BMI into account, there was no observed difference in change in MD 
between the two groups. While, in the statin group, there was a significantly elevated 
level of serum IGF-1. Thus, the authors concluded that no change in MD and significant 
change in other biomarkers suggests that statins may not act via change in MD although 
the short duration of the study is a potential limitation [294]. Additionally, the effect of 
atorvastatin on biomarkers in breast tissue and serum of women at increased risk of 
breast cancer were studied in another study and a significant decrease in serum CRP, 
cholesterol, and low-density lipoprotein (LDL), and rise in atorvastatin metabolites in 
serum and breast FNACs was observed. Thus, authors concluded that atorvastatin and 
its metabolites are detectable in breast samples and may decrease serum CRP in 
women without hyperlipidemia [295].Similarly, some studies have evaluated the efficacy 
of simvastatin in different cancers other than melanoma. A prospective study was 
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undertaken to identify potential biomarkers of prophylactic activity of simvastatin. A high-
risk model in the form of contralateral breast of women with a prior history of breast 
cancer was used. During the study, there was a significant decrease in total cholesterol, 
LDL cholesterol, triglyceride, and hsCRP (P values <0.001, <0.001, 0.003, and 0.05, 
respectively). Moreover, simvastatin treatment resulted in a significant decrease in 
concentration of estrone sulfate (P = 0.01 overall), especially among post-menopausal 
women (P = 0.006). Thus, authors concluded that this study depicts the feasibility of 
short-term biomarker modulation studies using the contralateral breast of high-risk 
women [296]. Another study explored the viability of nasopharyngeal carcinoma cell line, 
C666-1, after addition of simvastatin and assessed by the alamar Blue Cell Viability 
Assay. It was observed that simvastatin, in a concentration-dependent manner, resulted 
in a marked decline in cell viability, enhanced caspase 3 activity, and induction of 
apoptosis in C666-1 cells. Additionally, inhibition of the expression of cyclin D1 and 
cyclin-dependent kinase 4, and enhanced expression of p27 resulted in arrest of the cell 
cycle in the G1 phase. Thus, it was concluded that simvastatin is a potential 
chemotherapy agent in the treatment of nasopharyngeal carcinoma [297]. 
Various epidemiological studies have reported variable potential association between 
incident melanomas and statin use. A case-control study on cancer and statin use 
utilized data from the GPRD (General Practitioners’ Research Database) in the UK [298]. 
In a sub analysis within this study, they observed a relative risk of 2.5 (95% CI = 0.78-
7.3) for melanoma using records from 79 incident melanoma cases between 1990 and 
2002 and up to five controls per case matched on year of birth, sex, general practice 
providing the data, year of entry into the GPRD, and index date. The follow-up in this 
study ranged between 3 and 13.7 years with a median of 6.4 years [298]. However, the 
number of melanoma cases in this study was very small as reflected in the wide 
confidence intervals. Another case-control study had 1,318 melanoma cases and 6,786 
controls matched on sex, date of birth and geographic region, and they reported no 
association between statin use and melanoma incidence (OR = 0.98, 95% CI = 0.78-
1.2). However, interestingly the Breslow thickness in melanomas was lower among statin 
users (–19%, 95% CI = –33% to –2.3%). In a pre-specified stratified analysis they 
observed that the difference in thickness was non-significant among women (–4.8%, 
95% CI = –29.6% to 28.8%), but significant in men (–27.8%, 95% CI = –43.7% to –7.4%). 
The lack of an association with melanoma incidence in the study was potentially thought 
to have been explained by the relatively short follow-up period of 3 years for all 
individuals [299]. 
In a Cochrane review incident melanomas were assessed, included as a secondary 
outcome of RCTs with primary cardiovascular outcomes. In this review, 6 statin RCTs 
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providing data on incident melanomas were included. The resulting odd’s ratio was 0.90 
(95% CI = 0.56-1.44) indicating no statistically significant difference. However, due to the 
low numbers of incident melanomas, a (clinically relevant) association could not be 
excluded. More importantly, three of the included RCTs studied pravastatin, which may 
have, as in vitro studies have suggested, lower chemopreventive activity than other 
statins. Interestingly, a subgroup analysis by type of statin showed a reduced melanoma 
incidence for lovastatin (OR = 0.52, 95% CI = 0.27-0.99). This analysis was, however, 
importantly limited by the fact that there was only one trial with lovastatin. Thus, the 
authors concluded that they could not exclude the possibility that statin prevent 
melanoma [300].Additionally, a sub analysis among the trials for which melanoma 
incidence was available, the Cholesterol Treatment Triallists reported no statistically 
significant change in melanoma incidence (RR = 1.03, 95% CI = 0.71-1.50) in 14 RCT 
statin studies [279]. Other similar meta-analyses have reported melanoma incidence with 
estimates for melanoma incidence ranging from 0.84 to 1.5 [301, 302]. However, they 
mainly included the same RCTs.  
These clinical trials, however, have several disadvantages which include small numbers 
of incident melanomas, relatively short follow-up for melanoma incidence (ranging from 
3 to 6 years), and, generally, of being a retrospective reviews of cardiovascular trials, in 
which the design was not adapted for the analysis for melanoma incidence as they were 
not stratified for other factors known to influence melanoma survival as done in this study. 
Therefore, retrospective analyses on these trials will always be of limited value. 
In terms of melanoma survival and statins, which is the main focus of this study, the main 
study of relevance is a Dutch population based study by Livingstone et al. [303] involving 
a cohort of 709 melanoma patients. Neither timing, nor duration or dosage of statin use 
changed the hazard of death significantly. Stratification on sex, however, demonstrated 
possible superior survival of statin users compared to nonusers in males only and I, 
therefore, also carried out this stratification in the cohort of this study. In keeping with the 
cohort, in this study, almost half of all the statins dispensed were for simvastatin (47.4%), 
followed by atorvastatin (28.7%). 
Additionally, two abstracts appeared on a preliminary case control study comparing 
the use of statins among 74 melanoma cases and age, sex and race-matched controls. 
Preliminary results in this study were promising (OR = 0.55, p = 0.11) [304, 305]. 
However, to the best of my knowledge, the results of the final analysis have not been 
published. 
In summary, the results of secondary analyses of cardiovascular trials and of 
observational research on the potential relation between statin use and incident 
melanomas are conflicting. Both these RCTs as well as the epidemiological studies have 
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some important limitations such as potential residual confounding, and small numbers of 
incident melanomas and thus, limited power. Furthermore, there are limited studies 
looking at melanoma survival and statin use making this study all the more important.  
5.2.2.3 Laboratory data relating to statins and melanoma 
Several of the proteins dependent on posttranslational prenylation, either farnesylation 
or geranylgeranylation, such as ras, rhoA and rhoC, have been linked to cancer 
pathogenesis. For example, ras is a known oncogene and ~30% of human tumours 
harbour ras mutations resulting in aberrant ras activity which is dependent on prenylation 
[276]. Specifically, N-ras and B-raf mutations are observed in ~30% and ~60% of 
melanomas, respectively. N-ras and B-raf mutations both result in activation of the so-
called Ras/Raf/MEK/ERK signalling pathway [306]. Raf which is downstream of ras, 
however, does not require prenylation to achieve full biological activity [307]. Still, in 
melanomas with a B-raf mutation, but no ras mutation, possible antineoplastic effects 
may be mediated through for instance rhoA or rhoC. A potential  chemopreventive agent 
that may interfere in this pathway are the statins [276, 306]. Specifically, one hypothesis 
is that some of the potential beneficial effects of statins in terms of cancer, would relate 
to reduced activation of key pathways involved in carcinogenesis such as MAP kinase 
signalling. Furthermore, the rho family is involved in signalling and regulation of cell 
differentiation and proliferation [308].  
High-throughput screens for transcriptionally regulated targets involved in metastasis 
have shown that rhoC overexpression is strongly associated with the metastatic potential 
of inoculated melanoma in mice [309]. Indeed, in vitro and animal melanoma studies 
show a potentially chemopreventive activity of statins. More specifically, anti-tumour 
effects exerted by statins have been shown to be act in a number of different ways as 
listed below: 
1) Inhibition of tumour growth: Lovastatin, mevastatin, and simvastatin, but not 
pravastatin, reduced tumour growth of human melanoma cell lines HT144, M14, and SK-
MEL-28 in vitro with IC50 values between 0.8 and 2.1 μm [310]. 
2) Induction of apoptosis: Jani et al. observed induction of apoptosis by lovastatin in 
murine B16F10 melanoma cells through a geranylation-specific mechanism [311]; 
Additionally, increased apoptosis, in a dose-dependent manner, was observed in human 
M14 cells after 72-h incubations (4-8 μm) of lovastatin, mevastatin, and simvastatin 
[310]. In human A375 melanoma cells, Shellman et al. also showed induced apoptosis 
by lovastatin [312]. Interestingly, Shellman et al. also performed add back experiments 
showing that supplementation of GPP, but not FPP, blocked the apoptotic effect of 
105 
lovastatin which indicates apoptosis must involve proteins dependent on 
geranylgeranylation [312]. 
3) Reduce invasiveness and metastasis: Atorvastatin (1-3 μm) reduced invasiveness 
of A375M, CHL, SK-MEL-28 and WM 166-4 melanoma cells in an experiment performed 
by Collisson and colleagues [313]. In this experiment, atorvastatin (4 dd 10 mg/kg) orally 
also reduced metastasis of A375M melanocytes in severe combined immunodeficient 
(SCID) mice [313]. Likewise, Jani et al. showed reduced metastasis by lovastatin and 
simvastatin in murine B16F10 melanoma cells [311]. Experiments reported by Glynn et 
al. also showed decreased invasiveness by lovastatin, mevastatin, and simvastatin on 
HT144, M14, and SK-MEL-28 cells [310].  
4) Effects on angiogenesis: Lovastatin (2-12.5 μm) exhibited a concentration-
dependent pro-angiogenic influence on A375M and G361 cells in an angiogenesis model 
with a co-culture of HUVEC cells (human umbilical vein endothelial cells) and human 
diploid fibroblasts (HDF) [314]. However, in non-melanoma cells, some studies with low-
dosed statins have suggested increased angiogenesis [276]. 
5) Effects independent of HMG-CoA reductase and cholesterol lowering: some 
experiments with statins in the closed ring form, which do not inhibit HMG-CoA 
reductase, do show in vitro anticancer effects [315]. Further investigations on these 
cholesterol-independent pathways are needed. 
Examples of the cholesterol-independent pathways that have been suggested are: 
• binding to the leukocyte function antigen-1 (LFA1) which has an important role in 
leukocyte migration and T-cell activation [316]. 
• inhibition of the proteasome [315] which could for instance account for effects on 
the cyclin-dependent kinase inhibitors (CDKIs) p21 and p27 [317], and increased 
fibrinolytic activity [318]. 
• altered membrane receptor function due to changes in membrane fluidity caused 
by cholesterol depletion. For example, melanocortin receptor (MC1R) [319] or 
insulin-like growth factor receptor function [320], both of which are involved in 
melanocyte and melanoma growth. 
6) Potential direct effects of cholesterol lowering: Some investigators suggested that 
direct toxic effects of cholesterol lowering are involved [321]. Malignant cells metabolize 
cholesterol differently and, therefore, may be more sensitive. However, the evidence for 
this hypothesis is limited. 
Although in vitro and animal experiments in general show promising results, some critical 
issues should be mentioned. E.g., pravastatin, the only hydrophilic statin, does not 
exhibit clear chemopreventive effects in most experiments. Moreover, most studies have 
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used statins at serum concentrations and dosages that exceed doses applied for the 
treatment of hypercholesterolemia. Lovastatin dosed at ~1 mg/kg/ day, for example, 
yields steady-state serum concentrations of 0.15–0.3 μm [322]. Often tumour cell lines 
were only sensitive to lovastatin at higher concentrations, e.g. 1.0-12.5 μm [310, 312, 
314]. 
Additionally, the effects of various statins i.e., simvastatin, fluvastatin, or lovastatin on 
proliferation, apoptosis induction, cell cycle progression, autophagy, and migration of 
melanoma cell were evaluated in an in vitro study involving melanoma cell lines. It was 
observed that all the three statins exhibited a strong inhibitory effect on the growth of 
melanoma cells at submicromolar concentrations, in virtually all cell lines irrespective of 
genotype. Simvastatin induced apoptosis and autophagy, arrested cell cycle at G0/G1 
phase, and inhibited cell migration. Analogous effects were also observed with other 
inhibitors of the mevalonate pathways. Importantly, it was observed that combinations of 
simvastatin or fluvastatin with vemurafenib, CI-1040, ZSTK474, or NVPBEZ-235 
significantly enhanced the inhibitory effect toward melanoma cell growth in vitro. The in 
vivo effects of simvastatin were also investigated and it was found that simvastatin 
delayed the growth of NZM37 xenograft in athymic nude mice. Furthermore, they 
completed whole-genome, positive-selection CRISPR screens with the three statins and 
demonstrated evolution of marked resistance to these agents [323]. 
Apart from the above described mechanisms, statins have been reported to have anti-
inflammatory effects, including decreasing the concentrations of C-reactive protein 
(CRP) [80]. As LDL cholesterol itself is a strong promoter of inflammation, The effects of 
lowering low-density lipoprotein (LDL) cholesterol with statins may lead to anti-
inflammatory actions because [81]. Addition of statins to human hepatocytes reduces 
the levels of C-reactive protein induced by circulating interleukin 6 (IL-6), suggesting that 
the anti-inflammatory effects of statins are hepatic in nature [82]. Moreover, statins exert 
anti-inflammatory action by affecting mediators of inflammation such as IL-8, IL-1β, IL-
12, tumour necrosis factor α (TNF-α), and nuclear factor κB (NF-κB) [83]. In a cohort 
study, Brewer et al. analysed the effect of statin on the primary inflammatory breast 
cancer and reported that weakly lipophilic to hydrophilic statins were associated with 
significantly improved progression-free survival compared with no statin (HR = 0.49; 95% 
CI = 0.28–0.84; p < 0.01) [84]. However, these results needs to be confirmed in a 
randomized study. 
Interestingly, some agents may have synergistic chemopreventive action together with 
statins. For example, d-G-tocotrienol (5 μm) together with lovastatin (1 μm) totally 
blocked cell growth, whereas lovastatin (12%) and d-G-tocotrienol (8%) individually 
showed only limited growth inhibition in these concentrations [324]. Other agents that 
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have been suggested in combination with statins are NSAIDs, bisphosphonates, GGTIs, 
phosphoinositide 3-kinase (PI3K) inhibitors, CDKI, MEK inhibitors, and tyrosine kinase 
inhibitors [276]. The possible synergistic effects, alongside NSAID, is a particularly 
relevant to this study, but, as discussed in the methods chapter, is a limitation of the 
study as we cannot analyse both together. Although, I have looked at the number of 
patients who were on both drugs as shown in Chapter 3.  
5.2.2.4 Looking at different statins separately  
Although in vitro and animal experiments in general show promising results for statins 
as a group in cancer, there exists significant variability between the effects and potential 
mechanisms of actions of individual statins. The two main statins reported in the context 
of cancer and in our cohort are atorvastatin and simvastatin and I will compare these in 
order to determine how best to analyse them. 
As noted previously based on in vitro studies involving melanoma cell lines, simvastatin 
primarily mediates its effects via a strong inhibitory effect on the growth of melanoma 
cells, in virtually all cell lines irrespective of genotype. Simvastatin has also been found 
to induce apoptosis and autophagy, arrested cell cycle at G0/G1 phase, and inhibit cell 
migration. Analogous effects were also observed with other inhibitors of the mevalonate 
pathways and most significantly it was observed that a combination of simvastatin and 
vemurafenib, significantly enhanced the inhibitory effect toward melanoma cell growth in 
vitro. The in vivo effects of simvastatin were also investigated and it was found that 
simvastatin delayed the growth of NZM37 xenograft in athymic nude mice [323]. 
Atorvastatin whilst also a lipophilic statin mediates its effects via preventing RhoC and 
preventing invasion and metastasis as opposed to growth of cells and atorvastatin 
treatment has been shown to inhibit the colonization and formation of lung metastases 
of melanoma cells overexpressing RhoC [313]It is also reported to differentially enhance 
endothelial cell proliferation, whereas high concentrations (2.5 mg/kg per day) have been 
shown to significantly inhibit angiogenesis [325]. 
There are reasons to consider analysing both drugs together such as clear overlapping 
mechanisms of action in terms of effects mediated via reduction in cholesterol and the 
fact that they are both lipophilic statins, which would help with statistical power. However, 
I decided to analyse them separately, accepting a loss of power, in order to make the 
analysis cleaner in terms of the differing biological effects as well as the issues outlined 
in the methodology in chapter 2 with switches between these drugs. For instance, some 
patients would start out on simvastatin to control their hypercholesterolemia but then be 
switched to atorvastatin if they had for instance a stroke or a heart attack. A proportion 
of these, were subsequently found to have been switched back to simvastatin either as 
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a result of side effects with atorvastatin, or due to cost saving measures with the same 
group of patients being switched between these statins making the statistical analysis 
practically very difficult to perform. 
5.2.3 Safety and Compliance 
In the cancer chemoprevention literature, the excellent safety profile of statins in 
cardiovascular disease has often been noted [306, 326]. Statins have demonstrated 
relatively mild side effects in the doses used to prevent cardiovascular events. The most 
prominent side effects of statins are the so-called statin-related myopathy (i.e., muscle 
pain and weakness), elevated creatinine kinase (CK) levels and as a rare but life-
threatening side effect, rhabdomyolysis. In RCTs, the incidence of myopathy was 1.5-
5%, whereas estimates in observational research indicated 5-10% [326]. Moreover, the 
US FDA Adverse Event Reporting System database reports rates of statin-induced 
rhabdomyolysis of 0.3–13.5 cases per 1,000,000 statin prescriptions [78]. In spite of the 
fact that the majority of side effects are thought to be mild, compliance with statin use 
cardiovascular disease has been poor, with only ~25% of patients still compliant 5 years 
after starting statin therapy [327].  
In terms of cancer chemoprevention, higher day doses may be required and as such the 
tolerability of statins has been proven to be limited due to dose-dependent side effects 
such as myopathy. In phase I/II trials for cancer treatment, significant responses were 
only achieved with >25 mg/kg/day doses leading to dose-limiting toxicities (DLTs) 
including myalgia, muscle weakness, elevated CK activity, anorexia, ulcerative lesions, 
rhabdomyolysis, nausea, diarrhoea, and fatigue. With very high statin doses, 
cardiomyopathy may even be a side effect [328]. In the trials mentioned, among others 
cycled dosing with 3-4 week intervals was introduced to prevent DLTs [322].  
For melanoma chemoprevention, given the limitations of the studies as discussed above, 
it remains uncertain what doses are required. However, since cell lines studies often 
indicate cytostatic rather than cytotoxic effects at achievable in vivo statin 
concentrations, continuous dosing is likely to be required [329]. Numerous risk factors 
for statin-related myopathy have been described [330]. Among these risk factors is using 
high statin doses which, as mentioned before, may be required for chemopreventive 
effects. The risk of myopathy or rhabdomyolysis with simvastatin alone is dose related; 
the incidence, determined from clinical trials, is approximately 0.03% at 20mg, 0.08% at 
40mg and 0.4% at 80mg daily. This risk is increased with concomitant fibrates, as they 
alone can cause myopathy [79]. Some of the risk factors may be circumventable, such 
as excessive physical activity, use in the perioperative period, and concomitant use of 
drugs or grapefruit juice which precipitate drug interactions associated with elevated 
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serum statin levels. For atorvastatin, lovastatin, cerivastatin or simvastatin, 
concomitantly administered drugs resulting in drug interactions and subsequently, 
increased statin-induced myopathy are CYP3A4 inhibitors (fibrates, warfarin, macrolide 
antibiotics, azole antifungal, and others) and for fluvastatin these are CYP2C9 inhibitors 
(sulfaphenazole, valproic acid, flucaonazole, miconazole, amiodarone, and others) 
[330]. Avoiding the risk factor, temporary cessation of statin therapy, or drug alternatives 
for the inhibitors can be options in these cases. Non-preventable risk factors, such as 
advanced age, female sex, (relative) renal insufficiency, hypothyroidism, alcoholism or 
(family) history of myopathy or CK elevation [330], have been recommended for 
consideration as special subgroups in formal risk-benefit analyses. Some of the non-
preventable risk factors might be considered contraindications for statin therapy, e.g. 
(relative) renal insufficiency. 
The causal mechanism of statin-related myopathy is not entirely unravelled. Among the 
proposed mechanism is depletion of ubiquinone (also referred to as coenzyme Q10). 
Ubiquinone, a side-product in the mevalonate pathway, is widely used as a non-drug 
‘over the counter’ (OTC) anti-aging agent, but studies on its long-term safety are sparse. 
Concomitant use of ubiquinone may, however, prove to be a good candidate to increase 
statins’ tolerability. Indeed, Thibault et al. have used adding Q10 to lovastatin therapy for 
doses of 30 mg/kg/day as a strategy to prevent statin-related myopathy and increase 
tolerability. From these preliminary data, this strategy seems to be promising 
[322].Further research is needed to explore the precise mechanisms involved in statin-
related myopathy, and after required statin doses have been established, to determine 
the long-term safety of this chemopreventive strategy. 
In summary, long-term safety data for low dose statins is excellent, but may be less 
favourable for higher doses that are possibly likely to be required for chemoprevention 
of melanoma. Development of a chemopreventive strategy including risk factors for 
statin-related myopathy and preventive measures may ameliorate the risk-benefit ratio. 
 
5.3 Materials and Methods 
Simvastatin was the most frequently used statin in our cohort followed by atorvastatin in 
keeping with other studies, and as mentioned in the methodology, given the differing 
mechanisms of action of these, they were felt to be best analysed separately and I will 
discuss the limitations of this in the discussion. 
Having collected the drug data for all drugs used in our cohort, which is the largest cohort 
of melanoma patients as detailed in Chapter 2, and having identified Simvastatin and 
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Atorvastatin as drugs of interest as presented in chapter 3,, various further drug specific 
considerations were considered as detailed below.  
Firstly I had to ensure all entries for both statins were identified accurately by accounting 
for trade names, BNF codes, misspellings in data entry and missing data by cross-
checking all data sources. As discussed in Chapter 2 due to limitations of the study 
approach I did not examine the effects of drug dosages but also given that “standard 
doses” are used to prevent cardiovascular disease with no patients on doses referred to 
in the phase I /II trials for cancer treatment discussed above, I would not expect there to 
be a significant variation in results due to a dose effect. 
I then interrogated the data further by looking at the demographics of the population 
taking statins by examining the number of males and females on the drug in our cohort, 
their smoking status, their diabetic status, vitamin D levels and the distribution based on 
Breslow thickness. For statins, similar to aspirin, is prescribed to the same group of 
patients who are likely to have features of the metabolic syndrome with increased BMI 
and Diabetes and ischaemic heart disease. Therefore, we expected to see some 
common trends within our analysis.  
The effects of exposure to statins on melanoma specific (MS) and overall survival (OS) 
were then assessed using Cox Proportional Hazards models. Data was first checked to 
ensure that the proportional hazards assumption was met. Hazard ratios (HR) and 95% 
Confidence intervals (CI) were estimated and Kaplan-Meier curves were plotted. Firstly, 
unadjusted models were examined and then adjustment for common confounders were 
applied; firstly, sex and age at diagnosis, then Breslow thickness, ulceration, other 
comorbidity measures (smoking, body mass index (BMI), and serum level of vitamin D 
adjusted for seasonal variation. Analyses were conducted both with and without 
adjustment for stage (represented by Breslow thickness and ulceration), since statins 
may influence outcome through an effect on the growth of the tumour, which may be 
captured by stage at diagnosis. 
Given that men have a higher risk of these conditions we had expected to see more men 
being prescribed statins than women and we also expected to see more smokers and 
diabetics having been prescribed statin, as these are independent risk factors for 
ischaemic heart disease. We also expected this group of patients to be overweight 
compared to the rest of the cohort population (BMI > 25). 
As detailed in the methodology chapter, I then undertook a survival analysis based on 
firstly the ever versus never approach with the recognised guarantee time bias, first 
examining the unadjusted model and then adjusting for known confounders. 
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The second approach was a survival analysis looking at the effects of statins up to 
diagnosis or within 12 months of diagnosis. This method of analysis essentially replicates 
the traditional methods used in cancer incidence studies with no inherent bias but as 
discussed in the methodology section our study was not geared up for this in terms of 
the data collection with potentially poorer quality data before diagnosis and with some 
loss of power due to exclusion. As with the previous approach we first examine the 
unadjusted model and then adjust for known confounders 
Finally given the literature evidence of potential varying effects of drugs on survival based 
on sex as demonstrated in our literature survey with the large Dutch population based 
study on melanoma incidence as described above (ref), we also carried out a survival 
analysis whereby we stratified by sex to identify any sex specific trends whilst also 
adjusting for Breslow thickness given the possible effects of statins on this.  
 
5.4 Results 
In our cohort, simvastatin usage at any time was reported by 336 (15.87%) of melanoma 
participants in our cohort. Similarly, 126 patients (5.95%) reported ever using 
atorvastatin. Firstly I will present the results for simvastatin, which I will go though in 
some more detail but will then also present a summary of the results for atorvastatin.  
We first looked at the characteristics of the simvastatin users and as per Table 5.1 there 
were significant differences noted between users and non-users in the majority of 
characteristics examined. The majority of users were male (198, 58.93%) compared to 
women (138, 41.07%) taking simvastatin (p<0.001), which would be expected given that 
studies suggest that men are twice as likely as females to have ischaemic heart disease 
and as discussed in the aspirin chapter they are often prescribed both a statin and aspirin 
to reduce this risk. Although the discrepancy was not as great as in the aspirin group it 
is important to bear in mind that as shown in Chapter 3, Table 3.23, 155 patients were 
on both aspirin and simvastatin and therefore there is a significant overlap of the same 
patients on both drugs. 
  
112 
Table 5.1: Characteristics of patients ever treated with simvastatin 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05 
Ever Treated with Simvastatin? Yes - n (%) No - n (%) P-value 
Total no of patients 336 (100) 1,781 (100)  
Age at diagnosis 65 (11.1) 54 (20.7) <0.001 
Gender    
     Female 138 (41.07) 1,070 (60.08) 
<0.001 
     Male 198 (58.93) 711 (39.92) 
Diabetes     
     No 287 (86.97) 1,661 (97.76) 
<0.001 
     Yes 43 (13.03) 38 (2.24) 
Body Mass Index    
     </=24.9kg/m2 59 (17.66) 731 (41.42) 
<0.001      >24.9-29.9kg/m2 173 (51.80) 681 (38.58) 
     >29.9kg/m2 102 (30.54) 353 (20.00) 
Smoking Status    
      Never 147 (44.28) 979 (57.22) 
<0.001 
     Ever Smoked 185 (55.72) 732 (42.78) 
Smoking status    
     Not currently smoking 156 (83.87) 523 (71.45) 
<0.001 
     Currently smoking 30 (16.13) 209 (28.55) 
Breslow thickness    
     </=1mm 70 (21.02) 525 (29.83) 
0.013 
     1.01-2mm 143 (42.94) 663 (37.67) 
     2.01-4mm 82 (24.62) 382 (21.70) 
     >4mm 38 (11.41) 190 (10.80) 
Vitamin D    
     <20nmol/L 17 (5.92) 91 (6.28) 
0.719 
     20-59.9nmol/L 193 (67.25) 964 (66.57) 
     60-84.9nmol/L 68 (23.69) 323 (22.31) 
     85-99.9nmol/L 7 (2.44) 47 (3.25) 
     >100nmol/L 2 (0.70) 23 (1.59) 
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Further analysis of the cohort showed that a higher proportion of people on simvastatin 
were diabetic (43, 13.03% vs. 38, 2.24%; p<0.001) or ever smokers (185, 55.72% vs. 
732, 42.78%; p<0.001) compared to those not on simvastatin. This would be expected 
given that both diabetes and smoking are risk factors for IHD and this population is, 
therefore, more likely to be prescribed statins as in the case of aspirin.  Like in the case 
of aspirin, people who had ever used simvastatin were more likely to be current non-
smokers (30, 16.13% vs. 209, 28.55%; p<0.001), and may have stopped smoking 
possibly due to cessation advice. In terms of BMI, patients on simvastatin were more 
likely to be overweight or obese (p<0.001), and this would again be expected, as this is 
a risk factor for IHD. As discussed earlier, vitamin D is one of the factors thought to 
influence melanoma survival and we, therefore, wanted to analyse our cohort to see if 
there was a statistical difference in vitamin D levels between users and non-users by 
defining different ranges of vitamin D and comparing with the base group and we 
observed no statistical difference as shown (p=0.719).  
Similar to aspirin, a tendency to higher Breslow thickness was observed in this case in 
users of simvastatin compared to non-users (p<0.013). I therefore explored this 
association by performing a univariable regression analysis of factors associated with 
simvastatin use followed by a multivariable analysis (Table 5.2 and Table 5.3). As in the 
case of aspirin, higher Breslow thickness category was not associated with a higher odds 
of aspirin use following adjustment for age, male gender, diabetes and BMI. 
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Table 5.2: Univariable analysis of simvastatin use (ever-never) 
Regression analyses were performed using a logistic regression approach with 
simvastatin use as a dependent variable and age, gender, diabetes status, body 
mass index, Breslow thickness, and vitamin D as independent variables in each 
univariable analysis. 
 Odds Ratio 95% Confidence Interval P-value 
Age at diagnosis 1.08 1.07-1.10 <0.001 
Male gender 2.16 1.70-2.74 <0.001 
Diabetes 6.55 4.16-10.31 <0.001 
Body mass index    
     >24.9-29.9kg/m2 3.15 2.30-4.31 <0.001 
     >29.9kg/m2 3.58 2.54-5.05 <0.001 
Breslow thickness    
     1.01-2mm 1.62 1.19-2.20 0.002 
     2.01-4mm 1.61 1.14-2.27 0.007 
     >4mm 1.50 0.98-2.30 0.064 
Vitamin D 1.00 0.99-1.00 0.508 
 
Table 5.3: Multivariable analysis of simvastatin use (ever-never) 
Regression analyses were performed using a logistic regression approach with 
simvastatin use as a dependent variable and age, male gender, diabetes, body 
mass index and Breslow thickness as independent variables. 
 Odds Ratio 95% Confidence Interval P-value 
Age at diagnosis 1.08  1.07-1.09 <0.001 
Male gender 1.59  1.21-2.07 0.001 
Diabetes 3.77  1.28-6.23 <0.001 
Body mass index     
>24.9-29.9kg/m2 2.52    1.80-3.54 <0.001 
>29.9kg/m2 2.99    2.04-4.39 <0.001 
Breslow thickness     
1.01-2mm 1.32    0.94-1.85  0.111 
2.01-4mm 1.09    0.74-1.60 0.655 
>4mm 0.85    0.53-1.35 0.483 
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5.4.4 Effect of simvastatin ever use on survival outcomes 
As shown in Figure 5.1 below the unadjusted survival distribution between participants 
who had ever used simvastatin and those who had never used the drug appear to be 
different for both MSS and OS as shown in Table 5.4 with participants who had used 
simvastatin appearing to have non-significant negative effect with hazard ratios of 1.14 
(95% CI: 0.87-1.48, p = 0.342) and 1.15 (95% CI: 0.90-1.48, p = 0.263) respectively.  
 
 
Figure 5.1: Unadjusted Kaplan-Meier survival plots for melanoma participants who 
had ever or never used simvastatin – MSS and OS  
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Table 5.4: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients ever having taken simvastatin regularly (ever-
never) 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
 Melanoma-specific survival Overall survival 
 HR (95% CI) p-value HR (95% CI) p-value 
Unadjusted or crude 
model 
1.14 (0.87-1.48) 0.342 1.15 (0.90-1.48)) 0.263 
Adjusted for age at 
diagnosis and sex 
0.76 (0.57-1.00) 0.048 0.71 (0.55-0.92) 0.010 
Adjusted for age at 
diagnosis, sex and 
Breslow thickness 
0.79 (0.59-1.04) 0.096 0.75 (0.58-0.97) 0.028 
Adjusted for other risk 
factors* 
0.71 (0.50-0.99) 0.043 0.66 (0.48-0.90) 0.009 
 
However, as previously established increasing age and the male sex are known 
predictors of melanoma and overall survival. Similar to the case of aspirin, when the 
model was adjusted for age at diagnosis and sex, this effect changed and ever taking 
simvastatin was associated with a lower risk of dying from melanoma HR (MSS) 0.76 
(95% CI: 0.57–1.00; p = 0.048) and overall survival HR (OS) 0.71 (95% CI: 0.55-0.92; p 
= 0.010). The effect appeared to be maintained with significant protective effects seen in 
both MSS and OS even in our multivariable approach although it did appear to lose 
statistical significance for MSS when adjusting for Breslow (along with age and sex) 
(Figure 5.2) suggesting as per our literature review that simvastatin may be exerting 
some of this possible protective effect via a reduction in Breslow thickness. However as 
discussed in the methodology section this analysis is subject to the guarantee time bias, 
by virtue of the fact that, the longer someone lives, the higher the likelihood of them 





Figure 5.2: Adjusted Kaplan-Meier survival (MSS) plot for melanoma participants 
who had ever or never used simvastatin (adjusted for age, sex and Breslow) 
Chart axes: x – years, y – probability of survival. 
 
5.4.5 Simvastatin use within 12 months of diagnosis 
The Kaplan Meier plot as shown in Figure 5.3 below again suggested that participants 
who used simvastatin at diagnosis or within 12 months of diagnosis, have a poorer 
chance of survival for both MSS and OSS as compared with those who did not use 
simvastatin in the unadjusted model although again non-significant with HR (MSS): 1.17 
(0.88-1.55, p=0.278), and HR (OS) 1.18 (0.91-1.54, p=0.215). However as shown in 
Table 5.5, just as in the last analysis the hazard ratio is reversed when adjusting for the 
known predictors age and sex. However on this occasion the statistical significance was 
not maintained in the multivariate model, which as we discussed in the methods may be 




Figure 5.3: Unadjusted Kaplan-Meier survival plots for melanoma participants who 
had used simvastatin within 12 months of diagnosis. 
Chart axes: x – years, y – probability of survival. 
Table 5.5: Cox’s proportional hazards regression analysis on the effect of 
simvastatin use within 12 months of diagnosis on survival 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
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 Melanoma-specific survival Overall survival 
 HR (95% CI) p-value HR (95% CI) p-value 
Unadjusted or crude 
model 
1.17 (0.88-1.55) 0.278 1.18 (0.91-1.54) 0.215 
Adjusted for age at 
diagnosis and sex 
0.77 (0.58-1.04) 0.089 0.73 (0.56-0.96) 0.023 
Adjusted for age at 
diagnosis, sex and 
Breslow thickness 
0.82 (0.61-1.10) 0.184 0.77 (0.59-1.01) 0.059 
Adjusted for other risk 
factors* 
0.78 (0.55-1.11) 0.172 0.74 (0.53-1.02) 0.065 
 
5.4.6 Stratification by sex 
As discussed previously, based on literature evidence in other melanoma cohorts, an 
analysis was conducted and stratified by sex to explore if it was possible to identify any 
similar themes with this approach. Concerning the effect of simvastatin use on overall 
survival when stratified by sex i.e., males and females had different hazard ratios when 
the use of simvastatin was considered – whether ever-never or use within 12 months of 
diagnosis. In both cases of ever-never and 12 months of diagnosis analyses, males had 
hazard ratios less than 1, while females had hazard ratios greater than one globally. As 
presented in Table 5.6, exposure to simvastatin ever/never or within 12 months of 
diagnosis was associated with significantly reduced risk of death from melanoma with 
HRs of 0.54 (95% CI: 0.37-0.79) and 0.57 (95% CI: 0.38-0.85) respectively and with p-
value < 0.05 in both cases when compared to females who had HRs of 1.03 (95% CI: 
1.02-1.04, p-value < 0.001) and 1.21 (95% CI: 0.79-1.86, p-value = 0.379) in cases of 
ever/never and 12-months at diagnosis whilst also adjusting for age at diagnosis and 
Breslow’s thickness, suggesting that simvastatin use may have a preferentially protective 
effect in male participants as compared to women.  
 
Table 5.6: Simvastatin ever-never and 12 months survival analysis stratified by 
sex and adjusted for age and Breslow thickness 
Adjusted for age at diagnosis and Breslow’s thickness. Significant p-values are in 
bold figures. HR, hazard ratio; 95% CI, 95% confidence interval 
Sex stratified 
Ever-never 12 months of diagnosis 
Mortality HR (95% CI) p-value Mortality HR (95% CI) p-value 
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Melanoma-specific     
     Male 0.54 (0.37-0.79) 0.002 0.57 (0.38-0.85) 0.006 
     Female 1.22 (0.82-1.83) 0.327 1.21 (0.79-1.86) 0.379 
Overall survival     
     Male 0.60 (0.40-0.88) 0.009 0.62 (0.41-0.92) 0.019 
     Female 1.16 (0.77-1.76) 0.471 1.21 (0.79-1.87) 0.384 
 
5.4.1 Effect of atorvastatin on survival outcomes 
We first examined the characteristics of the atorvastatin users and as per Table 5.7 and 
as for simvastatin there were significant differences noted between users and non-users 
in the majority of characteristics examined. As with simvastatin, the majority were male 
(68, 58.62%) compared to women (48, 41.38%) taking atorvastatin (p<0.001), which as 
discussed would be expected. In this case as shown in Chapter 3, Table 3.23, 80 patients 
were on both aspirin and simvastatin. Further analysis of the cohort showed that as in 
the case of simvastatin a higher proportion of people on atorvastatin were diabetic (18, 
15.93% vs. 63, 3.29%; p<0.001) and users were also more likely to be overweight or 
obese compared to non-users (p<0.001).  
Atorvastatin users were current smokers (9, 14.75% vs. 230, 26.84%; p<0.001) as 
compared to those not on atorvastatin As discussed earlier, vitamin D is one of the 
factors thought to influence melanoma survival and we, therefore, wanted to analyse our 
cohort to see if there was a statistical difference in vitamin D levels between users and 
non-users by defining different ranges of vitamin D and comparing with the base group 
and we observed no statistical difference as shown (p=0.719). Users were less likely to 
have ever smoked (p<0.057) or currently smoking (p<0.038) 
As we have stablished Breslow thickness is an important predictor of survival and 
interestingly unlike in the case of aspirin and statin, there was no significant tendency to 
higher Breslow thickness in users of atorvastatin compared to non-users (p<0.013). 
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Table 5.7: Characteristics of patients ever treated with atorvastatin 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05 
Ever Treated with Atorvastatin? Yes No P-value 
Age at diagnosis 68 (10.7) 56 (20.4) <0.001 
Gender    
     Female 48 (41.38) 1,160 (57.97) 
<0.001 
     Male 68 (58.62) 841 (42.03) 
Diabetes     
     No 95 (84.07) 1,853 (96.71) 
<0.001 
     Yes 18 (15.93) 63 (3.29) 
Body Mass Index    
     <=24.9kg/m2 29 (25.44) 761 (38.34)   
     >24.9-29.9kg/m2 43 (37.72) 811 (40.86) 
<0.001 
     >29.9kg/m2 42 (36.84) 413 (20.81) 
Smoking status    
     Never 53 (46.49)    1073 (55.62)        
0.057 
     Ever 61 (53.51) 856 (53.51) 
Smoking Status    
     Not currently smoking 52 (85.25)         627 (73.16) 0.038 
     Currently smoking 9 (14.75)         230 (26.84)  
Breslow thickness    
     <=1mm 26 (22.81) 569 (28.75)        
0.218 
     1.01-2mm 47 (41.23) 759 (38.35)        
     2.01-4mm 23 (20.18) 441 (22.28)          
     >4mm 18 (15.79) 210 (10.61)       
Vitamin D    
     <20nmol/L 6 (6.0) 102 (6.24)         
0.937 
     20-59.9nmol/L 65 (65.0) 1,092 (66.79) 
     60-84.9nmol/L 24 (24.0) 367 (22.45)       
     85-99.9nmol/L 3 (3.0) 51 (3.12)         
     >100nmol/L 2 (2.0) 23 (1.41)          
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5.4.2 Effect of atorvastatin ever use on survival outcomes 
As shown in Table 5.8 below the unadjusted model again showed a poorer chance of 
survival for both MSS and OSS as compared with those who did not use atorvastatin 
and again non-significant with HR (MSS): 1.04 (0.69-1.56, p=0.858), and HR (OS) 1.05 
(0.72-1.53, p=0.799). However as before the hazard ratio is reversed when adjusting for 
the known predictors age and sex and becomes significantly protective. The effect 
appears to remain statistically significant in both MSS and OS after further adjustment 
for Breslow, number of pack years of smoking, vitamin D levels, diabetes, ulceration, and 
BMI - suggesting that atorvastatin use is protective. 
Table 5.8: Cox’s proportional hazards regression analysis of melanoma-specific 
and overall survival in patients ever having taken atorvastatin regularly (ever-
never) 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
Model Parameter 
Atorvastatin (ever-never) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 1.04 (0.69-1.56) 1.05 (0.72-1.53) 
p-value 0.858 0.799 
Age at diagnosis & 
sex-adjusted 
HR (95% CI for HR) 0.64 (0.42-0.99) 0.65 (0.44-0.95) 
p-value 0.046 0.026 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.63 (0.41-0.97) 0.65 (0.44-0.95) 
p-value 0.036 0.025 
Adjusted for other 
risk factors* 
HR (95% CI for HR) 0.56 (0.33-0.94) 0.55 (0.34-0.88) 
p-value 0.028 0.013 
 
5.4.3 Atorvastatin use within 12 months of diagnosis 
The survival analysis in this group as shown in Table 5.9 of patients who used 
atorvastatin at diagnosis or within 12 months of diagnosis, have a poorer chance of 
survival for both MSS and OSS as compared with those who did not use atorvastatin in 
the unadjusted model which on this occasion was significant. However as shown in 
previous analyses, the hazard ratio is reversed when adjusting for the known predictors 
age and sex. However, on this occasion there was no statistical significance seen in the 
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multivariable model, which as we discussed in the methods may be due to loss of power 
with this much smaller, analyses subtype.  
Table 5.9: Atorvastatin use within 12 months of diagnosis survival analysis 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
Model Parameter 
Atorvastatin 
(use within 12 months of diagnosis) 
Melanoma-specific Overall survival 
Unadjusted or 
crude model 
HR (95% CI for HR) 1.61 (1.03-2.53) 1.61 (1.03-2.53) 
p-value 0.037 0.037 
Age at diagnosis 
& sex-adjusted 
HR (95% CI for HR) 0.99 (0.63-1.55) 0.98 (0.62-1.55) 
p-value 0.952 0.938 
Adjusted for age, 
sex and Breslow 
HR (95% CI for HR) 0.97 (0.62-1.53) 0.97 (0.61-1.52) 
p-value 0.896 0.887 
Adjusted for other 
risk factors* 
HR (95% CI for HR) 0.91 (0.52-1.57) 0.91 (0.53-1.57) 
p-value 0.727 0.730 
 
As discussed previously, based on literature evidence in other melanoma cohorts, an 
analysis was conducted and stratified by sex to explore if it was possible to identify any 
similar themes with atorvastatin, particularly in light of our other findings with simvastatin. 
As can be seen in Table 5.10 stratification by sex, adjusted for age at diagnosis and 
Breslow thickness on this occasion did not show any significant changes in hazard ratios 
in either ever-never or use within 12 months of diagnosis analysis types. 
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Table 5.10: Atorvastatin use stratified by sex 
Adjusted for age at diagnosis and Breslow’s thickness. Significant p-values are in 
bold figures 
Sex 
Ever-never* 12 months of diagnosis 
Mortality HR (95% CI) p-value Mortality HR (95% CI) p-value 
Melanoma-specific     
     Male 0.74 (0.45-1.22) 0.244 0.97 (0.52-1.79) 0.917 
     Female 0.49 (0.21-1.11) 0.086 0.91 (0.37-2.23) 0.837 
Overall survival     
     Male 0.68 (0.43-1.09) 0.108 1.08 (0.63-1.84) 0.771 




In this section I will discuss my findings in relation to the literature and what we already 
know about potential associations of statins on melanoma survival and to determine 
whether these associations can explain my findings. I will also discuss the limitations of 
my study approach in examining these associations. 
As discussed in the literature review, although preclinical data shows possible anticancer 
effects of statins in melanoma, meta-analyses could not demonstrate reduced melanoma 
incidence in statin users. However the studies looked at in the meta-analysis did however 
have limitations in that some of them were looking at cardiovascular benefit as a primary 
outcome and there are also inherent difficulties with interpreting case control studies with 
a different primary outcome without being able to adjust for known factors that influence 
melanoma survival. These limitations were highlighted by the Cholesterol Treatment 
Trialists’ (CTT) collaborators who studied 14 RCTs of statins and reported that statins 
do not result in decreased incidence of cancer (RR = 1.00, 95% CI = 0.95-1.06) [279]. 
However, as discussed already, statins have been reported to decrease other cancer-
specific [42,48-52,54,55], and overall mortality [48,54,55]. 
The results of my study showed that firstly some of the characteristics of the simvastatin 
users were significantly different to non-users in terms of the majority of users being male 
(198, 58.93%), diabetic (43, 13.03% vs. 38, 2.24%; p<0.001) ever smokers (185, 55.72% 
vs. 732, 42.78%; p<0.001) and more likely to be overweight or obese (p<0.001)  
compared to those not on simvastatin. Similar results were seen for atorvastatin with the 
majority being male (68, 58.62%) compared to women (48, 41.38%) taking atorvastatin 
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(p<0.001) and a higher proportion of people on atorvastatin were diabetic (18, 15.93% 
vs. 63, 3.29%; p<0.001) and users were also more likely to be overweight or obese 
compared to non-users (p<0.001). This would be expected given that these are risk 
factors for IHD and this population is, therefore, more likely to be prescribed statins as 
well as aspirin with 155 patients being on both aspirin and simvastatin and 80 patients 
on both aspirin and atorvastatin. It would therefore be difficult to exclude the possibility 
of both these drugs having a synergistic effect for instance on “bad inflammation” via cox 
pathways and IL6 respectively. Given the characteristics of the population taking 
simvastatin, with for instance more smokers or obese patients compared to non-users, 
this “bad inflammation” is very likely to be playing a significant role. Measuring serum 
levels of CRP in this group of patients would have been highly desirable as a marker of 
inflammation. For example the Leeds group has previously shown that smoking, another 
variable linked to inflammation, is an independent risk factor for melanoma [33]  
As can be seen, the population characteristics of both simvastatin users and atorvastatin 
users are very similar and therefore if they had similar biological effects one might 
postulate that the results of the survival analysis should be similar taking into account 
the difference in power due to drug exposure. However based on literature evidence of 
different drug effects and given the difficulties and inaccuracies with the data collection 
process I chose to examine these separately and some differences in results were noted 
as discussed below.  
In the simvastatin group a tendency to higher Breslow thickness was observed in users 
of simvastatin compared to non-users (p<0.013) with no such association seen with 
atorvastatin. Given the that from literature evidence we would have expected the Breslow 
thickness to be reduced, particularly as simvastatin primarily mediates its effects via a 
strong inhibitory effect on the growth of melanoma cells I explored this association further 
by performing a univariable regression analysis of factors associated with simvastatin 
use followed by a multivariable analysis (Table 5.2 and 5.3). A higher Breslow thickness 
category was not found to be associated with a higher odds of aspirin use following 
adjustment for age, male gender, diabetes and BMI. However analysis of ever use of 
simvastatin was associated with a lower risk of dying from melanoma with a HR (MSS) 
0.76 (95% CI: 0.57–1.00; p = 0.048) and overall survival HR (OS) 0.71 (95% CI: 0.55-
0.92; p = 0.010). The effect appeared to be maintained with significant protective effects 
seen in both MSS and OS even in our multivariable approach although it did appear to 
lose statistical significance for MSS when adjusting for Breslow (along with age and sex) 
(Figure 5.2) suggesting as per our literature review that simvastatin may be exerting 
some of this possible protective effect via a reduction in Breslow thickness. A similar 
association was seen for simvastatin use at diagnosis or within 12 months, however on 
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this occasion the statistical significance was not maintained in the multivariate model, 
which as we discussed in the methods may be due to loss of power with this, analyses 
subtype. In terms of atorvastatin use and the same analysis types interestingly for ever-
never use atorvastatin use showed a significantly protective association when adjusting 
for age and sex, as well as when Breslow was adjusted for and finally even in our 
multivariate analysis with HR (MSS) 0.56 (95% CI: 0.33–0.94; p = 0.028) suggesting a 
much more protective association than with simvastatin for the same analysis showing 
HR (MSS) 0.71 (95% CI: 0.50–0.99; p = 0.043). This analysis could have been affected 
by the difference in power as a result of the difference in the number of patients on each 
drug as well as the potential of the guarantee time bias playing a role. Interestingly for 
both simvastatin and atorvastatin analysis of drug usage at diagnosis or within the last 
12 months, the statistically significant association was lost which may reflect the 
presence of the bias in the previous analysis or be related to loss of power with fewer 
patients in this group. 
None the less, our results point towards a potential protective effect of statins exposure 
on melanoma survival. The only other population‐based study investigated statin use 
and cancer mortality in melanoma among several other cancer types in Danish patients, 
as discussed earlier with all-cause mortality among patients with cancer who were taking 
statins being reduced by 15%, but this was similar to the observed reduction in all-cause 
mortality of 10% among patients at risk of death from cardiovascular causes cancer 
[282]. In this study, the use of statin was calculated in terms of total defined daily 
doses and patients using statins were 15% less likely to die from any cause (HR = 0.85, 
95% CI = 0.83–0.87) and from cancer (HR = 0.85, 95% CI = 0.82–0.87). Although a 
reduced cancer‐related mortality for statin users was found in 13 different cancers 
including lung, colorectal, prostate and breast, it was not seen in melanoma (HR = 1.21, 
95% CI = 0.95–1.52).  
In my analysis of simvastatin and sex stratification in cases of both ever/never and 12-
months at diagnosis analysis, whilst also adjusting for age at diagnosis and Breslow’s 
thickness, demonstrated that simvastatin use may have a preferentially protective effect 
in male participants as compared to women with MSS showing HR of 0.54 (95% CI = 
0.37–0.79; p-value = 0.002) in ever-never and MSS showing HR of 0.57( 95% CI = 0.38–
0.85; p-value = 0.006) in within 12 months of diagnosis analysis in males compared to 
females with an MSS showing HR of 1.22 (95% CI = 0.82-1.83; p-value = 0.327) in ever-
never and MSS showing HR of 1.21 (95% CI = 0.79–1.86; p-value = 0.379) in the within 
12 months of diagnosis approach. No such association was seen with the same 
stratification with atorvastatin again suggesting potentially a different mechanism of 
action, although the other possibility is related to loss of statistical power.  
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A sub-analysis for sex in melanoma patients was not performed in the Dutch registry 
study [60], but the HR for all cancer patients and cancer‐related mortality showed that 
the HR of death in male patients using statins was reduced more than in female patients 
(HR = 0.82, 95% CI = 0.81–0.86 vs. HR = 0.92, 95% CI = 0.88–0.92). In terms of this 
preferentially protective effect in male participants as compared to women, this was also 
shown in the Dutch population based study by Livingstone et al [303]. Unlike in this study, 
they, however, were unable to demonstrate that statin usage on its own changed the 
hazard of death significantly in their cohort of 709 melanoma patients which may reflect 
loss of power with their smaller cohort, but also as they have indicated themselves a 
short follow up period of three years. Stratification based on sex, however, demonstrated 
possible superior survival among statin users, compared to nonusers in males only. The 
female survival advantage in melanoma in general was confirmed in this study, as was 
the case in the Dutch study [303] . The favourable results of statin use only in male statin 
users are, therefore, surprising. As discussed in the introduction, cancer survival has 
been shown to be generally better in females than in males for most cancers, especially, 
in melanoma. Even after adjustment for potential behavioural differences (primarily 
diagnostic delay and healthcare consumption), sex remains an independent prognostic 
factor for melanoma progression and survival. It would suggest that biological differences 
are, therefore, highly likely to be playing a role. 
In our study as well as in the Dutch study, statin use somehow seems to negate the male 
survival disadvantage in melanoma. Therefore, the effects of statins on melanoma might 
be related to the underlying mechanism of the overall sex differences in melanoma 
survival. Two potential mechanisms were suggested by the Dutch group as moderating 
this sex difference in melanoma survival. As previously mentioned, somatic activating 
Rac1 mutations, ranking third after BRAF‐and NRAS‐mutations, in general, tend to occur 
significantly more often in men than in women. As statins have been shown to prevent 
Rac1 isoprenylation as explained earlier, and to inhibit the Rho‐pathway it might be 
possible that males have worse survival rates than females due to a higher rate of Rac1 
mutations leading to an increased activity of the Rho‐pathway in male melanoma cells, 
which in turn might be counteracted by statin use. It was also proposed that, as has been 
shown, melanoma is a highly immunogenic tumour and males have a weaker immune 
system than females, it might be possible that males benefit more from the activating 
effect of statins on the anti-melanoma immune response than females, potentially 
explaining the differential effect of statin use across sex. Alternatively, we have seen that 
statins exert anti-inflammatory action by affecting mediators of inflammation such as IL-
8, IL-1β, IL-12, tumour necrosis factor α (TNF-α), and nuclear factor κB (NF-κB) [83]. In 
the group there were more males who were smokers and obese suggesting high levels 
of bad inflammation and they may therefore benefit preferentially from these effects of 
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statins on inflammation. However, it was suggested that it is also possible that the sex 
differences might also only be an epiphenomena with the underlying cause being 
associated with sex but not caused by sex per se [303]. In terms of sex differences per 
se irrespective of exposure to drugs, as discussed in the literature review in Chapter 1, 
several studies demonstrate the fact that male melanoma patients are almost twice as 
likely to die compared with female patients. Although men are significantly more likely to 
have melanomas with unfavourable characteristics such as thicker and nodular 
melanomas located on the trunk, in accordance with previous observations [269], 
adjusting for these factors in our analysis do not explain the observed sex difference in 
melanoma survival with aspirin and statins.  
Although the most common explanation for the sex difference in melanoma survival 
generally, is the better stage at diagnosis among women, our results could not be 
explained on this premise. A number of possibilities have been proposed to explain the 
difference in survival by sex. The thicker tumours reported in men have been attributed 
to delayed presentation. Recently however, the assumption that Breslow thickness is a 
surrogate marker for the time between development and diagnosis of melanoma, which 
has been applied in many epidemiological studies, has been challenged [269]. A large 
epidemiological study showed no positive association between melanoma thickness and 
time to diagnosis on a population basis and a histological study concluded that 
aggressive tumour growth, rather than delay in diagnosis, is responsible for the 
development of thick melanoma [331, 332]. One possibility therefore is that more 
aggressive melanoma growth in men may contribute to the differences observed and 
that potentially in our case the statin has had a preferentially protective effect on tumour 
growth [269]. A sex difference in the prevalence of lifestyle factors such as sun exposure 
[269] and dietary habits such as vitamin supplements including vitamin D, ethanol 
consumption, soy isoflavones, essential fatty acids and drug have also sometimes been 
used to part explain the difference in survival across the two sexes [269]. That assumes 
that survival in men may be worse because of co morbidities resulting from these lifestyle 
variables. The field of epigenetics is an emerging one and related effects on host tumour 
interaction may be mediated epigenetically. It is postulated that this could be the missing 
link between the environment and genes. Chemical substances that surround us may 
indirectly inflict permanent DNA-changes and account for the changes seen 
The other possibility as alluded to is whether the effects of hormones such as oestrogen 
or testosterone may mediate differential survival per se and also differential response to 
different drugs. In terms of hormones, a few earlier studies indicated an increased 
melanoma risk in (long-term) oral contraceptive use [269], but meta-analyses did not 
confirm this association [333]. In randomised clinical trials, tamoxifen did not seem to 
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improve the survival rate in patients with metastatic melanoma either [269]. The 
likelihood of developing melanoma and its prognosis were also comparable in pregnant 
and non-pregnant females [334]. Furthermore a recent case–control study that focused 
on melanoma in women did not find reproductive, menstrual and hormonal factors that 
affected melanoma risk [335]. Dividing our cohort population into pre-menopausal and 
post-menopausal women and repeating the analysis would be an option to consider to 
try to elucidate this further. 
The strengths of this study are the fact that it involves the largest cohort of melanoma 
patients, giving us comparably more power than the other studies and the fact that we 
had a longer study period compared to other studies. It was also population ascertained. 
Given the significant amount of data collected at recruitment, I was able to control several 
known variables that effect melanoma survival unlike the registry-based Dutch study 
where they felt that this was one of the drawbacks of their study, as they had no 
information on smoking status, for instance [60]. In particular, we were able to separate 
out melanoma specific death whilst in the Dutch population the cause of death was 
unknown and only all‐cause rather than cancer‐specific mortality could be assessed and 
therefore, any improvement could also be attributed to a decreased death risk due to 
cardiovascular comorbidities [60]. 
The main limitations of this study was the lack of a national cancer linked pharmacy 
database, as in the Dutch study, making our drug data less robust although, as shown 
in Chapter 2, every effort was made to optimise this by collecting information from 
multiple sources. We also undertook a retrospective approach as opposed to Livingstone 
et al who undertook a prospective approach as well as validating the data from two large, 
nationally representative and linked cancer‐and pharmacy databases [60]. Our study 
options were also limited from analysis approach, as we were unable to look at dose and 
duration, given the potential biases in our methodology, as we were unable to perform 
the analyses with a time-dependent approach, as in the case of Livingstone et al. [60]. 
We also had insufficient data to investigate separately for lipophilic and hydrophilic 
statins, as this can have a variable improvement as shown in breast cancer, as discussed 
earlier. However, as in the other studies on melanoma, the majority of prescriptions in 
our cohort were for lipophilic statins and as we examined only these, our results are 
entirely attributable to lipophilic rather than hydrophilic statins. Other limitations of our 
study include the inability to look at the associations with combinations of drugs because 
as discussed in this chapter and as show in table 3.20 there is a significant overlap 
between these drugs used to treat similar conditions related to inflammation/metabolic 
syndrome and also the issue of differentiating the effects of the co morbidities from the 
drugs used to treat them. Not being able to examine duration of drug use was also a 
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significant limitation in this regard as was gaps regarding the recall of drug start or stop 
dates prior to diagnosis, adding to the difficulty in calculating the duration. 
 
In conclusion, my study did appear to show a significant beneficial effect of simvastatin 
ever use on survival of melanoma patients. However, when we look at usage within 12 
months of diagnosis, no significant effect was seen. The differential impact that statin 
use seems to have on male and female melanoma patients requires further research 
and the results as a whole require further validation in larger international data sets as 
well as an examination of biological models to assess if these represent real effects or 
whether confounding factors are responsible for these changes. One possibility is to look 
at using Public Health England data, as this is an increasingly common approach, 
although it will be limited in terms of having access to other confounding variables as in 
available in our cohort. Additionally, when in vitro experiments are conducted, both male 
and female melanoma cell lines should be used to see if sex differences can be noticed 
and I would that future studies looking at factors that may be associated with melanoma 
survival should consider stratifying their results by sex.. Future studies could also look at 
addressing the effects of lipophilic versus hydrophilic statins which was something we 





Metformin and Melanoma survivalIntroduction 
Metformin (N,N-dimethylbiguanide)  belongs to a group of drugs called the Biguanides 
and is the most prescribed anti-diabetic medication in the world, currently estimated to 
be used to treat more than 120 million people worldwide [336]. Other drugs in this group 
include phenformin, and buformin, which were widely used in diabetic treatments starting 
in 1920 until their high toxicity in patients was discovered and they were then withdrawn. 
It wasn't until a study by French chemist Jean Sterne in 1957, where he demonstrated 
metformin's effects on type 2 diabetes without any obvious toxicity or risk of 
hypoglycaemia, that metformin came back on the market [5]. 
After years of usage of metformin, retrospectives studies suggested that metformin 
treated diabetic patients had a decreased cancer incidence compared to those treated 
with another antidiabetic drug, with several subsequent studies confirming these results 
[4, 337, 338]. In this chapter I will examine the effects of metformin on melanoma survival 
specifically and I will begin by looking at the reported epidemiological associations and 
biological effects of metformin. 
 
6.2 Biological effects of metformin 
Metformin is able to exert its anti-diabetic function by reducing insulin resistance of 
glucose-intolerant patients as well as hepatic gluconeogenesis in type 2 diabetes, where 
it has been noted that hepatic gluconeogenesis is increased relative to healthy patients. 
In this sense, the liver is considered to be the principal site of action, where it can act on 
gluconeogenesis, glycolysis, and glycogen synthesis [5]. During treatment with 
metformin, glucose absorption and average glucose levels can decrease to 75%, which 
is also facilitated by increased absorption of glucose by skeletal muscles [339]. 
Furthermore, metformin also blocks the effects of glucagon, which normally enhances 
gluconeogenesis, by inhibiting essential enzymes in this process and stimulating 
glycolysis via the alteration of numerous enzymes in this signalling pathway [340]. 
In general, metformin increases glucose absorption by increasing the plasma membrane 
translocation of glucose receptors, such as glucose transporter 1 (GLUT-1), in both 
hepatic cells and skeletal muscle cells although we currently do not fully understand all 
the mechanisms of actions of metformin in these patients and consequently how these 
can impact on cancer [5].  
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In the next pages, I will summarise the reported epidemiological studies of the 
relationship between metformin and risk of cancers other than melanoma and then 
melanoma. I will then summarise laboratory data on metformin and cancers other than 
melanoma followed by specific experiments looking at melanoma. 
 
6.3 Review of literature of associations of metformin usage 
with cancer 
6.3.1 Epidemiological data on metformin in cancer other than 
melanoma 
Epidemiological data on cancer risks in diabetes overall suggest that diabetes is 
associated with an increased risk. 
In last few years, epidemiological studies involving type 2 diabetic (T2DM) patients have 
suggested around 2-times increased chances of developing cancers involving the 
endometrium, pancreas, and liver [341]. Similarly an increase in incidence of cancers 
involving breast, kidney, bladder, and colorectal region, has been reported with smaller 
associations (1.2-1.5 times) [342]. The prevalence of T2DM is higher in newly diagnosed 
cancer patients than non-diabetics and is estimated to be between 8 and 18% [343, 344]. 
An increased cancer risk is partly attributed to increasing levels of circulating growth 
factors, such as insulin or insulin growth factor 1 and 2 (IGF-1 and 2). An association 
between raised IGF-1 and diabetes risk has also been demonstrated in patients with 
acromegaly, characterized by a hypersecretion of growth hormone (GH) and 
consequently higher endogenous IGF, with studies showing a 2-fold increased risk of 
gastrointestinal cancers in these patients [345, 346]. 
Furthermore, studies have also shown a modest association between higher circulating 
IGF-1 and -2 levels and an increased risk for prostate, breast, colorectal, and ovarian 
cancers [347-353]. 
A number of retrospective studies showed that patients with T2DM treated with 
metformin however had lower cancer incidence and/or reduced cancer mortality [337, 
354-356], compared to other diabetics not on metformin, creating interest in metformin 
as an anticancer agent and I explored some of these studies in more detail below. 
Metformin was first linked to the prevention of cancer in a case-control study involving 
T2DM patients (n = 923) from the United Kingdom. The authors reported that use of 
metformin was associated with a reduction of the risk of developing cancer by 23% [337]. 
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This finding resulted in a rapid rise in the number of observational studies assessing the 
link between use of metformin and risk of developing cancer, leading to several meta-
analyses trying to quantify the emerging evidence. One such meta-analysis reported that 
use of metformin was linked with an overall 27% decrease in the risk of developing any 
malignancy [357]. Another study observed that 7.3% of type 2 diabetes patients treated 
with metformin developed cancers compared with 11.6% of patients treated with other 
anti-diabetics [354]. Similarly a recent study in a Korean population with type 2 diabetes 
showed a reduction in cancer development for patients treated with long-term metformin 
(5.8 years) with an incidence of 13.2 per 1000 compared with an incidence of 21.8 per 
1000 in patients treated with other treatments [358]. 
Further cancer specific meta-analyses have suggested that diabetic patients have 
around 1.3 to 1.5-times increase in all-cause and cancer-specific mortality across certain 
types of cancer including CRC, endometrial, and breast [359, 360]. Though prostate 
cancer is less prevalent in men with T2DM, mortality was reported to be increased in 
patients who develop the disease, especially in patients with hyperinsulinemia and high 
body mass index (BMI), highlighting the need to assess this complex association which 
I am attempting to do in this thesis [361, 362]. Hyperinsulinemia on its own, can also 
result in activation of chronic inflammatory processes that can act as a triggering factor 
for initiation and progression of cancer [363]. Additionally, cancer cells typically have 
high levels of glucose uptake, and in this regard hyperglycemia may create a fuel-rich 
environment for cancer progression. One study compared cancer mortality in diabetics 
treated with three different treatments, metformin, insulin, or sulfonylureas, over 5 years 
in approximately 10,300 diabetes patients. The results demonstrated that patients 
treated with metformin had a lower cancer-related mortality rate than patients treated 
with other treatments [364]. Furthermore, a study by Currie et al. showed that patients 
treated with insulin developed more solid cancers than those treated with metformin 
[365].  
6.3.2 Laboratory data on metformin in cancer other than melanoma 
Given the suggestive epidemiological data, many research groups have tried to 
understand the mechanisms of action of metformin in different types of cancers, such as 
lung, prostate, and ovarian cancers. The in vitro effects of metformin, alone or in 
combination with other drugs, have been studied in many different cancers [366-369]. 
Furthermore, in vivo studies have demonstrated the efficacy of metformin in decreasing 
tumoural growth [370, 371].   
The mechanisms through which metformin is postulated to promote anticancer effects 
can be broadly divided into indirect or direct effects. In this context, indirect refers to a 
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more systemic effect that modulates whole body physiology (such as by reduction of IGF 
levels) whilst I have used the term “direct” to refer to any mechanism acting directly on 
cancer cells inhibiting cancer progression. I will discuss the studies relating to each effect 
separately below. 
6.3.2.1 Indirect effects of metformin 
As discussed above, in the different studies looking at cancers, such as breast, colon, or 
prostate cancer, hyperinsulinemia and obesity induced by insulin and IGF1/2 are 
associated with a poorer prognosis. As already outlined, the liver, exposed to high levels 
of the drug after oral administration, is considered the main target organ of metformin. 
The cell surface organic cation transporter 1 (OCT1), necessary for the active transport 
of metformin (which is positively charged) into the cells is expressed in high quantities in 
the liver cells [372]. Within these cells, mitochondria appear to be the primary target of 
metformin whereby the drug inhibits the respiratory complex resulting in reductions of 
ATP as well as oxidation of NADH [373], This reduction in levels of ATP stimulates an 
increase in AMP levels inducing activation of the cell energy sensor 5’-AMP-activated 
protein kinase [230]. Once activated, AMPK seeks to down-regulate processes such as 
protein synthesis that require ATP resulting in catabolism and pathways that ultimately 
generate more ATP. This energy stress results in a reduction of hepatic gluconeogenesis 
[374] with a resulting reduction in circulating levels of glucose and insulin. This lowering 
of blood levels of glucose is also a result of increase of sugar uptake via skeletal muscles 
caused by the metformin-induced membrane translocation of the glucose transporter 
GLUT-4 specifically expressed in these tissues [375]. There is evidence to suggest that 
as elevated serum levels of insulin and insulin-like growth factor-1 (IGF-1) are frequently 
necessary to sustain the growth and survival of cells in different cancer types, the 
systemic reduction of these hormones can impair malignant growth inhibiting circulating 
insulin levels. Further evidence in mouse models shows that metformin inhibited lung 
cancer cell growth, induced by hyperinsulinemia and obesity, by decreasing the 
circulating level of insulin and by activating the AMPK pathway [376].  Furthermore, a 
study of non-diabetic woman with breast cancer, showed that metformin decreased 
circulating insulin levels by 22% and increased insulin sensitivity by 25% [377]. These 
results suggest that a decrease in insulin induced by metformin may mediate metformin 
inhibition of tumorigenesis.  
Metformin can also inhibit the inflammatory signalling that promotes carcinogenesis by 
suppressing different pro-inflammatory cytokines such as tumour necrosis factor αTNF-
α, nuclear factor kappa B (NF-κB) and interleukin 6 (IL-6) [378, 379]. It is possible 
therefore that metformin could have beneficial anti-inflammatory effects on cancer cells 
but additionally on systemic inflammation and risk of cardiovascular disease. There are 
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published papers discussed below in 7.4, which provide some evidence for a lower 
incidence of cardiovascular toxicity. The anti-angiogenetic effect of metformin is linked 
to reduction of the main factors involved in vascular remodelling such as VEGF and HIF-
1α [380, 381]. Finally it was also observed that metformin treatment can selectively target 
cancer stem cells (CSCs), a tumour sub-population characterised by self-renewal 
capacity, resistance to chemotherapy and increase in cancer recurrence [379, 382-387].  
 A further indirect effect may be related to the fact that metformin seems to impact the 
microbiota which may be relevant in its action on T2DM patients but also in cancer 
development [388]. In a randomised study, woman with breast cancer were given routine 
doses of metformin and it was observed that testosterone, insulin levels and several 
indices of insulin resistance deceased significantly [389]. In another randomised study, 
compared to controls, metformin in a dose of 250 mg/day resulted in reduction of 
colorectal aberrant crypt foci (surrogate marker) by 40% in non-diabetic patients [390]. 
6.3.2.2 Direct effects of metformin 
Despite the effects discussed above, the principal effects of metformin on cancer cells 
are reported to be direct effects, which predominantly induce inhibition of the mammalian 
target of rapamycin complex 1 (mTORC1). The protein mTORC1 is essentially complex 
composed of five different proteins: DEP domain-containing mTOR interacting protein 
(DEPTOR), mammalian LST8/G-protein β-subunit like protein (mLST8), regulatory-
associated protein of mTOR (RAPTOR), proline-rich AKT substrate of 40 kDa (PRAS40), 
and a mammalian target of rapamycin (mTOR). This complex is primarily involved in 
regulation of protein synthesis, which is pivotal to cell growth and tends to be activated 
in cancer cells and can be implicated in resistance to cancer treatment. In addition to this 
mTORC1 plays a pivotal role in the growth and proliferation of normal stem cells as well 
as cancer stem cells. Its role in cancer stem cell proliferation has been in a number of 
different cancer types [5].  
The direct anticancer effects of metformin can be broadly classified as AMPK dependent 
and AMPK-independent. AMPK has been shown to be directly activated by an increase 
of AMP/ATP ratio, or indirectly, through its upstream regulator serine/threonine liver 
kinase B1 [391]. Once activated, AMPK suppresses the mammalian target of rapamycin 
(mTOR) pathway either through the phosphorylation and activation of tuberous sclerosis 
complex 2 (TSC2) that in turn inhibits the mTOR activator Rheb [392] or by 
phosphorylation of Raptor, a positive regulator of mTOR [393]. The block of mTOR 
further inhibits the activation of its downstream target 40S ribosomal protein subunit S6 
kinase (S6K or S6) and of the translational repressor 4E-binding protein 1 (4E-BP1), 
inactivated by mTOR mediated phosphorylation [394]. Metformin can also inhibit mTOR 
signalling independently from AMPK activation by suppressing the Ragulatory complex, 
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consisting of the RAG family of GTPases [395], or by activating the negative regulator of 
mTOR regulated in development and DNA damage responses 1 [396]. In non-diabetic 
women with breast cancer, metformin therapy not only led to reduction in the load of 
Ki67-positive cancer cells but also in changes in gene expression of molecules 
implicated in the mTOR and AMPK pathways [397].  
The inhibition of protein synthesis via mTOR is only one of the mechanisms by which 
metformin can reduce cancer growth. Metformin exerts an inhibitory effect on glucose 
metabolism and has been shown to reverse the Warburg effect, present in most cancer 
cells. This term Warburg effect refers to the phenomenon by which, even in aerobic 
conditions, cancer cells tend to favour metabolism via glycolysis rather than the much 
more efficient oxidative phosphorylation pathway, which is the preference of most other 
cells of the body. Interestingly, melanoma appears to be one of the cancers that is the 
most dependent on and impacted by changes in metabolism as it requires glycolytic 
metabolism, which is mediated by mitochondrial activity [398, 399].  
Metformin appears to do this either through the decrease of the glycolytic enzyme 
hexokinase 2 [400] or through the suppression of oncogenes such as c-Myc, Akt and 
hypoxia-inducible factor 1 α (HIF-1α that support the glycolytic phenotype [401]. The 32 
metformin-induced AMPK activation can reduce enzymes involved in fatty acids 
biosynthesis as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), reducing 
energy supply and further counteracting tumour progression [402, 403]. Metformin can 
also promote cell cycle arrest through AMPK-mediated activation of TP53 and reduction 
of cyclin D1 expression [366, 404-406]. It has also been reported that metformin can 
reduce the risk of mutagenesis in cancer cells, either by the inhibition of reactive oxygen 
species (ROS) in the mitochondria production or through the activation of ataxia 
telangiectasia mutated (ATM) protein, a tumour suppressor involved in DNA repair [407, 
408].  
In terms of direct effects it appears therefore that metformin acts as a major metabolism 
disruptor in cancer cells and activates autophagy and apoptosis processes directly 
effecting cancer cells. 
In summary, metformin has two proposed anti-neoplastic mechanisms of action. Firstly, 
an indirect route connected to its insulin-lowering activity, which may decrease the 
proliferation of tumour in individuals with hyperinsulinaemia  and by effects on the stromal 
cells as above and secondly, a direct action in target tissues, preneoplastic and 
neoplastic cells, directed against respiratory complex I of the electron transport chain in 
mitochondria, thereby reducing the consumption of energy in the cells (118). Both these 
routes are associated with metformin mediated induction of AMP-activated protein 
kinase (AMPK), resulting in inhibition of the mammalian target of the rapamycin (mTOR) 
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pathway, reduction in cell proliferation, and induction of apoptosis and arrest of cell-cycle 
[409, 410]. Based on the target cell, the mechanism of action can be direct, indirect, or 
a combination of both. 
6.3.3 Metformin and melanoma 
In contrast to epidemiological studies looking at metformin and cancer in general there 
appears to be a real dearth of such studies looking at melanoma specifically with the 
majority of studies being laboratory based. A recent study by Tseng (2018) showed a 
reduced incidence of melanoma and non-melanoma skin cancer in Taiwanese patients 
with type T2DM although the study was limited by the number of patients with skin cancer 
in the study [411]. One large population cohort study in the US looked at rates of 
melanoma as well as colorectal, bladder, liver, and pancreatic cancers in patients treated 
with a number of anti-diabetics and reported no difference in incidence of any of these 
between treatment groups [412].  
On the other hand there are quite an extensive number of number of laboratory studies 
that have looked at metformin and its effects on melanoma cells, showing that metformin 
or phenformin (another biguanide compound) can inhibit melanoma cell proliferation 
[370, 413-415]. 
As previously discussed, metformin can inhibit cancer cell proliferation and induce 
cancer cell death by many different mechanisms. Metformin induces melanoma cell 
death by both AMPK-dependent and AMPK-independent pathways. Through a 
mechanism that is not fully understood, metformin induces cell cycle arrest in melanoma 
cells, which is responsible for the activation of autophagy, and in turn the activation of 
apoptosis, leading to melanoma cell death. In initiating melanoma cells, metformin 
decreased cell transformation and proliferation by inhibiting the NF-κB pathway and the 
inflammatory pathway. It has been shown that metformin induces cell cycle arrest in 
melanoma cells in the G0-G1 phase after 24 h of treatment at 10 mM [5]. Studies have 
reported evidence that that this cell cycle arrest is responsible for autophagy (at 72 h) 
and apoptosis (at 96 h) induction by metformin in melanoma cells [413]. In this model, 
inhibition of AMPK (by siRNA) induces a partial restoration of melanoma cell viability 
under metformin treatment, suggesting that AMPK plays a partial role in metformin-
induced melanoma cell death. This finding also suggests that another AMPK-
independent mechanism is implicated in metformin-induced melanoma cell death. 
Studies in mouse models have shown that metformin decreases the tumoural volume of 
melanoma cells with no cell death being observed in normal human melanocytes even 
if endogenous AMPK is expressed [416, 417]. In another recent study, metformin 
induced autophagy activation in melanoma cells by inhibiting a potentially new 
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therapeutic target, tribbles pseudokinase 3 (TRIB3) [370]. In this study, the authors 
showed that metformin attenuated melanoma growth and metastasis by reducing TRIB3 
expression in non-diabetic and diabetic mouse models. 
A further recent study showed that metformin can act not only on melanoma cells to 
induce cell death but also on the tumour microenvironment, particularly in the context of 
an immune response [418]. As described in the introduction, the immune system is very 
important in melanoma therapies, and current immunotherapies have revolutionized the 
treatment of advanced melanoma. This study showed that metformin activated both 
autophagy and apoptosis in melanoma cancer cells in vitro and confirmed the results in 
vivo in mouse models challenged with B16 murine melanoma cells. The results showed 
that metformin activity on melanoma cells was partly due to the immune system and that 
the antitumor activity of metformin was lost on immunodeficient (NSG) mice. This group 
also showed that metformin interaction with the immune system was principally 
associated with T cells [5]. Studies like this showing the interactions between the immune 
system and metformin, has led to further studies looking at a combination of metformin 
treatment and immunotherapies, such as anti-PD1, to increase the effects of 
immunotherapies in melanoma cells which I will discuss further below. 
These observations also suggest that it may be interesting to assess metformin in the 
context of other drugs or therapies that impact metabolism, such as targeted therapies 
(BRAF inhibitors) or immunotherapies (anti-PD1) in melanoma cells. Some studies have 
examined these effects of metformin in combination with BRAF inhibitors, such as 
vemurafenib and showed encouraging results with synergistic effects for inducing 
melanoma cell death [417]. Indeed, in vitro experiments show synergistic antiproliferative 
effects, particularly in BRAFV600E mutant cell lines. In other studies, metformin 
increased the toxicity of cisplatin, a chemotherapeutic drug, in melanoma cells [419]. 
6.3.3.1 Putative paradoxical effects of metformin in melanoma 
Although I have described epidemiological and laboratory research which supports a 
view of metformin as a drug which reduces the incidence of cancer and reduces the 
growth of cancer cells, paradoxical effects have been described. Work by the Marais 
group suggested that metformin accelerates the growth of BRAF-V600E driven 
melanoma [420]. Martin et al showed that melanoma cells that are driven by oncogenic 
BRAF are resistant to the growth-inhibitory effects of metformin because RSK sustains 
TORC1 activity even when AMP-activated protein kinase (AMPK) is activated and 
therefore accelerate the growth of these cells in vivo [420]. Thus, metformin usage in 
diabetics might be beneficial in terms of survival in non-BRAF mutated melanoma but 
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deleterious in BRAF mutated melanoma. Data on BRAF/NRAS mutation status was 
available only for a proportion of the Leeds Melanoma Cohort.  
It would therefore appear that the effect of metformin based on the mutation status of the 
tumour warrants more investigation. In this chapter I describe my analysis of the 
association of metformin use in melanoma patients with diabetes, and survival. In the 
majority of the Leeds Melanoma Cohort tumours, BRAF testing was not performed, so 
my analysis relates to an overall association between metformin usage and survival and 
an analysis comparing survival from melanoma on the trunk with that in other sites as 
the proportion of BRAF mutated tumours is reported to be higher in truncal primaries 
[17]. 
 
6.4 Safety and Tolerability  
Metformin is one of the most widely prescribed oral blood glucose lowering drugs. It is 
associated with a very low risk of developing hypoglycemia but a high risk of 
gastrointestinal (GI) side-effects (affects an estimated 25% of patients) [421, 422]. The 
risk of GI side effects can be lowered by recommending patients to take metformin along 
with food. A further recommendation to patients suffering from GI side effects is to take 
metformin in a divided dose three times daily. Lower doses are to be used depending on 
renal function, and it is contra-indicated in severe renal insufficiency. Metformin has also 
been associated with an increased risk of lactic acidosis. This is a serious complication, 
and there is an increased risk of lactic acidosis in patients with renal insufficiency, liver 
disease, dehydration and excessive alcohol intake [422-424]. 
Two studies analysed the adverse events of lactic acidosis, and metformin was not 
associated with an increased risk. However, according to a systemic review [425] these 
studies had several methodological limitations. There are only a few studies that provide 
data on adverse effects other than hypoglycaemia and falls related to metformin use in 
the elderly population such as nausea and diarrhoea.  
In summary, metformin is a safe, affordable and effective medication in the treatment of 
diabetes. The GI side effects do however affect compliance. Caution is recommended in 
patients with renal insufficiency and other conditions that can increase the risk of 
developing the rare, but serious complication of lactic acidosis.  
6.4.1 Metformin and all-cause mortality/ non-cancer health 
Observational studies have reported reduced all-cause mortality in diabetics taking 
metformin although others showed no such associations. Studies reported significantly 
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fewer deaths in patients on metformin compared to those taking, either no insulin [426], 
no other anti-diabetic drugs [427] or no metformin [428]. Another study reported reduced 
mortality in the group taking metformin as a mono-therapy (16% of 422 patients) 
compared to participants taking metformin and sulfonylureas as a combination therapy 
(32%) and participants on sulfonylurea as a monotherapy (51%) [429]. No significant 
difference in mortality was seen in patients aged over 80 years or for patients with a GFR 
≤60 [425] however and in a large study conducted by Inzucchi et al [430], there was no 
significant difference in mortality in the metformin group. 
Metformin compared to sulfonylureas showed fewer hospital admissions for acute 
myocardial infarction, stroke, hypoglycaemia or death. There were also fewer reports of 
non-fatal cardio-vascular disease and myocardial infarction, congestive heart failure, 
allcause mortality, and fewer fractures. Another study comparing metformin against 
thiazolidinediones showed a significant difference regarding mortality and all cause and 
heart failure readmissions. A comparison of metformin to rosiglitazone and pioglitazone 
showed no significant differences between the different treatments with regards to 
myocardial infarction, congestive heart failure as well as all-cause mortality [425] The 
UKPDS study showed cardio-protective effects while taking metformin doses as low as 
500mg daily [421]. 
 
6.5 Materials and Methods 
As discussed in Chapter 2, I first collected the drug data for all drugs used by participants 
in the cohort, which is the largest cohort of melanoma patients.  
Firstly I had to ensure all entries for metformin were identified accurately by accounting 
for trade names, BNF codes, misspellings in data entry and missing data by cross-
checking all data sources. As discussed in Chapter 2 due to limitations of the study 
approach and quality of the data I was unable to examine the effects of drug dosages on 
survival, which is a significant limitation given the evidence from particularly laboratory 
studies above that some effects seen are related to higher doses of metformin.  
I then went on to interrogate the data further by looking at the demographics of the 
population taking metformin by examining the number of males and females on the drug 
in our cohort, their smoking status, their diabetic status, vitamin D levels and the 
distribution based on Breslow thickness. Metformin, much like aspirin and statins, is 
prescribed to similar groups of patients who are likely to have features of the metabolic 
syndrome with increased BMI and ischaemic heart disease, aside from of course having 
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diabetes for which the drug is specifically used. Therefore I expected to see some 
common trends within my analysis.  
Given that men have a higher risk of these conditions we had expected to see more men 
being prescribed metformin than women and we also expected to see more smokers 
and diabetics having been prescribed metformin, as these are independent risk factors 
for ischaemic heart disease. We also expected this group of patients to be overweight 
compared to the rest of the cohort population (BMI > 25). 
The effects of exposure to metformin on melanoma specific (MS) and overall survival 
(OS) were then assessed using Cox Proportional Hazards models. Data was first 
checked to ensure that the proportional hazards assumption was met. Hazard ratios 
(HR) and 95% Confidence intervals (CI) were estimated and Kaplan-Meier curves were 
plotted. Firstly unadjusted models were examined and then adjustment for common 
confounders were applied; firstly sex and age at diagnosis, then Breslow thickness, 
ulceration, other comorbidity measures (smoking, body mass index (BMI), and serum 
level of vitamin D adjusted for seasonal variation. Analyses were conducted both with 
and without adjustment for stage (represented by Breslow thickness and ulceration), 
since metformin may influence outcome through an effect on the growth of the tumour, 
which may be captured by stage at diagnosis. No adjustment was made in the analyses 
for adjuvant cancer therapy since no therapy has been shown to influence melanoma 
survival until very recently and the cohort stopped recruiting in 2012. Requests have 
recently been made to Public Health England for data on exposure to immunotherapies 
via SACT (Systemic Anti-Cancer Therapy) but I did not have access to those data. 
As detailed in the methodology chapter, I then undertook a survival analysis, based on 
firstly, the ever vs never approach with the accepted guarantee-time bias, first examining 
the adjusted model and then, adjusting for known confounders. The second approach 
was an analysis examining the association of survival with reported exposure to 
metformin up to diagnosis or within 12 months of diagnosis. This method of analysis 
essentially replicates the traditional methods used in cancer incidence studies with no 
inherent bias, but as discussed in the methodology section our study was not specifically 
designed for this type of analysis, and we experienced some loss of power due to 
exclusion. As with the previous approach, we first examine the unadjusted model and 
then, adjusted for the known confounders. 
I also examined any potential varying effects of metformin on survival based on sex, as 
in the case of aspirin and statins as described previously, although there were no similar 
reported associations with sex in the literature with metformin. I however carried out a 
survival analysis whereby I stratified by sex to identify any sex specific trends whilst also 
adjusting for age and Breslow thickness  
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Finally given the literature evidence above of potential varying associations of metformin 
depending on somatic BRAF mutation status, I also carried out a stratification via site of 
primary using truncal melanomas as a potential surrogate marker for BRAF mutated 
tumours although my statistical power for this type of sub-analysis was low [17].  
 
6.6 Results 
6.6.1 Characteristics of patients ever treated with metformin 
Table 6.1 below shows the characteristics of patients who had ever been on metformin. 
Only 88 (4.4%) of the cohort had used metformin for any reason and at some point in 
their lives (ever-use). As expected a larger proportion of males (49, 56.98%) reported 
that they had used the drug compared to females (37, 43.02%) which fell just short of 
being significant (p= 0.07) and being an effective oral hypoglycemic agent, the drug was 
used by just over two-thirds (57, 68.67%) of diabetics in the study. Interestingly nearly a 
third of patients (26, 31.33%) reported having used metformin at some point in their life 
yet did not volunteer a diagnosis of diabetes. There are a number of possible 
explanations for this. As mentioned earlier in the chapter, although metformin is primarily 
used for frank diabetes it is also used in the case of pre-diabetes or impaired glucose 
tolerance where blood sugars haven’t quite got to the diabetic range for the patient to be 
labeled as a diabetic. As mentioned earlier it can also be used in other conditions such 
as PCOS and Hidradenitis suppurativa, which is probably less likely to be the case in 
our cohort. It is also possible that either patients were not diabetic when filling in their 
recruitment questionnaire and subsequently became diabetic. Of note, there was also 
missing data for sex for two patients on metformin as well as data regarding diabetic 
status being missing for a small number of patients who have ever used metformin (5, 
0.5%). Therefore, based on these assumptions all patients on metformin were assumed 
to be diabetic for the purposes of our analysis. 
As expected the majority of patients taking metformin were obese (55, 65%) which was 
statistically significant (p = <0.001) and they were also more likely to have smoked (51, 
61%, p= 0.02). As already discussed Breslow thickness is an important predictor of 
survival and there was again a statistically significant difference noted between the 
different categories. As discussed earlier, vitamin D is one of the factors thought to 
influence melanoma survival and we therefore wanted to analyse our cohort to see if 
there was a statistical difference in vitamin D levels between users and non-users by 
defining different ranges of vitamin D as outlined in Chapter 2 and 3, but no statistically 
significant difference was noted in this case. 
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6.6.2 Association of Metformin ever use on survival outcomes 
As per my proposed methodology I then examined the association between patients 
having ever taken metformin and both melanoma specific and overall survival. As shown 
in Table 6.2 and the two Kaplan Meier plots in Figure 6.1, the unadjusted model in each 
case, suggested a statistically significant increase in hazard of death in patients taking 
metformin HR (MSS) 2.06 (95% CI: 1.40-3.02, p= <0.001) and HR (OS) 1.74 (95% CI: 
1.18-2.57, p= 0.005). 
However, as previously established increasing age and the male sex are known 
predictors of melanoma specific and overall survival. As in the case of aspirin and statins, 
when the model was adjusted for age at diagnosis and sex, the hazard ratios were 
attenuated as reflected in the two adjusted Kaplan Meier survival plots in Figure 6.2, but 
still showed a statistically significant negative association with metformin ever use and 
melanoma specific survival HR 1.59 (95% CI: 1.07-2.36, p value = 0.021). However once 
adjustment was made for Breslow thickness this became non-significant with an HR 
(adjusted for age, sex and Breslow) of 1.28 (95% CI: 0.86-1.91, p value =0.215 and 
completely disappeared in our multivariate analysis when the analysis was adjusted for 
the variables associated with metformin exposure e.g. smoking, ulceration reported 
diabetes and BMI. 
  
144 
Table 6.1: Characteristics of patients ever treated with metformin 
Continuous variables are summarized as median (interquartile range) and p-values 
were generated using the Mann-Whitney U test. Categorical variables are 
represented as n (%) and p-values were generated using chi-squared test or 
Fisher’s exact test if expected cell count was less than five. P-values were 
considered statistically significant if <0.05 and are displayed in bold. *For some 
variables, the summed total is less than the total number of patients because of 
missing values. 
Ever Treated with Metformin? Yes No P-value 
Sex    
     Female 37 (43.02) 1,171 (57.66)    
0.007 
     Male 49 (56.98) 860 (42.34) 
Diabetes mellitus    
     No 26 (31.33) 1,922 (98.77)     
<0.001 
     Yes 57 (68.67) 24 (1.23) 
Body mass index    
     <=24.9kg/m2 3 (3.57) 787 (39.06) 
 <0.001      >24.9-29.9kg/m2 26 (30.95) 828 (41.09) 
     >29.9kg/m2 55 (65.48) 400 (19.85) 
Smoking status    
     Never 32 (38.55) 1,126 (55.12) 
 0.002 
     Ever 51 (61.45) 917 (44.88) 
Breslow thickness    
     <=1mm 7 (8.24) 588 (29.28) 
<0.001 
     1.01-2mm 38 (44.71) 768 (38.25) 
      2.01-4mm 25 (29.41) 439 (21.86) 
     >4mm 15 (17.65) 213 (10.61) 
Vitamin D    
     <20nmol/L 6 (8.96) 102 (6.12) 
0.514 
       20-59.9nmol/L 49 (73.13) 1,108 (66.43) 
       60-84.9nmol/L 11 (16.42) 380 (22.78) 
       85-99.9nmol/L 1 (1.49) 53 (3.18) 




Table 6.2: Analysis of melanoma-specific and overall survival in patients ever 
having taken metformin regularly (ever-never) 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
 Melanoma-specific survival Overall survival 
 HR (95% CI) p-value HR (95% CI) p-value 
Unadjusted or crude 
model 
2.06 (1.40-3.02) <0.001 1.74 (1.18-2.57) 0.005 
Adjusted for age at 
diagnosis and sex 
1.59 (1.07-2.36) 0.021 1.31 (0.88-1.95) 0.169 
Adjusted for age at 
diagnosis, sex and 
Breslow thickness 
1.28 (0.86-1.91) 0.215 1.09 (0.74-1.63) 0.641 
Adjusted for other risk 
factors* 







Figure 6.1: Unadjusted Kaplan-Meier survival plots for melanoma participants who 







Figure 6.2: Age and sex adjusted Kaplan-Meier survival plot for melanoma 




6.6.3 Association of Metformin usage at diagnosis or within 12 
months on survival outcomes 
I next examined the association between metformin usage at diagnosis or within 12 
months and survival outcomes (Table 6.3). There were 71 patients (3.34%) in this group 
as opposed to the 88 in the metformin ever category. Although the reduced number 
resulted in a modest loss of power this analysis, as discussed in the methodology 
section, does not have an inherent bias. Despite this, encouragingly the results are very 
similar to the results in the metformin ever group with an initial significant increase in 
hazard of death in patients taking metformin HR (MSS) 2.28 (95% CI: 1.51-3.45, p= 
<0.001) and HR(OS) 1.95 (95% CI: 1.28-2.96, p= 0.002). 
 
Table 6.3: Analysis of melanoma-specific and overall survival in patients having 
taken metformin at diagnosis or within 12 months of diagnosis 
*Adjusted for age at diagnosis, sex, Breslow thickness, number of pack years of 
smoking, vitamin D levels, diabetes, ulceration, and body mass index. Significant 
p-values are in bold. HR, hazard ratio; 95% CI, 95% confidence interval. 
 Melanoma-specific survival Overall survival 
 HR (95% CI) p-value HR (95% CI) p-value 
Unadjusted or crude 
model 
2.28 (1.51-3.45) <0.001 1.95 (1.28-2.96) 0.002 
Adjusted for age at 
diagnosis and sex 
1.71 (1.12-2.61) 0.014 1.42 (0.93-2.16) 0.107 
Adjusted for age at 
diagnosis, sex and 
Breslow thickness 
1.29 (0.84-1.97) 0.248 1.12 (0.73-1.71) 0.607 
Adjusted for other risk 
factors* 
1.00(0.51-1.95) 0.995 0.77 (0.41-1.46) 0.421 
 
However, as previously seen increasing age and the male sex are known predictors of 
melanoma and overall survival, and when the model was adjusted for age at diagnosis 
and sex, the hazard ratios were attenuated as shown but still showing a statistically 
significant negative association with metformin ever use and melanoma specific survival 
HR (MSS) 1.71 (95% CI: 1.12-2.61; p= <0.001). However in the multivariate analysis as 
shown in Table 6.3 and like the previous analysis, this statistical significance was again 
lost once Breslow was adjusted for with HR (MSS) 1.29 (95% CI:0.84-1.97; p= 0.248). 
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6.6.4 Stratification by sex 
As done previously with aspirin and statins, an analysis was conducted and stratified by 
sex to explore if it was possible to identify any similar themes with metformin, although 
in this case without previous literature evidence. When assessing the association of 
metformin in this manner as shown in Table 6.4 below, when adjusted for age at 
diagnosis males appear to have a statistically significant worse outcome in terms of 
melanoma specific survival when compared to females on metformin (HR=1.68, 95% CI 
1.03-2.74, p=0.036). However once adjustment is made for age as well as Breslow 
thickness, the hazard ration drops and the statistical significance is just about lost 
suggesting that some of the hazard maybe attributed to thicker tumours in males 
(HR=1.52, 95% CI 0.94-2.48, p=0.090) 
 
Table 6.4: Association of metformin use on melanoma specific survival stratified 
by sex 
Significant p-values are in bold figures 
 Metformin – Ever-Never 
 Adjusted for age at diagnosis 
Adjusted for age at diagnosis 
and Breslow thickness 
Sex Mortality HR (95% CI) p-value Mortality HR (95% CI) p-value 
Male 1.68 (1.03-2.74) 0.036 1.52 (0.94-2.48) 0.090 
Female 1.44 (0.74-2.83) 0.286 0.96 (0.49-1.90) 0.913 
 
6.6.5 Association of Metformin usage on survival when stratified by 
site of primary 
Finally given the literature evidence discussed above of potential varying associations of 
metformin depending on somatic BRAF mutation status, I also carried out a stratification 
via site of primary using truncal melanomas as a potential surrogate marker for BRAF 
mutated tumours. As expected my statistical power for this type of sub-analysis was very 
low as shown in Table 6.5 below. As shown, there appeared to be a statistically 
significant negative effect with metformin use in melanomas on the chest which although 
could be used as a surrogate marker BRAF mutated tumours given the relatively small 
number of cases (n=6) it is difficult to be certain of a real association and in fact the 
tumours on the back which make up the largest number (n=27) did not show a statistically 
significant result.  
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Table 6.5: Association of metformin use on melanoma specific survival stratified 
by site of primary 
Adjusted for age at diagnosis and Breslow. Significant p-values are in bold. HR, 
hazard ratio; 95% CI, 95% confidence interval. 
Site No of cases  Mortality HR (95% CI) (MSS) P-Value 
Abdomen 5   
Metformin ever use  1.28 (0.17 - 9.69)  0.81 
Acral 3   
Metformin ever use  2.08 (0.47 - 9.25)  0.34 
Back 27   
Metformin ever use  1.76 (0.89 - 3.49)  0.11 
Chest 6   
Metformin ever use  3.87 (1.29 - 11.57)  0.02 
Other sites (no of cases) : flank (1), foot (3), head/neck (9), lower arm (3), 
shoulder (1), subungal(3), thigh(7), upper arm (6), vaginal(1), vulval (1) 
 
6.7 Discussion 
As discussed in the literature review at the start of this chapter, a number of retrospective 
studies in cancers other than melanoma, showed that patients with T2DM treated with 
metformin have lower cancer incidence and/or reduced cancer mortality compared to 
other diabetics not on metformin, creating an interest in metformin as an anticancer 
agent. These findings also appear to be validated in meta-analysis of studies looking at 
metformin in these other cancers.   
In terms of melanoma however there are very limited epidemiological studies showing 
similar associations. On the other hand there are several laboratory studies done on 
melanoma cells showing that metformin can inhibit melanoma cell proliferation. In 
summary, metformin has two proposed anti-neoplastic mechanisms of action. Firstly, an 
indirect route connected to its insulin-lowering activity as well as recued levels of pro-
inflammatory cytokines such as IL6, which may decrease the proliferation of tumour in 
individuals with hyperinsulinaemia and secondly, a direct action in target tissues, pre-
neoplastic and neoplastic cells, directed against respiratory complex I of the electron 
transport chain in mitochondria, thereby reducing the consumption of energy in the cells 
[373]. Both these routes are associated with metformin's action on mitochondria, which 
requires the activation of metabolic checkpoint AMP-activated protein kinase (AMPK), 
resulting in inhibition of the mammalian target of the rapamycin (mTOR) pathway, 
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reduction in cell proliferation, and induction of apoptosis and arrest of the cell-cycle [409, 
410]. AMPK is implicated in several pathways, and following metformin activation, it 
decreases protein synthesis and cell proliferation. Many studies have demonstrated the 
role of metformin in the regulation of cancer cells, particularly its effects on cancer cell 
proliferation and cell death.  
However contrary to the large body of evidence reviewed showing a beneficial effect of 
metformin in many cancers including melanoma, two papers reviewed suggested a 
somewhat paradoxical effect of oral metformin in BRAF mutated melanoma. It would 
therefore appear that the effect of metformin based on the mutation status of the tumour 
warranted more investigation. 
In this chapter I attempted to investigate the association of metformin with melanoma 
survival in the LMC, the largest cohort of melanoma patients studied in an 
epidemiological study. As expected only a small number of patients in our cohort (n=88, 
4.4%) had been on metformin for any reason and at some point in their lives (ever-use) 
reducing our statistical power to identify significant associations.  
As expected from our literature review, a larger proportion of males (n=49, 56.98%) 
reported that they had used the drug compared to females (n=37, 43.02%) and it was 
the drug of choice in just over two-thirds (n=57, 68.67%) of diabetics in the study. Also 
as expected, because diabetes is associated with many co morbidities, the majority of 
patients taking metformin where obese (n=55, 65%) and more likely to have smoked 
(n=51, 61%) which we as we have identified previously are linked with inflammation. 
Given metformin’s indirect effects on inflammation via cytokines and IL6 it would have 
been interesting to see if for instance CRP levels were elevated or not in this subgroup. 
As the severity of diabetes and end organ damage is dependent on glucose control and 
the length of time someone has had diabetes this would also have been a useful sub-
analysis had this data been available.  Surprisingly nearly a third of patients (n=26, 
31.33%) reported to have used metformin in some point in their life yet did not volunteer 
a diagnosis of diabetes.  As discussed there are a number of possible explanations for 
this, including the possibility that patients with pre-diabetes or impaired glucose tolerance 
are started on metformin, possible use in other conditions such as PCOS and 
Hidradenitis suppurativa, the possibility that either patients were not diabetic when filling 
in their recruitment questionnaire and subsequently became diabetic or that it may have 
been a data quality issue in that they did not fill in this part of the questionnaire and the 
discrepancy is as a result of missing data. Either way, this was an unexpected finding 
and depending on the actual reason for the discrepancy as above, this may have had an 
effect on our further analysis.   
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As per my proposed methodology I then examined the association between patients 
having ever taken metformin and both melanoma specific and overall survival. The 
unadjusted model in each case, suggested a statistically significant increase in hazard 
of death in patients taking metformin HR (MSS) 2.06 (95% CI: 1.40-3.02; p= <0.001) and 
HR (OS) 1.74 (95% CI: 1.18-2.57, p= 0.005). However, as previously established 
increasing age and the male sex are known predictors of higher melanoma and overall 
death rates and therefore need to be adjusted for in any representative model. Once the 
model was adjusted for age at diagnosis and sex, the hazard ratios were attenuated but 
still showed a statistically significant negative association with metformin ever use and 
melanoma specific survival HR (MSS) 1.59 (95% CI:1.07-2.36; p= <0.021). The 
statistical significance was lost once the model was adjusted for Breslow thickness, HR 
(MSS) 1.28 (95% CI:0.86-1.91; p= <0.215), suggesting that some of this negative effect 
was accounted for by thicker melanomas which warrants further examination as will be 
discussed below. 
I next examined the association between metformin usage at diagnosis or within 12 
months and survival outcomes. There were 71 patients (3.34%) in this group as opposed 
to the 88 in the metformin ever category. Although there was a slight loss of power, as 
discussed in the methods chapter, this type of analysis does not have any inherent 
survival bias and despite this, encouragingly the results are very similar to the results in 
the metformin ever group suggesting that the guarantee bias may not actually be playing 
such a significant role in our ever-never analysis. As with our previous analysis there 
was an initial significant increase in hazard of death in patients taking metformin in the 
unadjusted model with HR (MSS) 2.28 (95% CI: 1.51-3.45; p= <0.001) and HR (OS) 1.95 
(95% CI: 1.28-2.96, p= 0.002). However, when the model was adjusted for age at 
diagnosis and sex, the hazard ratios were attenuated but still showing a statistically 
significant negative association with metformin use at diagnosis or within 12 months of 
diagnosis and melanoma specific survival HR (MSS) 1.71 (95% CI: 1.12-2.61; p= 
<0.001). However in the multivariate analysis once adjustment was made for Breslow 
thickness the statistical significance was again lost, HR (MSS) 1.29 (95% CI: 0.84-1.97; 
p= 0.248), although the trend towards a negative association was maintained as in the 
previous analysis which together with our results above does warrant more discussion. 
A meta-analysis by Qi et al suggests that T2DM on its own may be an independent risk 
factor for melanoma and results in increased growth of the tumour [208]. Although we 
were not able to show a significant association of T2DM on melanoma survival in our 
cohort it was as shown in chapter 3 associated with a significant negative overall survival. 
A previous study from the Leeds group in this cohort has already shown that low vitamin 
D and smoking are associated with ulceration of primary melanomas and a poorer MSS 
153 
[33]. As shown above, patients in the cohort on metformin were more likely to have been 
smokers. We have seen in chapter 1 how all these factors are potentially related to 
inflammation and we accounted for all of these in our multivariable model where the 
hazard ratio dropped below 1 suggesting that the potential negative association first seen 
was mediated by these exposures rather than the metformin itself. Another possibility 
would be that diabetics or patients with multiple co-morbidities present later and 
therefore have thicker melanomas although I could find no evidence of this in the 
literature.  
Accepting the low statistical power given the small numbers involved the results are still 
in contrast to the larger body of epidemiological and laboratory evidence suggesting a 
protective effect with melanoma in most studies. However evidence for a further 
explanation may be sought from the results of two laboratory studies with specific 
somatic mutations in the melanoma cells that did show a negative effect on survival and 
one would wonder if these somatic mutations (BRAF and NRAS) were potentially more 
prevalent in these patients in my cohort to potentially account for the negative trend in 
terms of an association between metformin use and melanoma survival in our cohort.  
In order to be consistent with my methodology, as previously done with aspirin and 
statins, an analysis was conducted and stratified by sex to explore if it was possible to 
identify any similar themes with metformin, although in this case without previous 
literature evidence of such an association. When assessing the association of metformin 
in this manner when adjusted for age at diagnosis males appeared to have a statistically 
significant worse outcome in terms of melanoma specific survival when compared to 
females on metformin (HR=1.68, 95% CI 1.03-2.74, p=0.036). However once adjustment 
is made for age as well as Breslow thickness, the hazard ratio drops and the statistical 
significance is just about lost suggesting that most of the hazard maybe attributed to 
thicker tumours in males (HR=1.52, 95% CI 0.94-2.48, p=0.090), or potentially due to 
the fact that they are more likely to be smokers or obese and more likely to present late. 
In the absence of any epidemiological or laboratory evidence of a sex effect this is 
unlikely to be significant to metformin itself.  
Finally given the laboratory evidence discussed above of potential varying associations 
of metformin depending on somatic BRAF mutation status, I also carried out a 
stratification via site of primary using truncal melanomas as a potential surrogate marker 
for BRAF mutated tumours. As expected my statistical power for this type of sub-analysis 
was very low and although there appeared to be a statistically significant negative effect 
with metformin use in melanomas on the chest specifically, given the relatively small 
number of cases (6) it is difficult to be certain of a real association and in fact the tumours 
on the back which make up the largest number (27) did not show a statistically significant 
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result. Combining the two groups may have been a better reflection of truncal 
melanomas but the way in which the data was coded, and limitations of the statistical 
software made me unable to perform this analysis.  
Although our results are interesting, the main limitation of our study was the lack of 
statistical power given the relatively small number of patients on metformin and our 
power calculations done in chapter 2. Furthermore we had insufficient power to look at 
combinations of drugs because as show in table 3.20 in Chapter 3, in terms of patients 
on metformin 39 (48%) patients were also on aspirin, 52 (62%) patients were also on 
simvastatin, and 18 (35%) were also on atorvastatin, with 22 (27%) patients being on 
both aspirin and simvastatin together with the metformin. Therefore, it is difficult to 
ascertain how much of the associations seen are to do with metformin or indeed if the 
associations could have been strengthened or weakened because of potential 
synergistic or opposing effects. The other main drawback, common to the whole thesis, 
is with problems of differentiating the effects of the co morbidities from these drugs used 
to treat them. 
Further limitations include the retrospective approach and quality of drug data prior to 
diagnosis and the lack of a national cancer linked pharmacy database. Our study options 
were also limited from an analysis approach as we were unable to look at dose and 
duration given the potential biases in our methodology, as we were unable to perform 
the analyses with a time-dependent approach. These biases generally would result from 
not properly classifying exposure during the follow-up period as well as the guarantee 
time bias discussed in our methods section with our ever-never analysis. Although the 
guarantee time bias should have meant that it would be very difficult to look at exposure 
to the drugs after diagnosis interestingly my results were very similar to the at diagnosis 
or within 12 months of diagnosis analysis which does not have an inherent bias, 
suggesting that the guarantee time bias may not be such an issue in my analysis.  
On the other hand, in terms of strengths of the study, we had the largest cohort of 
melanoma patients allowing us the ability to perform an epidemiological study on the 
effects of metformin on melanoma survival given the real lack of such studies in the 
literature. I also had access to high-quality survival data given that it was a cohort study, 
which utilised multiple routes to obtaining those data. Given the significant amount of 
data collected at recruitment were also able to adjust for several known variables that 
can be associated with melanoma survival.  
In conclusion, our study did appear to show a trend toward a significant harmful 
association of metformin use on melanoma survival in our cohort with a possible 
suggestion that this could be related to somatic mutations in BRAF by using truncal 
melanomas as a surrogate marker for this mutation, although there was a significant lack 
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of power to demonstrate this fully. Given the conflicting laboratory evidence this requires 
further research and the next step would be to repeat the analysis with data regarding 
mutation status (BRAF and NRAS), which has now been collected for the cohort.  
Our results as a whole require further validation in larger international data sets as well 
as an examination of biological models to assess if these represent real associations or 
whether confounding factors are responsible for these changes. One possibility is to look 
at using Public Health England data as this is an increasingly common approach 
although it will be limited in terms of having access to other variables known to effect 
melanoma survival as was available in our cohort.  
The link between diabetes and inflammation and the effects of multiple drugs is another 
point that needs further research in terms of developing an approach to adjust for these 
varying effects and potentially measuring markers of inflammation such as CRP and 
given the effects related to Breslow thickness potentially stratifying based on thickness 
would be further considerations.  As mentioned, there is also a suggestion that metformin 
acts on the gut microbiome, which may have an effect on melanoma survival directly 






7.1 Aims  
The aims of this chapter are:  
• To review the rationale for undertaking this study and my proposed hypothesis;  
• To summarise my findings; 
• To discuss my findings in relation to existing literature; 
• To discuss the limitations of my study; 
• To draw final conclusions and suggestions for future work. 
 
7.2 Introduction 
Cancer patients are prescribed drugs intended to treat incidental medical conditions, 
which potentially could have effects on host-tumour interaction and therefore survival. 
These effects might be positive or negative. Evidence suggestive of beneficial effects for 
some drugs on cancer survival paved the way for the identification of drugs that can be 
used in chemoprevention, e.g. aspirin for colon cancer prevention. Yet, other drugs, e.g. 
immunosuppressants can have harmful effects leading to an increased death rate.  
Several commonly prescribed drugs such as non-steroidal anti-inflammatories, lipid and 
blood sugar lowering medications used to treat conditions associated with the obesity 
and diabetes related metabolic syndrome are postulated to moderate cancer risks and 
survival. In this thesis I have addressed what the role of such drugs is in melanoma, by 
examining the association of these incidental drug exposures, whilst adjusting for the 
effects of the metabolic syndrome itself (as represented by BMI and diabetes status) and 
other known predictors on melanoma survival. This work was carried out in the largest 
cohort of melanoma patients represented by the Leeds Melanoma Cohort (LMC). 
As outlined in Chapter 1, this study was prompted firstly, by epidemiological studies in 
other cancers suggesting that the use of commonly used drugs such as aspirin, statins 
or metformin may modify cancer risk. Secondly, laboratory data suggesting biological 
mechanisms to support the hypothesis that drugs might modify the likelihood of survival 
e.g., metformin in BRAF mutated melanoma. Thirdly, by the observation that although 
the American Joint Committee of Cancer (AJCC) predicts survival reasonably well, there 
is still a significant degree of variance which remains unexplained (30 to 40%). I would 
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therefore postulate that lifestyle or exposure to drugs, may moderate host/tumour 
interaction and therefore survival contributing to the unexplained variance.  
In carrying out this study I had to be wary of the fact that most drugs, are more frequently 
used in older individuals with concurrent diseases associated with systemic inflammation 
and increased age is associated with poorer melanoma survival.  
My specific aims were: 
(i) To test the hypothesis that BMI and Diabetes, as components of the 
inflammation/metabolic syndrome may independently be associated with 
melanoma survival outcomes in the Leeds Melanoma Cohort (LMC). 
(ii) To test the hypothesis that there are incidental drugs that the LMC may have 
been exposed to, having examined the literature, that are associated with survival 
outcomes independent of the effects on the inflammation/metabolic syndrome.  
(iii) To test the hypothesis that my selected drugs, aspirin, statins and metformin are 
associated with survival outcomes in the LMC. The hypothesis is that these drugs 
may moderate outcomes independent of the underlying medical problem for 
which these drugs have been prescribed. or as moderators of the 
inflammation/metabolic syndrome which may also modify survival outcome as 
above. 
 
7.3 Summary of findings and discussion 
My findings in relation to my aims above were as follows: 
(i) In terms of BMI, 63% of patients in the cohort were classed as overweight or obese, 
with 22% being specifically classed as obese which was less than expected in the 
general population based on the literature evidence. Our results suggested that BMI 
did not have a statistically significant independent association with melanoma 
survival in the LMC neither in the unadjusted or adjusted model with a hazard ratio 
(HR (MSS) of 1.01 (95% CI: 0.99-1.04; p= 0.364) seen in the multivariate model 
when adjusting for all our known cofounders. There was also no significant 
association when the analysis was stratified by sex. Although this does not exclude 
a deleterious effect of obesity: failure to show such could be a power effect if the risk 
is small, or due to the unrepresentative nature of the cohort population as above. 
The observation suggests that there was no strong association between obesity and 
MSS in the LMC.  
In terms of diabetes, 81 patients (4%) in the cohort were diabetic. Our results 
suggested again that diabetes did not have a statistically significant independent 
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association with melanoma survival in the LMC neither in the unadjusted or adjusted 
model with a hazard ratio (HR (MSS) of 1.51 (95% CI: 0.74-3.07; p= 0.250) seen in 
the multivariate model when adjusting for all our known cofounders. There was also 
no significant association when the analysis was stratified by sex apart from a slight 
suggestion that males with diabetes may do worse. Although diabetes did not appear 
to have a directly significant association on melanoma specific survival, within our 
power constraints, it did appear to be significantly associated with overall survival in 
the LMC with a hazard ratio (HR (OS) of 2.37 (95% CI: 1.31-4.30; p= 0.004) seen in 
the multivariate model when adjusting for all our known cofounders. This was 
expected given its association with the inflammation/metabolic syndrome and organ 
damage as described in the literature. 
(ii) Aside from our chosen drugs aspirin, statins and metformin the following drug 
categories were identified in the literature as having multiple reports of potential 
associations with melanoma survival: fibrates, retinoids, b-blockers, ace inhibitors, 
calcium channel antagonists and immunosuppressants. Unfortunately, there were 
not enough patients on fibrates, retinoids or individual immunosuppressants to carry 
out a meaningful analysis due to a lack of statistical power. With the other drugs 
examined including other drugs that could play a role in the metabolic syndrome and 
inflammation, including other non-steroidal anti-inflammatories, anti-hypertensive 
and other oral anti-diabetic drugs such as diclofenac, bisoprolol, and gliclazide there 
were no statistically significant effects on melanoma survival seen. However, I noted 
some interesting results with my chosen drugs as presented below.  
(iii) Aspirin - when the analysis was stratified by sex, whilst adjusting for age and 
Breslow thickness, women who had ever taken aspirin were significantly less likely 
to die from their melanoma compared with those who never used the drug at any 
point in their lifetime with hazard ratios (HR) for MSS of 0.51 (95% CI: 0.30-0.87, P= 
0.014) compared to men with an HR (MSS) 0.99 (95% CI: 0.71-1.37, P= 0.948). This 
suggests that aspirin use may have a preferentially protective effect in female 
participants as compared to males.  
Statins - Similarly in the case of both ever/never use of simvastatin and at diagnosis 
(including 12 months prior) analysis, when adjusting for age and Breslow thickness, 
men had a significantly reduced risk of death from melanoma with HRs of 0.54 (95% 
CI: 0.37-0.79, P=0.002) and 0.57 (95% CI: 0.38-0.85, P=0.006) respectively when 
compared to females who had HRs of 1.22 (95% CI: 0.82-1.83, P=0.327) and 1.21 
(95% CI: 0.79-1.86, P = 0.379) respectively. This would suggest that simvastatin use 
may have a preferentially protective effect in male participants as compared to 
women. 
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Metformin - In keeping with a previous smaller unpublished study done within our 
cohort, metformin usage appeared to have a trend towards a negative effect on 
melanoma survival in our cohort. I saw a significant association with ever-never 
metformin use when adjusting for age and sex with an HR 1.59 (95% CI: 1.07-2.36, 
p value = 0.021) but once adjustment was made for Breslow thickness this became 
non-significant with an HR (adjusted for age, sex and Breslow) of 1.28 (95% CI: 0.86-
1.91, p value =0.215 and). In the at diagnosis (or within 12 months prior)  analysis, 
metformin use showed a similar significant association when adjusting for age and 
sex with an HR 1.71 (95% CI: 1.12-2.61, p value = 0.014) but once adjustment was 
made for Breslow thickness this again became non-significant with an HR (adjusted 
for age, sex and Breslow) of 1.29 (95% CI: 0.84-1.97, p value =0.248). In view of the 
publications referred to previously suggesting that metformin has different effects on 
BRAF mutated tumours, such that patients on BRAF mutated tumours might do less 
well on metformin but those without BRAF mutations would benefit from metformin, 
I repeated the analysis, stratifying by tumour site, given reported evidence that 
truncal tumours are more likely to be BRAF mutated than tumours arising in other 
sites. On stratification for the site of primary, for melanomas on the chest, which as 
part of melanomas on the trunk could be used as a surrogate marker for BRAF 
mutated tumours, showed an HR of 3.87 (95% CI 1.29-11.57, p-value = 0.02) 
although this was not significant for tumours on the back HR of 1.76 (95% CI 0.89-
3.49, p-value = 0.11). 
 
7.4 Discussion of findings in relation to existing literature 
As discussed in my literature review, the effects of BMI and Diabetes and the metabolic 
syndrome and inflammation on cancer incidence and survival are well documented. 
There has been increasing reported evidence particularly in cancers other than 
melanoma, that host factors such as obesity may drive cancer incidence and 
progression. The changes which are identified in response to the obesity related so-
called metabolic inflammatory state is said to be orchestrated by metabolically active 
cells in response to excess nutrients and energy [431]. The fat cells generate 
inflammatory responses (increased TNF-α, and many inflammatory cytokines such as 
IL-6), which sustain low-grade chronic inflammation in affected patients, and this 
sustained inflammation is hypothesised to lead to the development of co morbidities such 
as cardiovascular disease.  
Suppression of this pathway was recently explored as a means of prevention of 
significant cardiovascular disease in people at risk. This recently published data by 
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Ridker et al from the CANTOS trial suggests that the IL1 pathway is crucial in mediating 
cardiovascular disease, with evidence that it mediates cancer risk too. In this trial, more 
than 10,000 patients agreed to be randomised to placebo, 50, 150, and 300 mg 3 
monthly of canakinumab, which blocks IL1 signalling, after a myocardial infarction. 
Eligibility required elevation of high sensitivity C reactive protein levels. The trial reports 
describe a dramatic reduction in serious cardiovascular events in the active treatment 
arms and notably, a reduction in death from lung cancer as a secondary outcome [139].  
The Leeds group reported an investigation of microscopic ulceration of primary 
melanoma in 2015 (Jewell et al) in which the gene expression data suggested that 
ulcerated tumours have a pro-tumourigenic inflammatory environment with raised IL6 
and IL8 gene expression [101]. The group then asked, if there is a role for IL6 in tumour 
progression locally, is there an association between conditions associated with systemic 
inflammation and ulceration? The group looked at data from the Leeds Melanoma Cohort 
and asked if factors related to low grade systemic inflammation (obesity, smoking, 
vitamin D deficiency and diabetes) might be associated with ulceration of primary 
melanomas [33]. It was shown that ulceration was associated with all of these factors in 
a univariate analysis lending support to the view that systemic inflammation may play a 
role in modulating host tumour interaction in melanoma and therefore survival. This was 
the justification for my examination of the role of drugs, which are reported to reduce 
systemic inflammation, in melanoma survival. 
In observational studies such as mine, patients commonly use a multitude of drugs. For 
instance patients with a history or risk of cardiovascular disease may very easily be 
prescribed all of the drugs in question at the same time and co-administration of 
metformin, statins and aspirin might affect several different cellular pathways and 
inflammatory pathways at the same time. As shown in our cohort characteristics for the 
patients on these individual drugs they are often more likely to be obese or overweight 
and to have diabetes when compared to patients not on these drugs. Although in this 
study I was unable to demonstrate a statistically significant association in terms of BMI 
and Diabetes alone on melanoma survival that could be due to the limitations of my study 
that will be discussed in more detail below. Despite this, BMI and Diabetes as part of the 
metabolic syndrome would still be a very important consideration in any similar future 
studies.    
In terms of my chosen drugs as discussed in the individual chapters there are already 
pre-clinical observational and laboratory studies suggesting potential effects of these 
drugs on melanoma incidence with a range of potential mechanisms of action for their 
anti-cancer effects having been proposed but with many fewer studies examining 
associations with survival. In most studies, only the effects of exposures prior to cancer 
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diagnosis were examined and in these as well as studies assessing survival, there was 
a lack of information on potential confounding factors, that I have been able to adjust for 
due to the presence of high-quality cancer data, which enabled detailed consideration of 
tumour staging and survival in particular.  
My significant findings in terms of the aspirin and statin results when stratifying by sex, 
have not previously been reported in any studies of this size looking at melanoma 
survival outcomes as this was conducted in the largest cohort of melanoma patients 
reported in the literature. Interestingly similar significant protective effects in melanoma 
incidence, as opposed to survival, in woman taking aspirin and men taking statins have 
been shown in the same Dutch population-based study by Joosse et al [258]. 
Furthermore Livingstone et al in 2014 conducted a smaller but similar study to ours and 
again found that statins may reduce melanoma mortality, particularly in males [303]. 
Furthermore there are also other studies suggesting a similar association with Aspirin in 
females with melanoma incidence. [257].  
The factors underlying the observed differences in association with drug exposure and 
melanoma survival, are not understood. In terms of sex differences per se irrespective 
of exposure to drugs, as discussed in the literature review in Chapter 1, several studies 
demonstrate the fact that male melanoma patients are almost twice as likely to die 
compared with female patients. Although men are significantly more likely to have 
melanomas with unfavourable characteristics such as thicker and nodular melanomas 
located on the trunk, in accordance with previous observations [269], adjusting for these 
factors in our analysis do not explain the observed sex difference in melanoma survival 
with aspirin and statins.  
Although the most common explanation for the sex difference in melanoma survival 
generally, is the better stage at diagnosis among women, our results could not be 
explained by this argument. A number of theories have been developed to explain the 
difference in survival by sex. The thicker tumours reported in men have been attributed 
to delayed presentation. Recently however, the assumption that Breslow thickness is a 
surrogate marker for the time between development and diagnosis of melanoma, which 
has been applied in many epidemiological studies, has been challenged [269]. A large 
epidemiological study showed no positive association between melanoma thickness and 
time to diagnosis on a population basis and a histological study concluded that 
aggressive tumour growth, rather than delay in diagnosis, is responsible for the 
development of thick melanoma [331, 332]. One possibility therefore is that more 
aggressive melanoma growth in men may contribute to the differences observed [269]. 
A sex difference in the prevalence of lifestyle factors such as sun exposure [269] and 
dietary habits such as vitamin supplements including vitamin D, ethanol consumption, 
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soy isoflavones, essential fatty acids and drug have also sometimes been used to part 
explain the difference in survival across the two sexes [269]. That is that survival in men 
may be worse because of co morbidities resulting from these lifestyle variables. Lifestyle 
related effects on host tumour interaction may be mediated epigenetically. The field of 
epigenetics is currently emerging. It is theorised to be the link between the environment 
and genes. Chemical substances that surround us may indirectly inflict permanent DNA-
changes and account for the changes seen 
Could it be that the effects of hormones such as oestrogen or testosterone mediate 
differential survival per se and differential response to drugs? In terms of hormones, a 
few earlier studies indicated an increased melanoma risk in (long-term) oral 
contraceptive use [269], but meta-analyses did not confirm this association [333]. In 
randomised clinical trials, tamoxifen did not seem to improve the survival rate in patients 
with metastatic melanoma either [269]. The likelihood of developing melanoma and its 
prognosis were also comparable in pregnant and non-pregnant females [334]. 
Furthermore a recent case–control study that focused on melanoma in women did not 
find reproductive, menstrual and hormonal factors that affected melanoma risk [335]. 
Dividing our cohort population into pre-menopausal and post-menopausal women and 
repeating the analysis would be an option to consider to try to elucidate this further. Given 
the similarity in findings with Joosse et al [258] with these associations seen with aspirin 
and simvastatin on melanoma incidence our results may point to a common biological 
pathway mediating these effects via sex differences both in development of melanoma 
as well as influencing survival from melanoma, which warrants further investigation and 
I will propose some potential future study options in the next section.  
With regards to metformin, as significantly fewer patients were on this drug in our cohort 
compared to aspirin and statins I had much less statistical power to undertake an 
analysis, although my results did appear to show a trend towards a non-significant 
harmful association of metformin use on melanoma survival in our cohort. This is in 
contrast to most epidemiological and laboratory studies as presented in the metformin 
chapter, in which in cancer overall, metformin exposure is reported to be of benefit in 
terms of survival. As I did not have access to somatic mutation status for cohort 
participants overall and I was therefore unable to explore the hypothesis that the results 
generated were driven by adverse effects in BRAF mutated tumour [420].   
As alluded to previously, co-administration of multiple drugs at the same time are typical 
for many patients and in our study co-administration of metformin, statins and aspirin 
could well have influenced the individual effect on inflammation and tumorigenesis as 
well as effecting several different cellular pathways, at the same time. In terms of patients 
on metformin 39 (48%) patients were also on aspirin, 52 (62%) patients were also on 
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simvastatin, and 18 (35%) were also on atorvastatin, with 22 (27%) patients being on 
both aspirin and simvastatin together with the metformin. Therefore, it is difficult to 
ascertain how much of the associations seen are to do with metformin or indeed if the 
associations could have been strengthened or weakened because of potential 
synergistic or opposing effects. Furthermore, although metformin is currently the first-
line treatment in type 2 diabetes its effectiveness may be impacted depending on 
whether patients have early or late stage diabetes for instance, which may also correlate 
to levels of chronic inflammation. This issue is related to the main challenge, common to 
the whole thesis, with the issue of differentiating the effects of the co morbidities from 
the drugs used to treat them. 
 
7.5 Limitations of study 
There were a number of limitations with my study that I will discuss in this section.  
One of the main limitations was that despite the large cohort of melanoma patients in the 
study the study itself was observational only and indeed a retrospective one as the cohort 
had already been recruited prior to the setup of this particular study. I therefore did not 
have the benefit of setting specific inclusion and exclusion criteria specific to the aims of 
my study and to enable me to collect data specific to the study to try to limit potential 
biases. In the next section I will discuss some of these biases in more detail and assess 
how much of an impact they could have had on my results. 
A bias is defined as a distortion of study results, which may occur when the study groups 
under investigation (exposed and unexposed) are identified, treated or evaluated 
differently to each other. There are a number of different forms of bias including selection 
bias, where exposed and unexposed patients are selected for study due to reasons, 
which may influence the outcomes, and information bias, where data is collected in an 
unbalanced manner between exposed and unexposed groups. The main selection bias 
with regards to my study would be with regard to whether the patients in the study were 
more or less likely to have co-morbidities that could influence survival outcomes 
irrespective of drug use and other known variables that we adjusted for in our analysis. 
This could lead to confounding, where the results of a study are not due to a true 
association between exposure and outcome, but may in fact be explained by another 
factor, e.g. age, which is associated with both the exposure and the outcome. The main 
confounders in our study are likely to be other mediators of inflammation and the 
metabolic syndrome that we have not accounted for such as hypertension and 
hyperlipidaemia.  
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This was a significant limitation of being able to assess an association of the metabolic 
syndrome with melanoma survival, as I was unable to adjust for all the components of 
this syndrome, as I did not have access to blood pressure recordings or measurements 
of lipid profile for instance. Although as discussed in the methodology I considered 
capturing this data by recording the use of an anti-hypertensive as a marker that a patient 
has a diagnosis of hypertension, this was flawed by the fact that certain drugs like 
diltiazem or bisoprolol can be used both as an anti-hypertensive but also to treat 
arrhythmia and this approach was abandoned. As discussed in Chapter 1.13, other 
measures such as hip to waist measurement ratio and presence of insulin resistance 
would potentially have been helpful adjuncts, particularly with defining obesity as 
calculating BMI is not always felt to be an accurate indicator. Related to this, it is also 
generally expected that in observational studies, exposure to the drug under 
investigation occurs in a non-random manner. A patient may receive a certain drug for a 
variety of reasons known or unknown to the researcher. For example, the age of a patient 
or the cost of a treatment may be a factor in deciding whether a particular drug is suitable 
for a patient. If these factors are also associated with the outcome under investigation, 
the exposure/outcome relationship is likely to be confounded. Various methods have 
been suggested to reduce confounding in observational studies and include both study 
design and analysis approaches. Study design approaches include matching exposed 
and control patients by a common potential confounding factor, or restriction of the 
analysis to only one level of a particular confounding factor, which given the complexity 
of my data set would be insufficient to analyse my data. Alternative proposed approaches 
in dealing with confounding at the analysis stage include stratification and multivariate 
analysis both of which I utilised in my study. 
A further limitation is related to the issue of the use of multiple drugs at the same time as 
mentioned above where co-administration of metformin, statins and aspirin might affect 
several different cellular pathways, at the same time. Ideally a population based study 
using public data bases could be used to address the relative associations of exposure 
to pairs of drugs but after discussion with the team, I accepted that the current data set 
was sufficient only to look at exposures to single drugs with an agnostic approach, 
accepting that this is a weakness of this approach.  
Another related issue is what is referred to as a Detection bias. Detection bias occurs in 
cohort studies where the follow-up procedures for detecting adverse events are different 
for patients with and without the drug exposure. Patients using a multitude of drugs or 
with a strong history of cardiovascular disease for instance, may visit the health services 
more frequently, and therefore increase their chance of having a melanoma relapse 
picked up earlier and better survival and which may introduce a bias whereby this is seen 
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as a potential protective effect falsely attributed to the medications in question. This form 
of bias may also play a role with regards to the recognised side effects of aspirin, statins 
and metformin, which may cause patients to visit health services. For instance, among 
diabetic patients, those using metformin, as compared to patients exposed to 
sulfonylureas, have been shown to have a slightly increased risk of undergoing a 
colonoscopy, (HR-1.12, 95% Cl 1.06-1.18) potentially due to patients experiencing 
gastrointestinal side effects following metformin treatment (ref) which led to earlier 
detection of colon cancer. In RCTs, the random assignment of a large number of 
participants into either the treatment or control group is expected to result in a balance 
of known and unknown risk factors/confounders for the outcome among the two groups. 
However, in observational studies, as discussed earlier, exposure to the drug under 
investigation occurs in a non-random manner.  
An additional concern relating to the detection bias is the 'healthy user/adherer' effect. 
This form of bias is highly prevalent in epidemiological studies looking at drug effects 
and is also relevant to my study. The healthy adherer/user effect occurs as a result of 
patients who use a drug, or have high adherence to a drug therapy, being more likely to 
partake in healthy behaviours; for example, patients who adhere consistently to their 
drug therapy have been shown to be more likely to engage in cancer screening activities 
[432]. However, it is expected that adjustment for factors related to healthy choices (e.g. 
smoking status), or early detection of cancer (as represented by tumour stage), as done 
in my study, should reduce any potential healthy user bias.  
A further bias that is likely to be present in my study is the concept of “recall bias.” The 
data obtained at recruitment to the cohort was based on questionnaire data, which is 
going to be influenced by what the patient accurately recalls in terms of drug usage and 
co-morbidities. Although I supplemented the drug data by including GP returns data this 
recall bias may explain why a proportion of the nearly a third of patients on metformin 
did not volunteer a diagnosis of diabetes on the questionnaire.  
Another important limitation of the study was that I was unable to incorporate timing, 
duration or dosage of exposure to the drugs due to incomplete or missing data as result 
of the manner in which the data had been collected. Given the literature evidence in 
colorectal cancer for instance with aspirin, where effects on incidence are only seen after 
5 years of use of aspirin, this would suggest that duration of drug use would have been 
a significant consideration to fully assess the associations with some drugs in the cohort. 
Another issue with the missing data and lack of detailed exposure data was our inability 
to study continuous versus infrequent drug exposure. 
Selection of an appropriate analysis method for investigating the effects of drugs on 
melanoma survival was one of the most challenging aspects of our study. As discussed 
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in the methods (Chapter 2), we considered the following analysis methods and their 
limitations. 
7.5.1 Ever-never analysis 
This is the simplest and most frequently used analysis method in the epidemiology 
literature and divides the cohort into patients that have been exposed to the drug at some 
point (we only included patients into this group if we had evidence that they had been on 
the drug for at least 30 days) and those that had never been exposed to the drug in 
question. Although this type of analysis works well in studies looking at the effects on 
incidence of cancer, in studies like ours looking at survival, it does however introduce a 
potential bias referred to as the guarantee-time bias. This refers to the likelihood of 
someone who survives longer having a greater chance of being exposed to the drug in 
question and ending up in the ever user category. This longer survivorship could 
therefore be incorrectly interpreted as being as a result of having been exposed to the 
drug. Although we would have expected that due to this bias these results needed 
cautious interpretation, interestingly for most of our ever-never analysis the results were 
remarkably similar to our less biased drug use until within 12 months of diagnosis 
approach described in further detail below, suggesting that this bias played less of a role 
in our cohort.  
7.5.2 Drug usage up until diagnosis 
This method of analysis essentially replicates the traditional methods used in cancer 
incidence studies with no inherent bias but as my study was not specifically designed for 
this I did experience some loss of statistical power as well as the issue of poorer quality 
data before diagnosis.  
7.5.3 Time-dependent or time-varying covariate analysis 
This type of analysis is particularly suited for survival analysis and aims to minimise the 
biases discussed above and was used by Joosse et al in their study [258]. It reflects the 
phenomenon that a covariate such as drug use is not necessarily constant through the 
whole study. For instance, a patient may have been on and off a drug at different time 
points in the study and this could then be introduced in the statistical model as a time-
varying covariate. In survival analysis, this would be done by splitting each study subject 
into several observations, one for each period of drug use/non-use. This method of 
analysis apart from being very complicated was not ideally suited to our data as we had 
to make some assumptions regarding continued use of drugs due to a lack of such 
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specific drug usage data as opposed to Joosse et al [258] who had very accurate drug 
data linked to a national pharmacy database. The results from this type of analysis were 
therefore largely unchanged for any drug in our cohort and the approach was 
abandoned. 
An additional important concern is the risk of misclassifying patients who are exposed to 
drug as unexposed; this issue was highlighted in a recent review of studies examining 
associations between aspirin and improved colorectal cancer survival [433]. The quality 
of the exposure data in our study to aspirin for instance can be questioned due to the 
fact that low-dose aspirin is available over the counter in the UK for analgesic purposes. 
Practically however as we defined use as a minimum of one month, its unlikely that the 
majority of these patients eligible for NHS prescriptions would be likely to pay 'out-of-
pocket' for aspirin in this way, at least over a long-term basis. Therefore, while some 
patients with infrequent exposure to analgesic doses of aspirin purchased over the 
counter may have been misclassified as 'unexposed', the vast majority of aspirin 
exposure would be expected to be correctly classified within my study.  
When it comes to analysis of my results one of the significant limitations alluded to 
throughout the study is the lack of statistical power to examine several of the drugs of 
interest such as immunosuppressants to which the exposure in the cohort was very 
small. This is shown by the power calculations in Chapter 2 and the exposures to various 
drugs as demonstrated in Chapter 3. Further power issues relate to our stratified/sub-
analysis and the number of melanoma specific deaths where the results do need to be 
interpreted with caution due to further loss of power.  
 
7.6 Final conclusions and suggestions for future work 
As discussed, the results from my study are broadly consistent with previous studies on 
associations between aspirin, and statin use on melanoma survival in the literature. The 
trend toward a negative association with metformin on melanoma survival differs from 
the majority of epidemiological studies as discussed although the proposed potential 
pathway of a negative effect via effects on BRAF mutated tumours has been reported in 
a laboratory study. My findings in terms of differential effects of aspirin and statins on 
melanoma survival within the same cohort when stratifying by sex is a significant finding 
although backed up by a large study on melanoma incidence in a Dutch population study 
as discussed. Although our study did not demonstrate an independent association of 
diabetes and BMI on melanoma survival, from our literature review it is clear that they 
play an important role in inflammation and cancer pathways. 
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The possibility of anti-cancer effects of drugs such as aspirin and statins, commonly used 
for other clinical indications is an exciting prospect particularly as these drugs are off-
patent and relatively inexpensive, in contrast to agents considered in conventional 
cancer drug discovery. Although in contrast to our findings, some studies have examined 
the effects of metformin in combination with BRAF inhibitors, such as vemurafenib and 
showed encouraging results with synergistic effects for inducing melanoma cell death 
and represent yet another use of this commonly prescribed medication.  
In considering the use of an existing drug towards a new therapeutic indication as 
proposed above, it is important to try to establish a strong evidence base to support 
testing of the drug in clinical trials. Evidence may be generated from preclinical studies 
(i.e. laboratory studies of in vitro or in vivo effects) or through analyses of data from 
patients who have already been taking the drug for other indications as in this study. 
Drug repurposing (also referred to as repositioning, redirecting, or reprofiling) is the 
investigation of existing drugs, such as aspirin, statins or metformin, for application 
outside the scope of their original therapeutic indications [434]. This concept represents 
a substantially faster route of drug development than what would conventionally be 
expected and some examples of its application previously include the repurposing of 
thalidomide for erythema nodosum laprosum and multiple myeloma, or the repurposing 
of sildenafil as a treatment for erectile dysfunction [435]. The additional advantage of this 
approach is that several phases of the process can be bypassed as the drug candidate 
will often have undergone these testing procedures for their original indication; the 
pharmacokinetic, pharmacodynamics and toxicity profiles of the drug candidates are 
already well established, meaning their progression to phase II and III clinical studies 
may be expedited. This is particularly relevant in the field of cancer therapeutics where 
toxicity and expense of new therapies often limit their application. Repurposing may also 
involve the consideration of drugs such as aspirin, statins or metformin as lead 
compounds; identification of anti-cancer effects of these drugs results in new drug 
development efforts to improve upon the original chemicals [434]. 
A further consideration would be the use of biomarkers to identify which patients may 
benefit from chemoprevention with information from a blood sample probably being the 
most optimal. It is estimated that only 30-50% of patients will experience a 
chemopreventive effect from aspirin which may reflect levels of inflammation, and so far, 
regular use of aspirin as chemoprevention is not recommended generally, 
notwithstanding the potential toxicities discussed previously [436]. Some studies have 
explored polymorphisms of the metabolising enzymes of aspirin, and it may be beneficial 
to have the slower metabolising variant. Others have seen different responsiveness of 
aspirin depending on sex and body-mass-index [436].  
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In general, drugs have different response between individuals and whether there are 
chemopreventive or carcinogenic properties seems to depend on the cancer subtype 
[437]. As already alluded to, when taking into account different mutations, patient gene 
polymorphism, and epigenetics this becomes a very complex field of study. This 
emphasizes the need for epidemiological studies and knowledge about genetics in order 
to establish a better picture. Biomarkers to identify the patients with potential benefits 
must be continued to be developed and evaluated in future studies. 
In order to increase the robustness of further studies looking at the effects of incidental 
drugs, the use of healthcare databases should be encouraged. Examples of healthcare 
databases include pharmacy dispensing records, health insurance claims databases, 
general practice research databases, electronic hospital records, and disease registries; 
but crucially such databases should be linked in order to provide access to specific 
outcome related information, e.g. the linkage of pharmacy claims databases to disease 
registries in order to determine particular medications received by patients with a 
condition of interest. Simply having a healthcare database without cancer registry 
information is a flawed approach, as one is then unable to adjust for known predictors of 
cancer survival as in the case of Joosse et al [258] where they were unable to adjust for 
ulceration as in our study, which is an independent predictor of melanoma survival and 
used in the AJCC staging. Cancer registries are typically a comprehensive source of 
information in cancer research and usually include detailed tumour information such as 
stage, grade and morphology. They may also include details of cancer treatment and 
may include accurate outcome data. Medical record linkage of a cancer registry to 
pharmacy dispensing records can provide information on the type of regular medications 
patients were receiving, thus permitting the evaluation of associations between the drugs 
and tumour characteristics and/or cancer outcomes. This type of linked database 
represents a valuable resource as it comprises independently collected prospective data, 
reducing concerns regarding recall bias which may affect studies of cancer patients as 
discussed with our study. However, as these databases contain previously collected 
data, they often lack information on potential confounding factors relevant to the study 
being performed. Public Health England is working towards building such a data 
resource. 
The associations seen in my thesis require further validation in larger international data 
sets as well as examination of biological models to assess if these represent real effects 
or whether confounding factors are responsible for these changes. In particular 
additional epidemiological and basic research is warranted to investigate this important 
sex differences in melanoma survival identified and therefore I would propose that future 
studies looking at factors influencing melanoma survival should consider stratifying their 
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findings by sex. It would also be important to repeat my analysis for metformin within the 
cohort when the complete somatic mutation (BRAF and NRAS) status is available for the 





 : Drug history information 
 Recording of drug history 








A.2 Extraction of specific drug information 
Example of coding/searches needed to identify a drug in the cohort: 
 
use "/Users/medfla/Documents/DRUG DATA/newest drug data/Faheem time 
dependent/masterdrug.dta", clear 
tab code if regexm(code, "^2.1") 
keep if regexm(code, "^2.1") 
tab name  




replace atorvastatinever = 1 if name == "atvastatin" 
replace atorvastatinever = 1 if name == "atovastatin" 
replace atorvastatinever = 1 if name == "atrovastatin" 
replace atorvastatinever = 1 if name == "artovastatin" 
replace atorvastatinever = 1 if name == "atrovastatin" 
replace atorvastatinever = 1 if name == "atorvastatn" 
replace atorvastatinever = 1 if name == "atrovastatin" 
replace atorvastatinever = 1 if name == "lipitor" 
replace atorvastatinever = 1 if name == "lipator" 
 
tab name atorvastatinever,m 
 
drop if atorvastatinever == . 
 
keep patientnumber atorvastatinever  
duplicates drop  





 : British National Formulation Classifications 
 Drug Grouping and Classification 
 Overview of Drug Groups (BNF) 
1. Gastro-intestinal system 
2. Cardiovascular system 
3. Respiratory system 
4. Central nervous system 
5. Infections 
6. Endocrine system 
7. Obstetrics, gynaecology, and urinary-tract disorders 
8. Malignant disease and immunosuppression 
9. Nutrition and blood 
10. Musculoskeletal and joint diseases 
11. Eye 
12. Ear, nose, and oropharynx 
13. Skin 
14. Immunological products and vaccines 
15. Anaesthesia 
 
 Classification of drugs used 
1 Sub-sections NSAIDs 





7 ACE inhibitors 
8 AIIR antagonists 
9 Beta-adrenoceptor blocking drugs 
10 Thiazides and related diuretics 
11 Calcium-channel blockers 
12 Thyroid hormones 
175 
13 Proton pump inhibitors 
14 Loop diuretics 
 
1 Sub-Sections NSAIDS 
10.1.1 COX II selective and non-selective. 
























2 Aspirin  
2.9 Antiplatelet drugs 
2.10 Stable angina, acute coronary syndromes, and fibrinolysis  
2.10.1 Management of stable angina and acute coronary syndromes 
Central nervous system > 4.7 Analgesics > 4.7.1 Non-opioid analgesics and compound 
analgesic preparations >  
Musculoskeletal and joint diseases > 10.1 Drugs used in rheumatic diseases and gout > 




SUB-SECTIONS- Cardio-selective and non-selective 






















8.2.1 Antiproliferative immunosuppressants 
Azathioprine 
Mycophenolate Mofetil 
8.2.2 Corticosteroids and other immunosuppressants 











































9 2.4  



















10 2.2.1  



























13 1.3.5  
















 : Drug Exposure Analyses 
Extract of results obtained with time dependent analysis that was subsequently 
abandoned 
 Aspirin 
Cumulative aspirin exposure: Unadjusted; adjusted for age and sex; adjusted for age, 
sex and Breslow 
 
Adjusted for age, sex, Breslow and smoking; adjusted for age, sex, Breslow, smoking 
and serum Vitamin D. 
 
Adjusted for age, sex, Breslow, smoking and ulceration; adjusted for age, sex, Breslow, 
smoking, serum Vitamin D and presence of diabetes 
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Adjusted for age, sex, Breslow, smoking, serum Vitamin D, presence of diabetes and 
BMI 
 




10 year aspirin exposure: Unadjusted; adjusted for age and sex 
 
 Simvastatin 
Cumulative simvastatin exposure: Unadjusted; adjusted for age and sex; adjusted for 
age, sex, Breslow and smoking. 
 
Adjusted for age, sex, Breslow, smoking and serum Vitamin D. 
 
5 year simvastatin exposure: Unadjusted; adjusted for age and sex 
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Adjusted for age, sex and Breslow 
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